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MEM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Minimum Essential Medium
MSC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mesenchymal Stromal Cell
MIF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mean Fluorescence Intensity
MP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Milk Powder
XVI
PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Polyacrylamide Gel Electrophoresis
PBS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Phosphate-Buffered Saline
PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Number of Population Doublings
PDGF(R) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platelet-derived Growth Factor (Receptor)
PE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Phycoerythrin
PerCP-Cy5.5 . . . . . . . . . . . . . . . .Peridinin-chlorophyll Protein-Cyanin 5.5 Tandem Conjugate
PFA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Paraformaldehyde
PGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prostaglandin E
PI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Propidium Iodide
PMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Postmenstrual Age
pO2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Partial Pressure of Oxygen
PPV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Positive Pressure Ventillation
PSF . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fix Penicillin/Streptomycin/Amphotericin B-combination
q(RT)PCR . . . . . . . . . . . . . . . . . . . . . . . . . . Qualitative (Real-Time) Polymerase Chain Reaction
RSV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Respiratory Syncytial Virus
SCA-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stem Cell Antigen 1 / Lymphocyte Antigen 6A-2/6E-1
SCID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Severe Combined Immunodeficiency
SDF-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stromal Cell-derived Factor 1
SDS-PAGE . . . . . . . . . . . . . . . . . . Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
sGAG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sulfated Glycosaminoglycans
SSEA-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Stage-specific Embryonal Antigen 1
STC-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stanniocalcin-1
TG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Triglyceride
TGF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Transforming Growth Factor
TIMP1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Tissue Inhibitor of Metalloproteinases 1
TNF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Tumor Necrosis Factor
TRIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-Amino-2-(hydroxymethyl)propane-1,3-diol
TSG-6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tumor Necrosis Factor α-stimulated Gene-6 Protein
TSP1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Thrombospondin 1
TTF-1 . . . . . . . . . . . . . . . . . . . . . . .Thyroid Transcription Factor 1, Homeobox Protein NKX-2.1
U . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Unit(s)
UCB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Umbilical Cord Blood
UCMSC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Umbilical Cord-derived Mesenchymal Stromal Cell
uPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Plasminogen Activator, Urokinase-type




Eight to twelve percent of all infants are born premature. Outnumbering even communicable
diseases and intrapartum-related complications, birth before completing 37 weeks of gesta-
tion remains the leading cause of child mortality in the first month of life – accounting for
approximately one million deaths per year, worldwide [Liu et al., 2016]. In developed coun-
tries, premature birth and its short- and long-term complications represent the leading cause
of death in children less than five years of age [Liu et al., 2015; Lawn and Kinney, 2014;
Goldenberg et al., 2008].
Out of the many complications of prematurity, bronchopulmonary dysplasia (BPD) re-
mains the most frequent [Shah et al., 2016; Frey and Klebanoff, 2016]. Over the past decade,
great advances in neonatal medicine and care led to reduced incidences of many of the se-
vere complications of prematurity, including death, retinopathia of prematurity, necrotizing
enterocolitis, late-onset sepsis and intraventricular hemorrhage; only the numbers of BPD
remained stabile [Horbar et al., 2017]. The incidence of the disease varies across centers and
countries [Shah et al., 2016], but about one out of four infants born before the gestational age
(GA) of 32 weeks and weighing less than 1500g will develop BPD; the younger the infant, the
higher the risk [Frey and Klebanoff, 2016; Farstad et al., 2011; Stoll et al., 2010].
BPD was first described in the late 1960s as a neonatal lung injury caused by mechanical
ventilation [Northway et al., 1967]. In the 1990s, improvements in ventilation technique,
antenatal steroid therapy and the introduction of surfactant allowed more immature infants
below 32 weeks GA to survive, which led to a change in the overall pathology of the disease
[Jobe and Bancalari, 2001].
The current, so-called “new” BPD is characterized by impaired alveolarization and dis-
rupted vascular development of the very immature, typically less than 32 weeks GA old lung
– as opposed to the “old” BPD of the pre-surfactant era, hallmarked by bold fibrotic changes
due to mechanical and oxidative lung injury [Jobe and Bancalari, 2001; Jobe, 1999]. Table 1
gives a brief overview over the histopathological features and differences of the “old” BPD of
the pre-surfactant aera as opposed to the “new” BPD. However, neither type of BPD does
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exclude the other; old and new forms represent the maxima of a disease continuum influenced
by the developmental and ventilatory inhomogeneity of the immature lung. Radiographic and
histopathological features of the “old” BPD can also be found in infants with “new” BPD and
vice versa [Coalson, 2006].
The key clinical feature of BPD is the failure of the infant’s lung to adequately oxygenize
the blood at room air oxygen levels. The current NIH diagnostic criteria for BPD (Table 2)
as set by the National Institute of Child Health and Human Development, the National Heart,
Lung and Blood Institute and the Office of Rare Diseases [Jobe and Bancalari, 2001] therefore
focus on the duration and extend of supplemental oxygen need to define and stage the disease.
Pathological feature "old" BPD "new" BPD
Spatial distribution diffuse disease with simultaneous more homogeneous disease
atelectasis and hyperinflation pattern throughout lung
Airway epithelial severe hyperplasia with signs of rare signs of epithelial
lesions epithelial metaplasia lesions
Airway smooth muscles pronounced hyperplasia mild hyperplasia
Vascular pathology hypertensive remodeling of in par- reduced numbers of arteries
ticluar smaller pulmonary arteries “dysmorphic” apperance
Fibroproliferation ubiquitous; extensive and diffuse rare fibroproliferation
Alveolar pathology alveolarisation reduced, overall fewer, larger and simplified
alveolar surface area ↓ alveoli
Table 1. Histopathological features of “old” and “new” bronchopulmonary dysplasia.
Modified from [Kinsella:2006aa].
Besides short- and mid-term consequences like higher hospital admittance rates of BPD-
survivors due to pulmonary infections like respiratory syncytial virus (RSV)-caused bronchi-
olitis [Greenough et al., 2001], the impaired lung growth – especially the disruption in alveolar
and vascular development seen in “new” BPD – leads to persistent impairment of pulmonary
function. Specifically obstructive ventilation disorders [Islam et al., 2015] and pulmonary em-
physema [Wong et al., 2008; Baraldi and Filippone, 2007] are common in BPD-survivors and
compromise further development of the child.
Due to the combined vascular and alveolar pathogenesis of BPD, the clinical course of
the disease can also be complicated by pulmonary hypertension [Mourani et al., 2015], with
all of its adverse outcomes [Mourani and Abman, 2015; Baker and Alvira, 2014]. Severe
BPD is moreover an independent risk factor of adverse neurodevelopmental and psychosocial
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outcome, causing lifelong affliction of the patient and thus creating a large socioeconomic
burden [Frey and Klebanoff, 2016].
Right now, treatment options for BPD are limited. Prevention of prematurity seems the
best rational therapy, as all current pharmacological and respiratory support approaches have
failed to significantly impact the severity or incidence of the disease in clinical trials [Iyengar
and Davis, 2015] or demonstrated adverse effects [Taha et al., 2014]. Moreover, initially
promising therapies such as vitamin A or caffeine failed to improve long-term outcome in
follow-up studies [Schmidt et al., 2012; Darlow and Graham, 2011; Ambalavanan et al., 2005],
despite of an initial reduction of BPD incidence and/or severity [Schmidt et al., 2006; Tyson
et al., 1999].
< 32wk GA > 32wk GA
Time point of assessment 36wk PMA or discharge*
> DOL28, but < DOL56
or discharge*
O2 treatment FiO2 > 0.21 for ≥ 28d FiO2 > 0.21 for ≥ 28d
criteria above plus criteria above plus
⇓ ⇓
Mild BPD
no need for supplemental no need for supplemental
oxygen at 36wk PMA oxygen at DOL56
or discharge* or discharge*
Moderate BPD
need for FiO2 < 0.3 at need for FiO2 < 0.3 at
36wk PMA or time point DOL56 or time point
of discharge* of discharge*
Severe BPD
need for FiO2 > 0.3 with need for FiO2 > 0.3 with
or without CPAP or PPV or without CPAP or PPV
at 36wk PMA or discharge* at DOL56 or discharge*
Table 2. Diagnostic criteria for BPD. GA - gestational age, PMA - postmenstrual age, DOL -
day of life, CPAP - continuous positive airway pressure, PPV - positive pressure ventilation. Asterisk
* - whichever time point comes first. One day with supplemental oxygen is defined as FiO2 > 0.21
for > 12h/d. Modified from [Jobe and Bancalari, 2001].
The “new” BPD can be considered as a multifactorial disease of the immature newborn
exposed to extrauterine conditions it is not prepared for at this stage of development (“ex-
trauterine fetus”). Indeed, when a baby is delivered preterm, the immature lung – which
matures in deeply hypoxic conditions in utero – is suddenly exposed to oxygen levels exceed-
ing the levels in the amniotic fluid by at least five times [Sjostedt et al., 1958]. Maternal
factors, ventilation, infection, inflammation and oxidative stress; malnutrition, genetic and
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epigenetic factors then add on top of this first hit of being prematurely born and contribute
to BPD pathogenesis [Silva et al., 2015; Baker and Abman, 2015].
However, BPD is not caused by only a single molecule or pathway - the complete patho-
physiology of the disease is far from being understood. Animal models of disrupted pre-
and postnatal lung development mimicking features of BPD are extensively used to elucidate
the pathways leading to the disease; however, the nature of these models allow only limited
extrapolation to the actual human pathology [Jobe, 2015; Hilgendorff et al., 2014; Yoder
and Coalson, 2014]. But as the main pathophysiological feature of BPD is the failure of the
immature lung to thrive, a dysfunction of the endogenous facilitators of growth and differ-
entiation – stem- and progenitor cells – is a highly plausible contributor to the development
of BPD [Möbius and Rüdiger, 2016]. Indeed, dysfunction of various stem- or progenitor cell
types has been described (reviewed by [Möbius and Thébaud, 2017]).
Cell-based therapies represent a completely new therapeutic approach for BPD. Being part
drug, part device, stem cells are thought to sense, integrate and respond to the surroundings
they are delivered to and dispense bioactive factors appropriate to the current disease state
of the preterm lung, making the therapy eventually “personalized” [Fischbach et al., 2013].
Numerous preclinical trials (see Table 4) have shown efficacy and efficiency of a cell-based
BPD treatment, demonstrating prevention and rescue in animal models of the disease. First
phase I [Chang et al., 2014b] and phase II clinical tials (NCT01828957) have also been initiated.
However, the mechanisms of exogenous cell product’s actions are not well understood [Prockop
et al., 2014] and subject of further research [Möbius and Thébaud, 2015].
The original research presented within here provides evidence for a contribution of the
human endogenous stem- or progenitor cells from the actual lung mesenchyme to normal lung
growth as well as to the development of BPD and identifies these cells as potential target
for a goal-directed BPD therapy. Moreover, in vitro evidence for a partial restoration of the
impaired endogenous cell function by exogenous stem- or progenitor cells is presented. Novel
methods – including the isolation of MSC from human fetal lung tissue and the generation
of long-term conditioned media as alternative to the traditionally used, concentrated 24h-
conditioned medium – are described.
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2. Background and Rationale
2.1 Stem- and progenitor cells: facilitators of growth, develop-
ment and regeneration
Stem- or progenitor cells reside in virtually all tissues at all stages of development. They
are generally defined by the ability to (I) undergo self-renewal and (II) give rise to more
differentiated cells. The extent to which these cells can differentiate is called potency. Stem
cells harbor the potential to differentiate into placental and embryonic tissue (totipotent stem
cells of the morula stage) and along the various embryonic germ layers (pluripotent, embryonic
stem cells). They further give raise to several adult cell types (multipotent, e.g. hematopoietic
stem cells). Conversely, (non-hematopoietic) progenitor cells are thought to provoke only one
specific adult cell type (unipotent, e.g. type 2 alveolar epithelial cells).
Toti-, pluri- and multipotent stem cells enable early development of the embryonal struc-
tures and subsequent organ differentiation until the beginning of the fetal period approxi-
mately 8 weeks post conceptionem. After this period, derivates of these cells can be found as
somatic (i.e. non-germ line committed) resident stem- or progenitor cells in virtually all fetal
and adult tissues deriving from all three germ layers, including the bone marrow [Till and
McCulloch, 1961], gut [Stoffels et al., 1979], brain [Temple, 1989] and lung [Barkauskas et al.,
2013; Wansleeben et al., 2013; Hennrick et al., 2007; Lama et al., 2007; in ’t Anker et al.,
2003b; Akeson et al., 2000; Evans et al., 1973; Kapanci et al., 1969].
The major task of somatic stem- and progenitor cells is the facilitation of growth and
tissue maintenance. They provide new, differentiated cells to the organ after cell loss due to
normal usage or injury while remaining in a proliferative, lesser differentiated state on their
own. This process is called self-renewal by asymmetric division. In vitro, this genuine feature
of stem- or progenitor cells can be investigated by assessing colony forming efficacy of single
cell suspensions (see 3.6.2).
Not every organ has the same capabilities to regenerate or repair itself; resident stem- and
progenitor cells proliferate to various extends. Some tissues – such as the gut or bone marrow
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– contain stem cells with high proliferative and regenerative capacity, while others – such as
the brain and the heart – grow until adulthood, but have only limited regenerative potential
once damaged [Kotton and Morrisey, 2014].
Cell type Examples Differentiation potential
Totipotent stem cell Cells of the zygote and All embryonic and extraembryonic
morula tissues (embryo- and trophoblast)
Pluripotent stem cell Inner cell mass / blastula All embryonic tissues
Multipotent stem cell Entodermal cells of the All cells of a specific lineage or family
(embryonic) foregut e.g. liver parenchyme, lung epithelium
Multipotent stem cell Mesenchymal stem- or Multiple cells of a specific lineage, e.g.
(adult) stromal cell (MSC) chondro-, adipo- and osteocytes
Unipotent stem cell Type 2 alveolar epithelial One specific cell type (e.g. AEC 1)
(adult) cell (AEC 2) self-renewal of stem cell
Unipotent progenitor Most differentiated lung One specific cell type; no or only
cell (adult) epithelial cells limited self-renewal of progenitor cell
Table 3. Terminology and respective potency of non-hematopoietic stem cells with spe-
cial regard to the lung. The term adult stem cells refers to all non-embryonic stem cells, e.g.
cells found after 8 weeks post conceptionem. The distinction between unipotent (lung) stem cells
and unipotent (lung) progenitor cells remains blurred and subject of further research, especially as
some unipotent cells can become multipotent in response to an injury. Conversely, so-called obligate
unipotent progenitors completely loose their proliferation-, self-renewal-, and differentiation potential
once committed. Table adapted from [Möbius and Thébaud, 2017].
Mesenchymal stem- or stromal cells are spindle-shaped (Figure 3, A), plastic adherent
cells residing in connective tissues of virtually all organs. First described in hematopoietic
tissues by [Friedenstein et al., 1970], MSC have been identified in adult organs deriving from
the mesodermal germ layer, including the bone marrow and adipose tissue. Furthermore,
they can be found in fetal-restricted mesodermal derivates like the umbilical cord stroma
[Sarugaser et al., 2005; Wang et al., 2004] and cord blood [Erices et al., 2000] as well as in
the placenta [In ’t Anker et al., 2004] and the amniotic fluid [De Coppi et al., 2007] and
membranes [Marongiu et al., 2010]. Interestingly, MSC have also been identified in tissues
deriving from the (ectodermal) neural crest – such as the mandibula [Yamaza et al., 2011]
– suggesting a origin of this cell type from more than one germ layer or complex migration
patterns during development.
As implied by their multiple residence tissues, MSC represent a very heterogeneous cell
population [Wuchter et al., 2015; Prockop, 2009; Dominici et al., 2006]. MSC from one
source exert different properties than MSC from another [Mendicino et al., 2014; Hass et al.,
6
Stem- and progenitor cells: facilitators of growth, development and regeneration
2011]. Some cells within the MSC population are “true” stem cells with the potential to
undergo complete self-renewal and some are not. Therefore, the global population of MSC
should be identified as “mesenchymal stromal cells” rather than “mesenchymal stem cells”
[Keating, 2012]. In here, according to the latest version of the NLM-MeSH (National Library
of Medicine - Medical Subject Heading database), the term “mesenchymal stromal cell” or the
respective abbreviation “MSC” is used to refer to these cells (MeSH ID D059630, tree numbers
A11.329.830.500 & A11.872.590.500).
The minimal criteria to define a MSC set by the ISCT - International Society for Cellular
Therapy [Dominici et al., 2006] are widely accepted, but relatively loose and include the
following four:
• The ability of the cell to adhere and grow on plain, uncoated, tissue culture treated
plastic surfaces – e.g. the ability to secrete large amounts of extracellular matrix.
• The presence of CD73, CD90 (thymocyte antigen Thy-1 ) and CD105 (Endoglin 1 ) on
the cell’s surface.
• The absence of the surface markers CD34, CD45, CD14/CD11b, CD19/CD79α and
HLA-DR, which label various cell lines from the hematopoetic lineage.
• The ability of the cells to differentiate along adipogenic, osteogenic and chondrogenic
lineages when stimulated in vitro.
These criteria were initially created to define MSC derived from the bone marrow, where
they need to be distinguished from the hematopoietic stem- and progenitor cells giving rise to
the blood cell lines. But as mentioned previously, MSC can also be found in other organs and
tissues where they need to be distinguished from mature fibroblasts, epithelial- and endothelial
cells as well as other (non-hematopoetic) organ-speific cell types.
Especially fibroblasts are hard to distinguish from MSC as some fibroblast populations
can also meet all ISCT criteria. Moreover, some MSC can be differentiated along epithelial
[Sueblinvong et al., 2008; Spees et al., 2003], endothelial [Janeczek Portalska et al., 2012;
Yue et al., 2008; Oswald et al., 2004] and even neural lineages [Ferroni et al., 2013] while
lacking the ability to differentiate along certain other, i.e. chondrogenic lineages [Keating,
2012]. Therefore, several additional surface markers including CD10, CD29, CD106, CD146,
CD166 or CD200 [Mendicino et al., 2014], GD2 [Martinez et al., 2007] and CD271 [Jones
et al., 2002] as well as gene-expression based characterization approaches are currently being
discussed [Galipeau et al., 2016].
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2.2 Normal and impaired lung development – the mesenchymal
cell’s point of view
2.2.1 Normal lung development and alveolarization
The lung is a complex organ deriving from the endodermal (→ epithelium) and mesodermal
(→ mesenchyme, endothelium) germ line [Morrisey and Hogan, 2010]. It harbors over 40
different cell types [Crapo et al., 1982; Sorokin, 1970]. Numerous of them exert more or less
characteristics of stem- or progenitor cells, each with specific characteristics and (proposed)
roles in lung development and regeneration [Kotton and Morrisey, 2014; Hogan et al., 2014;
Wansleeben et al., 2013; Morrisey and Hogan, 2010]. However, unlike stem- and progenitor
cells from the epithelial lineage – which have extensively been investigated over the past
decades – lung-resident mesodermal derived precursors are only poorly understood [Kotton
and Morrisey, 2014].
Early normal lung development depends on the separation of the (endodermal) foregut into
trachea and esophagus, followed by the start of a dichotomous airway branching process. At
the tips of the so-originated conducting airways, epithelial buds form (pseudoglandular stage),
which subsequently narrow (canalicular stage) and septate into sacs, the alveolar precursors
(saccular stage). Afterwards, remodeling and thinning of the mesenchymal compartment
results in a convergence of capillaries and lung epithelium and triggers septation of the sacs
into mature alveoli (alveolar stage). This immensely increases the alveolar surface area of the
lung and facilitates gas exchange between blood and air. In humans, alveolarization starts at
approx. 32 weeks of gestation and continues until the 5th year of life [Baker and Alvira, 2014;
Morrisey and Hogan, 2010]. Birth before the beginning of the alveolar stage often results in
disrupted lung maturation, leaving the organ hypo-alveolarized with a dystrophic vasculature
– the pathoanatomical hallmarks of the new BPD [Niedermaier and Hilgendorff, 2015; Jobe,
1999].
During the whole lung developmental process, close crosstalk between endothelial, epithe-
lial and mesenchymal cells enables coordinated growth of the respective compartments [Kotton
and Morrisey, 2014; Morrisey and Hogan, 2010]. This “crosstalk” is mainly facilitated by the
Wnt/β-catenin pathway [Ota et al., 2016; Volckaert and De Langhe, 2015], which is thought
to integrate the signals from the other central lung development pathways – such as the retino-
lic acid pathway, FGF-pathway and BMP-pathway [Valenta et al., 2012]. Out of the many
molecules triggering these pathways, mesenchyme-derived FGF10 is of outstanding interest
as it induces VEGF-production in the developing epithelium [Scott et al., 2010]. VEGF itself
then plays a pivotal role in lung alveolar and vascular growth [Thébaud et al., 2005].
Besides that, lung cell growth and -differentiation is critically regulated by a network of
transcription factors, including GATA6, TTF1/NKX2-1, and various members of the fork-
head box (FOX) - transcription factor family [Lam et al., 2013; Morrisey and Hogan, 2010].
The genuine role of FOX - proteins in development is the final integration of various stem cell
signaling pathways, thus leading to repression or induction of gene transcription [Lam et al.,
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2013]. Especially the FOXP-family (P1/P2/P4) is critically involved in both, early lung mor-
phogenesis and subsequent lung maturation [Shu et al., 2001]. In fetal lung tissue, FOXP1 and
FOXP4 regulate epithelial differentiation while being expressed in mesenchymal and epithelial
cells of mid- and late-stage mouse embryo lungs, whereas FOXP2 is thought to be restricted to
epithelial cells [Morrisey and Hogan, 2010; Shu et al., 2001]. Notably, loss of FOXP1 and/or
FOXP2 [Shu et al., 2007] as well as FOXP1 and FOXP4 [Li et al., 2012] results in fatal defects
of postnatal alveologenesis and alveolar regeneration upon injury. Interestingly, FOXD1 – an-
other forkhead box protein transcription factor – labels postnatal mesenchymal progenitor
cells that progenitors become reactivated and give raise to pro-fibrotic lung fibroblasts upon
lung injury [Hung et al., 2013].
The lung’s mesenchyme – consisting of a variety of mesenchymal cell types, including
numerous fibroblast types and MSC plus their secreted extracellular matrix (ECM) – arises
from the ventral anterior foregut mesoderm at very early stages of lung development. All
components of the mesenchymal lung compartment crucially drive and modulate organ growth
and maturation during the whole embryonal and fetal period [Mižíková and Morty, 2015;
Niedermaier and Hilgendorff, 2015; Chao et al., 2015; Baker and Alvira, 2014; Kotton and
Morrisey, 2014; Morrisey and Hogan, 2010]. Within this developing lung mesenchyme, lung-
MSC (L-MSC) represent a diverse population of organ-resident mesenchymal progenitors.
L-MSC are thought to act as precursors for a varitey of lung fibroblasts, including alveolar
myofibroblasts and lipofibroblasts [Collins and Thébaud, 2014].
The role of the actual L-MSC in early lung development has been investigated by geneti-
cally labeling individual cells in the mouse lung. Kumar and colleagues described a diversity
of stem-/ progenitor cell populations within the mesenchyme utilizing a multicolor clonal
analysis approach. Each MSC population exerted distinct lineage and migration boundaries
and contributed to the formation of stalk mesenchyme, mesothelium and smooth muscle sur-
rounding the developing airways or pulmonary vasculature. Moreover, labeled progenitors
of airway smooth muscle cells orchestrated lung morphogenesis by inducing differentiation
of stalk mesenchymal cells into airway smooth muscle cells during epithelial budding and
branching morphogenesis. Epithelial signaling alone was unable to induce this essential pro-
cess [Kumar et al., 2014], thus suggesting that L-MSC do not only act as progenitors of mature
mesenchymal cells but also as “control center” of lung development by coordinating the fate
of other cell types.
Another way of investigating the L-MSC’s contribution to lung development is sorting
mouse whole lung cells for high expression of stem cell antigen 1 / lymphocyte antigen
6A-2/6E-1 (SCA-1) and absence of CD326 (EpCAM), CD45 and CD31 [McQualter and
Bertoncello, 2012; McQualter et al., 2009]. This leads to a population of cells that repre-
sent (postnatal) progenitors of adult lung fibroblast populations, which are virtually absent
in neonatal and fetal mouse lungs [McQualter et al., 2009]. So obtained MSC directly promote
survival and proliferation of lung epithelial stem/progenitor cells [McQualter et al., 2010], fur-
ther indicating a crucial role in regulation of lung development. However, due to the general
absence of SCA-1 on species other than mouse, studies in other animal models of normal and
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disrupted lung development or even investigations in human tissues have always been influ-
enced by the fact that lung MSC and lung fibroblasts share almost the same surface marker
profile. In rats, this problem has been overcome by sorting CD73pos / CD90pos / CD105pos
mesenchymal cells for high expression of cell surface glycoprotein MUC18 (CD146) [Collins
et al., 2016]. In humans, no marker has been described in the literature to distinguish lung
fibroblasts form lung MSC.
The direct descendants of L-MSC are also critically involved in normal lung develop-
ment. Especially alveolar myofibroblasts, along with the mesenchymal cell products elastin,
fibroblast growth factors 9 and 10 (FGF9, FGF10), Wnt and platelet-derived growth factor
alpha (PDGFα) drive normal lung development by enabling both, early epithelial budding
and subsequent alveologenesis by formation of secondary septa [Mižíková and Morty, 2015;
Chao et al., 2015; Morrisey and Hogan, 2010]. Lung-resident lipofibroblasts have been shown
to be involved in early surfactant production by transferring triglycerides (TG) to AEC 2.
The epithelial cell triggers this reaction by secretion of prostaglandin E2 and parathyroid
hormone-related protein (Pthr-p). AEC 2 further metabolize the received TG – additionally
stimulated by lipofibroblast-derived leptin – to surfactant (reviewed by [Collins and Thébaud,
2014] and [El Agha and Bellusci, 2014]). Moreover, co-culture of AEC 2 and adult lipofi-
broblasts leads to the formation of small alveolar-like structures (alveolospheres) in vitro,
indicating the vital role of mesenchymal-epithelial crosstalk in postnatal lung development
and regeneration [Barkauskas et al., 2013]. Lipofibroblasts further store and secrete retinolic
acids, important mediators of alveolar septation and lung development [El Agha and Bellusci,
2014].
2.2.2 Impaired lung development
Dysfunction of the endogenous L-MSC has been shown to contribute to lung hypoplasia fol-
lowing congenital diaphragmatic hernia [Jay et al., 2007], bleomycin-induced lung fibrosis [Jun
et al., 2011] and bronchiolitis obliterans syndrome in adult patients following lung transplan-
tation [Walker et al., 2012]. Evidence for a contribution of the resident lung mesenchymal
cells to disrupted lung development in BPD arises from studies analyzing MSC derived from
the tracheal aspirate (TA) of newborns [Bozyk et al., 2011; Hennrick et al., 2007] and pre-
mature infants. Hershendson et al. demonstrated that presence of MSC in TA predicts later
development of BPD [Popova et al., 2010a]. Moreover, these MSC demonstrated functional
impairment and disrupted myofibroblastic differentiation via aberrant platelet-derived growth
factor (PDGF)- receptor-α [Popova et al., 2014] and TGF-β1 / glycogen synthase kinase-3β
/ β-catenin– signaling [Popova et al., 2012] in vitro. Disruptions in these pathways have been
described to lead to interstitial fibrosis and reduced formation of secondary septa, consistent
with the histopathological presentation of BPD [Popova et al., 2014]. However, the relation-
ship between the MSC present in the tracheal aspirate and the tissue-resident L-MSC is not
clear and subject of further research.
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As the lung matures in a hypoxic environment in utero, postnatal (relative) hyperoxia
represents a potent stressors to the immature lung and leading cause of BPD [Niedermaier
and Hilgendorff, 2015]. Hyperoxia triggers inflammatory processes in the lung which results
in aberrant mesenchymal signaling, especially along the FGF10 pathway [Chao et al., 2015].
Moreover, disrupted mesenchymal PDGF α / PDGFR-α signaling was observed in neonatal
rodent lungs subjected to 75% O2 [Popova et al., 2014]. Distortions in both pathways are
known to lead to disrupted alveolar development.
It has further been shown that the – presumably MSC and fibroblast generated – extra-
cellular matrix (ECM) plays a crucial role in BPD pathogenesis [Mižíková and Morty, 2015].
Dysbalances, structural abnormalities and disrupted deposition patterns of ECM components
have been described in BPD [Niedermaier and Hilgendorff, 2015; Chao et al., 2015]. For ex-
ample, quantitative impairment of lung elastin, i.e. in Eln−/− mice leads to a complete arrest
of terminal airway formation [Wendel et al., 2000]. Thickened, disorganized and generally
disrupted collagen deposition has been described in the lungs of preterm infants at high risk
for BPD dying while being ventilated [Thibeault et al., 2003].
2.2.3 Cell therapy for impaired lung development
Further evidence for a role of MSC in BPD arises from the observation that exogenous MSC
prevent and cure the pathoanatomical hallmarks of the disease - at least in animal models
mimicking BPD [O’Reilly and Thébaud, 2014; Berger and Bhandari, 2014; Hilgendorff et al.,
2014]. Intraveneous, intraperitoneal and intratracheal administration of whole cells or cell-
free concentrated tissue culture supernatants (“conditioned medium” or CdM) containing the
MSC’s secreted factors have been shown to demonstrate beneficial effects in vivo. Table 4
briefly summarizes the current literature on the usage of MSC or MSC-CdM in models of
BPD. All reports described consistent preventive effects in models of BPD. Moreover, MSC
and their CdM have also been shown to restore established oxygen induced lung injury [Pierro
et al., 2013].
The effects of treatment persisted until adulthood; rats receiving MSC before [Pierro et al.,
2013], during [Sutsko et al., 2013], or after exposure [Pierro et al., 2013] to hyperoxia show
persistent improvements in lung architecture, exercise capacity and vascularization in long-
term follow-up studies up to 6 months. Engraftment of MSC is surprisingly low in all of these
studies, indicating a mainly paracrine action rather than an integration and differentiation into
lung cells. This is further supported by the effective usage of cell-free CdM and intraperitoneal
administration routes – which mainly assume a paracrine mechanism of the injected cells.
However, some authors described that treatment with CdM fails to cause long-term effects
comparable to whole cell therapy [Sutsko et al., 2013], whereas short-term effects of CdM
are equal or even superior [Aslam et al., 2009] to an administration of whole cells (reviewed
by [Fung and Thébaud, 2014]). A direct interaction of the exogenous MSC with the damaged







Author Model Design Therapy Dose/kg Route Outcome vs. Control
[Sammour et al., 2016] rat O2 (P2-P21) prevention ♂ or ♀ 66.6 x 106 i.t. P21: vascular density, alveolarization ↑, pulmonary hypertension ↓
roBM-MSC in both groups, vascular effects ♀ donor cells > ♂ donor cells
[Luan et al., 2016] mouse O2 (P1-P14) prevention roBM-MSC P2: 500 x 106 i.v. P21: fibrosis, radial alveolar count ↑, reduced epithelial to mesen-
± EPO P7: 100 x 106 chymal transition; effects MSC < MSC + EPO
[Luan et al., 2015] mouse O2 (P1-P14) prevention roBM-MSC 1000 x 106 i.v. P28: weight ↑, pulmonary VEGF ↑, lung structure ↑
[Liu et al., 2014] SCID mouse O2 prevention hUC-MSC 10 x 106 i.t. P60: improved lung structure, lung function ↑ with high dose i.p.
(P1-P7) 50 x 106 or treatment; no therapeutic effects of intranasal application or
100 x 106 i.n. low-dose i.p. treatment
[Chang et al., 2014a] rat O2 (P1-P14) prevention hUCB-MSC 10 x 106 i.t. P14: lung structure & alveolarization ↑, angiogenesis ↑ with
± VEGF-KO wt-MSC; no therapeutic effects of VEGF-KO MSC
[Pierro et al., 2013] rat O2 (P1-P14) prevention hUCB-MSC 40 x 106 i.t. P22/P35/6 months: prevention and rescue of impaired alveolar
rescue 20 x 106 growth with CdM and whole cells, pulmonary hypertension ↓,
prevention MSC-CdM 7ml/d P4-P21 i.p. vascular remodeling ↓, exercise capacity ↑, overall effects
rescue 7ml/d P14-P28 of [CdM in prevention/rescue] ≈ [cells in prevention/rescue]
[Chang et al., 2013] rat O2 (P1-P14) prevention 100 x 106 P21: inflammation ↓, alveolar growth ↑ in animals treated either
rescue roBM-MSC 25 x 106 i.t. preventive or preventive+rescue, no synergies of combined admin-
combined 125 x 106 istration, effects [prevention] ≈ [prevention+rescue] > [rescue]
[Sutsko et al., 2013] rat O2 (P2-P16) prevention roBM-MSC 100 x 106 i.t. P16, P30, P100: alveolarization & vascularization ↑, inflamma-
MSC-CdM 2.5ml tion ↓, effects at P100: [cellular therapy] > [CdM therapy]
[Hansmann et al., 2012] mouse O2 (P1-P14) rescue MSC-CdM 1mg protein i.v. P28/P42: lung function ↑, pulmonary hypertension ↓ fibrosis ↓
[Waszak et al., 2012] rat O2 (P1-P14) combined roBM-MSC- 1ml/d i.p. P21: alveolarization ↑, pulmonary hypertension ↓ when CdM
CdM ± O2 P1-P21 from hyperoxia-treated MSC was used
[Zhang et al., 2012b] mouse O2 (P1-P45) prevention roBM-MSC 5 x (1 x 106) i.p. P45: survival ↑, fibrosis ↓ alveolarization ↑
[Zhang et al., 2012a] rat O2 (P3-P10) rescue roBM-MSC 5 x 106. i.v. P14, P18, P25: weight ↑, lung inflammation ↓ alveolarization ↑
[Tropea et al., 2012] mouse O2 (P1-P14) prevention roBM-MSC 5 x 106 i.v. P14: pulmonary hypertension ↓, alveolarization ↑, inflammation ↓
MSC-CdM 6.6 ml in both groups, number of BASC ↑
[Chang et al., 2009] rat O2 (P1-P14) prevention hUCB-MSC 50 x 106 i.t. P14: inflammatory cytokines ↓, alveolarization ↑, inflammation ↓
200 x 106 i.p. all therapeutic effects [i.t.] > [i.p.]
[Aslam et al., 2009] mouse O2 (P1-P14) prevention roBM-MSC 25 x 106 i.v. P14: pulmonary hypertension ↓, alveolarization ↑, inflammation ↓
MSC-CdM 5ml alveolarization [CdM] > [whole cells]
[van Haaften et al., 2009] rat O2 (P1-P14) prevention roBM-MSC 13 x 106 i.v. P21: survival ↑, alveolarization ↑, execise capacity ↑
rescue 3 x106 P45: effects [prevention] > [rescue]
[Tian et al., 2007] rat O2 (P3-P10) n.a. roBM-MSC n.a. i.v. P14: radial alveolar count ↑, TNFα and TGFβ1 ↓
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← Table 4. Studies investigating MSC or MSC-derived products in experimental BPD.
ro – rodent-derived cells, h – human-derived cells, BM – bone marrow, UCB – umbilical cord blood,
UC – umbilical cord tissue KO – knock-out, SCID – severe combined immunodeficiency, EPO –
erythropoietin. Timepoints specified as either PX – postnatal day or dX – day of gestation. Doses/kg
calculated on base of the animal weights given in the respective papers or the following assumptions:
7.5g per P4, 10g per P5, 15g per P8, 20g per P10, 30g per P14 rat pup [Kromkhun et al., 2013];
1g per P1, 2g per P4, 5g per P7, 7.5g per P10, 10g per P14, 15g per P21 and 20g per P45 mouse
pup [Donahue, 2015].
This may be explained by the observation that MSC exert their beneficial effect via
two pathways: paracrine effects – the secretion of anti-inflammatory and lung-protecting
cytokines – and cellular effects mediated through direct cell-cell interaction. The inflam-
mation-modulating effect in the lung is mainly caused by secretion of various directly anti-
inflammatory interleukins and other cytokines [Fontaine et al., 2016] as well as via indirect
pathways involving prostaglandin E2 (PGE2) [Nemeth et al., 2009] and TNFα-stimulated
protein/gene 6 (TSG-6) [Wang et al., 2012]. PGE2 stimulates the systemic secretion of the
potent anti-inflammatory IL-10 by resident lung macrophages; the effects of TSG-6 are more
complex and include the modification of extracellular matrix (ECM) molecules and inhibition
of leukocyte migration (reviewed by [Prockop, 2013]).
The lung-protecting, paracrine effects of MSC include the secretion of stanniocalcin-1
(STC-1) [Waszak et al., 2012]. This molecule modulates the mitochondrial metabolism of lung
cells [Ohkouchi et al., 2012] to increase their resistance to reactive oxygen species, thereby
protecting them from oxidative damage and apoptosis. Moreover, MSC secrete exosomes,
small microvesicles containing nucleic acids, proteins and lipids [Colombo et al., 2014]. Puri-
fied exosomes have been shown to ameliorate pulmonary hypertension [Lee et al., 2012] and
endotoxin-induced lung injury [Zhu et al., 2014] in animal models. Interestingly, a specific
nucleic acid in exosomes – so called microRNA – is capable of transposing into the nucleus of
the target cell and modulating gene expression [Pegtel et al., 2010]. This leads to modulations
of lung growth mechanisms [Dong et al., 2012b] and may represent a potent mechanism of
MSC’s action in BPD [Sdrimas and Kourembanas, 2014].
The direct, cell-cell contact-mediated effects of MSC in the lung are less clear. In a model
of acute lung injury, MSC have been shown to transfer mitochondria towards the damaged
epithelial cells, thereby restoring the impaired ATP-metabolism [Islam et al., 2012]. The
influence of this process in the therapy of BPD is unclear and currently under investigation.
However, direct cell-cell contact between MSC and lung cells is required to trigger several anti-
inflammatory pathways. Most notably, the previously described PGE2 – IL10 mechanism
requires direct interaction between the MSC and lung macrophages in order to avoid the
systemic effects of PGE2 [Prockop, 2013].
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2.3 The isolation and culture of MSC
2.3.1 General concepts of MSC isolation and expansion
The isolation of MSC utilizes two characteristic features of these cells - their ability to form
colonies when not in direct contact with other MSC and their capability to produce vast
amounts of ECM, thereby being able to adhere to plain, uncoated, tissue culture- or vacuum
plasma-treated polystyrene surfaces. Both attributes have traditionally been used to isolate
MSC – first accurately termed “colony-forming fibroblasts” – from bone marrow samples
[Friedenstein et al., 1974]. Aspirates of the marrow were diluted in culture media and plated
onto cultureware, incubated, and checked for the emergence of colonies while rinsing away
non-adherent contaminants. Due to the low frequency of MSC in the starting material, each
of these so-obtained colonies is clonal-derived from a single BM-MSC. Once subcultured and
expanded, a more or less homogeneous cell population is achieved.
This method has been applied to a vast amount of human tissues and body fluid samples
[Hass et al., 2011], including the adult [Lama et al., 2007] and fetal [in ’t Anker et al., 2003b]
lung as well as tracheal aspirate [Popova et al., 2010b]. However, these methods always
require extensive expansion of the originally derived cells - to form a visible colony of approx.
1000 cells, the single cell has to undergo 10 population doublings (PD). If 50 colonies emerge
from one bone marrow aspirate, pooled together and expanded, every cell has to undergo
up to 20 population doublings until enough cells (approx. 20 million) can be harvested for
initial characterization and analysis. It has been shown that expansion over several passages
with > 20 - 25 PD alters the gene-expression profile, morphology and proliferation rate of
MSC [Wagner et al., 2010a]. Therefore, analysis of cells obtained by this method – regardless
their source – is always biased by the fact that even passage one cells are already senescent.
The easiest way to overcome this obstacle is to increase the number of MSC in the starting
material. This can either be done by harvesting larger volumes of starting material to yield
more colonies to start expansion with or by purifying the preperation of cells before placing
them into culture, thereby omitting the initial selection by colony formation. A more pure
MSC population can be expanded directly, and remaining minor amounts of contaminant cells
will either not adhere or become overgrown by MSC.
Due to the abundant expression of the individual surface markers labeling MSC on poten-
tially contaminating cells, a single antibody-based purification of the broad MSC population
– in analogy to e.g. the CD4 selection of T-helper lymphocytes – out of a crude starting
material like the bone marrow or a digested organ is not possible. However, small numbers of
specific subsets of MSC have successfully been isolated using this approach [Kuci et al., 2010].
Besides using antibodies and optical or magnetic methods to separate populations of cells, a
convenient way to achieve a basic separation is to fractionate a cell population by its density,
i.e. with the aid of density gradient centrifugation. This has long been done with 1.077 g/cm3
gradient media to separate erythrocytes and thrombocytes from white blood cells in whole
blood samples [Fuss et al., 2009]. Recently, a more selective, 1.073 g/cm3 density gradient for
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the purification of MSC from bone marrow aspirates has been developed, which depletes all
erythrocytes, hematopoietic precursors cells and the majority of mature leukocytes, leaving
monocytes and MSC in the interphase [Grisendi et al., 2010]. The latter method is applied
herein to isolate MSC from the umbilical cord tissue and the fetal lung.
2.3.2 Isolation and culture of MSC from human fetal lung tissue
MSC-like, CD90pos/CD105pos/CD166pos cells have first been isolated out of the CD34pos hu-
man, second-trimester fetal lung fraction by [Noort et al., 2002]. After mincing the tissue and
initial magnetic bead-based CD34-enrichment, cells resembling fibroblasts emerged in cul-
ture and differentiated along adipogenic and osteogenic lineages upon induction. They were
therefore termed lung mesenchymal stem cells. Later, the same group showed that unex-
panded, CD45neg/CD34pos fetal lung cells supported engraftment of hematopoietic stem cells
in immunocompromised mice [in ’t Anker et al., 2003a], indicating a regulatory and bioactive
function of these mesenchymal cells. Moreover, the closer characterization of so-derived and
expanded cells revealed that colonies with fibroblast-like cells emerged at higher frequencies
from minced lung tissue than from bone marrow, indicating a relatively high number of these
cells in the fetal lung [in ’t Anker et al., 2003b; Noort et al., 2002]. However, it should be
noted that this paper was published before the first MSC characterization guidelines were es-
tablished and it was proven that CD34 represents a negative marker for MSC [Dominici et al.,
2006]. Nevertheless, it has been described that CD34pos./CD90pos cells crucially contribute to
the postnatal endogenous lung fibroblast pool in mice, acting as a clonogenic progenitor cell
– although not being detectable before (term) birth of the animals [McQualter et al., 2009].
Another group then demonstrated that enzymatically (trypsin and collagenase IV in
EDTA-containing buffer) liberated fetal lung cells, plated and selected by their ability to
form colonies of fibroblast-shaped cells can differentiated along adipogenic, osteogenic, neural
and even germ-like lineages [Hua et al., 2009]. However, due to methodological inconsistencies
within the publication, it is not clear what cells (MSC or not?) have actually been isolated
and analyzed. For example, CD105 was absent on some isolated populations, present on
others; CD90 was totally absent on all isolated cells. Nevertheless, a robust differentiation
potential along adipogeneic and ostegeneic lineages was reported.
Lately, a paper by Rolandsson-Enes an colleagues [Rolandsson Enes et al., 2016] utilized
commercially available total fetal lung cells aged 16+0 to 17+5 weeks GA cultured in media
designed to support the expansion of BM-MSC. The so-expanded cells were fibroblast-shaped
and therefore termed MSC. Again, robust differentiation potential along adipogeneic and
osteogeneic lineages was demonstrated, along with > 95% positivity for mesenchymal markers
CD73 and CD90. However, investigated cells demonstrated only 68% CD105 expression,
thereby not meeting the characterization criteria for MSC [Dominici et al., 2006]. Comparing
the so-derived cells to BM-MSC, the authors described a significantly higher colony-forming
ability of the so-obtained cells.
In all reports described above, cells were cultured in atmospheres containing 21% oxygen.
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2.3.3 The role of oxygen in MSC culture
MSC are usually expanded in standard incubators maintaining atmospheres containing 5-10 %
CO2 without additional oxygen control (21 % O2 ≈ pO2 160 mmHg). But in vivo, MSC – like
most other stem and progenitor cells – reside in deep hypoxic niches [Mohyeldin et al., 2010].
This especially holds true for the non-vascularized Wharton’s jelly of the umbilical cord. The
partial pressures of oxygen in the umbilical cord stroma do not exceed 30 mmHg in the direct
umbilical vein periphery; pO2 in the remaining cord tissue are way below that value (< 15
mmHg). In the fetal lung, oxygen is provided to the resident lung cells from the amniotic
fluid and the pulmonary vasculature. The amniotic fluid the infant in- and exhales in utero
contains oxygen with a partial pressures comparable to an FiO2 of 0.04 [Sjostedt et al., 1958].
The pulmonary bloodflow is low due to an extensively constricted vasculature before the first
breath ex utero. Therefore, culture in deep hypoxia may represent the physiologic situation
of lung cells ante natally better than in vitro expansion in “normoxic” room air atmospheres.
The same holds true for the umbilical cord stroma cells.
Exposing therapeutic MSC to short periods of high oxygen levels has been described to
potentiate their effects - at least if the concentrated CdM of the cells was used as therapy,
and not the cells itself [Waszak et al., 2012]. Conversely, if the cells were kept in hypoxic
atmospheres, the effects of the whole cell therapeutic were superior to those of a whole cell-
preparation obtained from “normoxic” cultured cells [Cruz and Rocco, 2015; Lan et al., 2015],
thus indicating different mechanisms of action of CdM and whole cell therapy. It is thought,
that brief hyperoxia exposure leads to a secretion of danger-signal/stress-induced paracrine
factors by MSC in vitro, which can be harvested with the conditioned medium. At least some
of these factors then protect the lung tissue from hyperoxia damage. However, hyperoxia
impairs the therapeutic cells in the long run, thus blunting their function when given directly.
2.3.4 The generation of conditioned medium
Conditioned media is usually derived from subconfluent cultures of MSC. The culture medium
is rinsed away with PBS, and a dedicated amount of serum-free medium is added for 12-
24h. After that period, the supernatant is harvested and cellular particles removed by either
centrifugation [Waszak et al., 2012; Aslam et al., 2009] or filtration [van Haaften et al.,
2009]. In most studies investigating the therapeutic effects of CdM in BPD (Table 4), the
so-obtained CdM was subsequently concentrated by centrifugation over 3-10 kDa membranes
and administered.
However, this method is not suitable to analyze the actual secretion of cells. The cells are
stressed by the withdrawal of protein in the culture medium [Kojima and Kozuka, 1962] and
thereby secrete a “stress-proteome” rather than protein mix co-responding to the conditions
in vivo. Moreover, as the cells are not confluent, cell-cell interactions – which are abundant in
vivo and most likely influence the secretion of cells – have not been established. Eventually,
a standardization of the obtained results (e.g., analyte concentrations in the supernatant) is
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not validly possible when using short-term, serum-free CdM. As the culture is sub-confluent
and therefore proliferating prior to the start of CdM-preparation, a total cell count can not
simply been obtained. Moreover, a significant proportion of cells dies during the preparation
procedure due to serum starvation, making cell counting after the process impossible. It
is therefore not possible to conclude whether an increased level of a certain analyte in such
prepared CdM is caused by an actual cellular effect or by a slightly higher proliferative culture.
2.4 Hypothesis
In here, the hypothesis that human endogenous lung MSC contribute to normal and oxygen-
impaired lung development was tested. Given the previously discussed prerequisites, the
following five sub-hypotheses were developed and tested within the subsequently described
experimental settings:
1. High numbers of mesenchymal cells can be liberated and purified from the human fetal
lung tissue using an enzymatic digestion with subsequent density gradient purification.
2. The so-obtained cell population contains MSC.
3. These MSC support normal lung development when cultured in physiologic, hypoxic
conditions.
4. Exposure to hyperoxia impairs the function of these endogenous MSC.




Note that the preparation instructions for buffer and reagent solutions described herein are
given in the appendix, section A.2 - A.6. Values given in percent refer to volume percent
[vol/vol], unless otherwise stated. Mean refers to the arithmetic mean. The manufacturers
and/or suppliers of used reagents and materials are listed in the appendix, section A.1 in the
interest of a better text readability. Trademarks ( TM) and registered trademarks ( ®) are
indicated as such only upon their first appearance in the text.
3.1 General tissue culture regiemen
3.1.1 Culture media and culture surfaces
For all experiments described herein, HCO−3 -buffered culture media supplemented with fetal
bovine serum (FBS) as growth supplement was used. A fix combination of antibiotics (PSF
antibiotic / antimycotic) was added to all media to achieve final concentrations of 0.1 U/l
penicillin, 0.1µg/l streptomycin and 25 ng/l amphotericin-B, respectively. Cells were kept in
humidified incubators with 5% CO2 atmospheres to maintain media pH of 7.2 - 7.4. Oxygen
was controlled independently, based on the experimental conditions.
Mesenchymal cells were cultured in α-modified Minimum Essential Medium with Earl’s
salts, which was supplemented with 2 mmol/l L-glutamine and antibiotics. 20% FBS were
added, based on preliminary in-lab studies with other fetal cells. Within one set of ex-
periments, just one lot of FBS was used to eliminate the inherent inter-lot variability of
FBS [Karnieli et al., 2017]. The supplemented, ready-to-use medium is further referred to as
“αMEM”. Cells of other sources are cultured in the respective media described below. 0.2 ml
media per cm2 culture surface were used in all experiments, unless otherwise stated.
All cells were expanded on plain, uncoated, polystyrene surfaces treated with vacuum-
plasma by the manufacturer to facilitate cell attachment, unless otherwise stated. The stiffness
of culture surfaces and different plastic manufacturing processes are known to influence the
19
Methods
adherence and growth capacity of cells [Seib et al., 2009]; therefore, in experiments where
either cell adherence, cell proliferation, or colony formation was assessed as primary outcome,
a single batch of culture vessels from one manufacturer was used to minimize bias. For
routine cell expansion, filtercap-vented vessels ranging from 25 cm2 to 1000 cm2 (5 × 200 cm2)
culture surface were used. In case large quantities of cells were needed (e.g., for screening
surface molecules) non-vented, membrane-based culture vessels with 1720 cm2 culture surface
(CellBind® HYPERFlasksTM, 10 × 172 cm2) were utilized. Experiments were routinely
performed in open-vented culture vessels like petri dishes and multiwell-plates. For certain
imaging experiments, cells were grown on glass slides with tissue culture-treated surfaces or
glass coverslips coated with collagen as described in (A.2.2).
3.1.2 Expansion of cells, medium changes
After the first passage, cells were routinely seeded at 5000 cells per cm2 in 0.2 ml media
per cm2. First medium change was performed on the 3rd day after inoculation by replacing
the complete medium volume with fresh, pre-warmed medium. Cells were checked daily for
signs of contamination, overall morphology and levels of confluency (percent covered culture
surface) using an inverted microscope. Further medium changes were carried out as described
every 3rd day, until cells reached desired level of confluence.
3.1.3 Passage, counting of cells
Once spreading out to approx. 90% of the culture surface (“90% confluent”), cells were rinsed
three times with 0.25 ml per cm2 room-temperature PBS to remove trypsin-inactivating FBS.
Detachment of cells was facilitated using a gentle, pre-formulated solution of recombinant
trypsin and EDTA (TrypLETM Express) in accordance with the manufacturers instructions.
Following inactivation of potentially cytotoxic tryptic enzyme activity with 0.1 ml/cm2 culture
media, cells were pelleted at 500×g for 5min. The pellet was resuspended in a defined volume
of either culture medium or PBS, based on the intended subsequent cell use. An aliquot of
10 µl was drawn. To count cells optically and determine viability, the aliquot was mixed
1:1 with Trypan Blue to label dead cells. Using a modified Neubauer chamber, four large
squares representing 4 × 0.1µl were evaluated at 10 × 10 magnification. To electronically
count the cells, the aliquot was further diluted to a final volume of 100 µl and loaded into a
60 µm probe of a Scepter® Cell Counter as indicated in the device’s manual. Events > 12.5
µm were counted to exclude debris.
To re-plate cells, the resuspended cell pellet was further diluted to a concentration of
25000 cells/ml with pre-warmed medium and seeded in the appropriate culture vessels at
5000 cells in 0.2 ml media per cm2. This complete process was called a passage. Cells were
used up to passage three (P3) herein to minimize effects of cellular aging and senescence in
culture [Wagner et al., 2010b].
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3.1.4 Cryoconservation
If cells were not intended to be plated directly, the pellet obtained after harvesting and spin-
ning down the cells was resuspended in an in-house made dimethylsulphoxide (DMSO)-free
cryomedium stock solution (A.2.2). Cells were counted as described, the cell concentration
adjusted to 0.25 - 4 × 106 cells per ml using cryomedium stock solution and transferred to the
respective cryovials. DMSO was added up to a final concentration of 5% with gentle mixing
right before transferring the cells to -80°C to minimize the toxic effects of this cryoprotectant.
Cells were transferred to the vapor phase of a liquid nitrogen tank (-196°C) for long-term
storage (> 1 week).
When required, cryovials were quick-thawed in a 38°C water bath, resuspended in culture
media, spun down, and re-plated as described in 3.1.
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3.2 Isolation of mesenchymal cells from human fetal lung tissue
3.2.1 Development of the protocol
As outlined previously, outgrowth methods and antibody-facilitated enrichment of minced
lung tissue does not yield satisfying quantities and purities of fetal lung MSC. Therefore, a
new protocol was developed, based on an enzyme cocktail adapted to the extracellular matrix
of the immature lung to gently, but thoroughly liberate mesenchymal cells from the tissue in
order to ensure high cell yields.
The fetal lung connective tissue is relatively loose, and mainly constituted of fibrillar
collagen types I and III along with elastic fibers consisting of cross-linked elastin and fib-
rillin (reviewed in in [Mizikova:2015aa]). Therefore, a combination of collagenase I – an
enzyme mix derived from Clostridium histolyticum with collagenase, clostripain, caseinase
and trypric activity [Worthington and Worthington, 1993a] – and neutral protease, a Bacillus
polymyxa-derived, mild, non-specific metalloprotease [Worthington and Worthington, 1993b]
was employed. Despite being used and published in several papers [Barkauskas et al., 2013],
plain trypsin (pancreatin) was avoided due to known cytotoxicity and inefficacy to liberate
cells at non-cytotoxic concentrations [Worthington and Worthington, 1993c]. Due to the
long transport time of the tissue and therefore possible autolytic processes with liberation of
viscosity-enhancing free DNA, deoxyribonuclease I was added to the enzyme cocktail. Con-
centrations of enzymes were chosen based on published protocols for liberation of tumor or
epithelial cells from adult human and fetal rodent tissues [Santangelo, 2008], and adapted to
match the ECM composition of the fetal lung. Eventually, 250 U/ml collagenase I, 3 U/ml
neutral protease, and 50 U/ml deoxyribonuclease I were used. To facilitate optimal enzyme
activity while promoting cell survival, supplemented D-PBS (A.3.1) was chosen as diges-
tion medium. It provides the essential collagenase and neutral protease co-factors Ca2+ and
Mg2+ [Worthington and Worthington, 1993a; Worthington and Worthington, 1993b] as well
as glucose and pyruvate as substrates for liberated cell’s catabolic metabolism. Moreover,
digestion of the tissue can easily been stopped by chelating Ca2+ and Mg2+ with EDTA or
citrate, thus avoiding the usually employed cooling of the cell-suspension.
To separate mesenchymal cells from contaminants and increase the number of MSC prior
to adherence culture, a 1.073 g/cm3 Ficoll density gradient designed to deplete erythrocytes
and most white blood cells from bone marrow aspirates included into the protocol. Adherence
selection an culture of fetal cells was planned to take place in physiologic, hypoxic atmospheres
as outlined previously.
3.2.2 Collection of tissue
The herein described procedures were approved by the respective ethics committees at the
University of New Mexico, Albuquerque, New Mexico / United States of America and the
University of Alberta, Edmonton, Alberta / Canada under IRB approval # 15-573. Follow-
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ing informed consent, lung tissue from six aborted fetuses was obtained. The fetuses had
been aborted at gestational ages between 10+4 and 24+0 weeks, estimated by last ultrasound.
Refer to Table 8 for further information. Following dissection, the lung tissue was immedi-
ately placed in chilled lung transport solution. Tissue was de-identified by the pediatric and
pathology research staff at the University of New Mexico and shipped to the laboratory in
Edmonton on wet ice, where it arrived within 24 h.
It was not possible at any time to draw conclusions regarding the name, ethnicity or
age of the parents; nor the sex of the fetus or the method or reason for the abortion or
interruptio. However, tissue from one fetus (24+0 wk GA) arrived with the information
that digitoxin has been administered for undisclosed reasons. Results of the post mortem
pathological examinations at the University of Albuquerque were not disclosed in accordance
with the ethics protocol.
3.2.3 Isolation of lung mesenchymal cells
Upon arrival, the lungs were examined in a Class II biological safety cabinet. In case both
lungs were shipped, the optical less disrupted one was rinsed in PBS + 30% CPDA-1 to
remove debris and blood prior to fixing in 10% Zinc Formalin for subsequent embedding in
paraffin and Hematoxylin and Eosin-staining by the Alberta Diabetes Pathology Core. In
case only one lung was sent, a small part of the lower lobe (ca. 50-100 mm3) was dissected
and fixed as described above. Refer to Table 8 in the results section for further information.
The remaining lung piece was weighed, rinsed two times in PBS to remove remaining
citrate and placed in a 50 ml tube after another rinse with supplemented D-PBS. The tissue
was then minced using a sterile scalpel prior to adding the sterile filtered enzyme mix. After
60 minutes of incubation and gentle agitation at 38°C, lung tissue was completely digested.
EDTA was added up to a concentration of 3 mmol/l to stop the digestion. The cell suspension
was then diluted with an equal volume of PBS + 5% FBS and passed through a 100 µm mesh.
Cells were pelleted by centrifugation (5 min, 500×g, 4°C), rinsed two times with 40 ml PBS
+ 5% FBS, counted, and re-suspended in 4 ml PBS + 5% FBS at room temperature. The
cell solution was subsequently layered over a 1.073 g/cm3 Ficoll density gradient and spun
for 20 min at 900×g, 19°C. The centrifuge’s brake was disabled to avoid a disruption of the
interphase.
Cells from the interphase and the pellet were collected separately to check efficacy of
density-gradient separation. Cell fractions were rinsed two times in PBS and re-suspended
in αMEM (interphase) or F-12 Ham’s + 10% FBS and antibiotics (pellet). Interphase cells
were plated in plain, uncoated plastic surfaces to select mesenchymal cells, pellet cells in
vessels with collagen-coated surfaces to facilitate the adherence of epithelial, mesenchymal or
endothelial cells. Culture was carried out in a humidified 5% oxygen, 5% carbon dioxide, 90%
nitrogen atmosphere at 37°C.
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Figure 1. Isolation of mesenchymal cells from human fetal lungs. Following removal of the
larger airways, mechanical and enzymatic dissociation liberated resident lung cells. Mesenchymal cells
were selected by selective density gradient centrifugation and plated for expansion. Pellet cells were
also collected and analyzed to demonstrate efficacy of density gradient centrifugation.
3.2.4 Initial culture of isolated cells
Interphase cells were seeded onto plain, uncoated plastic surfaces to select mesenchymal cells.
Approx. 20 000 primary cells were plated per cm2 in 0.2 ml/cm2 αMEM. Culture was carried
out in a humidified 5% oxygen, 5% carbon dioxide, 90% nitrogen atmosphere at 37°C. The first
media change was performed 24 h after isolation after rinsing the cells with PBS to remove
remaining non-adherent contaminant cells. Thereafter, culture was maintained as described
in 3.1.
Pellet cells were plated in collagen-coated cultureware (refer to A.2.2 for coating regimen)
to enable the adherence of epithelial or endothelial cells. 0.2 ml/cm2 F-12 Ham’s containing
10% FBS and 1% PSF was used as primary culture medium. Pellet cells were also cultured
in 5% oxygen and checked every day as described. The medium was first changed after three
days without rinsing. These cells were analyzed directly after adherence without passaging.
Following fixation with 4% PFA (A.6.2) for 10 min, cells were permeabilized with 0.1%
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Triton X. After a 20 min blocking step (A.6.2), samples were incubated for 60 min with anti-
SP-C diluted 1:100 in DAKO’s background reducing diluent. Following three wash steps in
IHC wash buffer (A.6.2), PE-labeled anti-rabbit immunoglobulins were added, diluted 1:1000
in the same reagent as the primary. Three further wash steps and embedding in water-based
mounting media completed the staining process.
3.2.5 Characterization of lung mesenchymal cells
3.2.5.1 Surface marker analysis (FACS)
BD’s StemFlowTM human MSC analysis kit was used as directed by the manufacturer, us-
ing freshly harvested passage two cells. Additional antibodies (PE-conjugated αGD2, PE-
conjugated αCD146) and the respective isotype controls were dropped in as per manufac-
turer’s instructions; refer to Table 5. Following staining, cells were fixed overnight at 4°C
by adding 4% PFA to the flow buffer at equal volumes. Analysis was carried out using a BD
FACSCantoTM II and FACSDivaTM software at the University of Alberta Flow Cytometry
Core or the Dako MoFlowTM system at the Ottawa Hospital Research Institute’s Flow Cy-
tometry Core Facility. 10000 gated events were recorded. Data was analyzed using Tree Stars
FlowJoTM software package.
Recognized Molecule Isotype Clone Label Purpose
CD11b Integrin α M mIgG1κ ICRF44 PE Negative Marker
CD19 B-lymphocyte antigen mIgG1κ HIB19 PE Negative Marker
CD34 Hematopoietic progen-
itor cell antigen
mIgG1κ 581 PE Negative Marker
CD45 LCA, Leukocyte com-
mon antigen
mIgG1κ HI30 PE Negative Marker
CD73 Ecto-5’-nucleotidase mIgG1κ AD2 APC Positive Marker
CD90 Thy-1, Thymocyte dif-
ferentiation antigen 1
mIgG1κ 5E10 FITC Positive Marker
CD105 Endoglin mIgG1κ 266 PerCP-
Cy5.5
Positive Marker
CD146 Melanoma cell adhe-
sion molecule - MCAM
mIgG1κ P1H12 PE Positive Marker*
GD2 Ganglioside G2 mIgG2aκ 14.G2a PE Positive Marker*
HLA-DR Human leukocyte
antigen - antigen D related
mIgG2aκ G46-6 PE Negative Marker
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← Table 5. Antibodies used for FACS-analysis of human mesenchymal cell cell pop-
ulations. Antibodies recognizing Keyhole limped protein (clone X40, mIgG1κ) and Trinitrophenol
(clone G155-178, mIgG2aκ) were used isotype controls with respective labeling. Asterisk * - suggested
positive markers for MSC, GD2 [Martinez et al., 2007] and CD146 [Halfon et al., 2011].
3.2.5.2 Differentiation
To assess differentiation along the adipogenic lineage, passage two mesenchymal cells were
plated in 24-well plates at 10000 cells per cm2 and grown to post-confluency (100% conflu-
ence + 3 days) in 0.2 ml/cm2 α-modified MEM supplemented with 10% FBS and antibiotics
at hypoxic atmospheres. Lonza’s PoieticsTM adipogenic differentiation kit was used as di-
rected by the manufacturer, with slight modifications. 18 wells were differentiated using three
induction cycles (3 days induction medium, 3 days maintenance medium). 6 wells were left as
controls in α-modified MEM supplemented with 10% FBS and antibiotics. Induced and con-
trol cells were kept in 21% oxygen atmospheres as per the manufacturer’s protocol to support
differentiation. At the end of the experiment, cells were rinsed with PBS, fixed 20 min with
4% PFA in PBS (A.6.2) and stained 15 min with Oil Red O-solution (A.6.1). Following
clearing with PBS, cells were imaged directly using an inverted microscope.
For differentiation along osteogenic lineages, passage two mesenchymal cells were plated
in 24-well plated pre-coated with collagen as described in A.2.2. 2500 cells per cm2 were
seeded in 0.2 ml/cm2 α-modified MEM supplemented with 10% FBS and antibiotics at hy-
poxic atmospheres. Following a 24 h adherence period, cells were transferred to 21% oxygen
atmospheres. 18 wells were induced with Poietics’ osteogenic differentiation media as directed
by the manufacturer. Six wells were kept as controls as described for the adipogenic assay.
Administration of fresh induction media every third day for three weeks resulted in deposition
of visible extracellular matrix. Following fixation in ice-cold 70% ethanol at -20°C, calcified
matrix was stained for 2 min with fresh Alizarin Red S solution (A.6.1). Following clearing
with PBS, cells were imaged directly using an inverted microscope.
Differentiation along chondrogenic lineages was facilitated using R&D’s StemXVivo®
chondrogenic differentiation media with slight modifications of the manufacturer’s protocol.
1.25×106 passage two cells were pelleted by centrifugation (200×g, 5 min) in 5 ml serum-
free αMEM in 15ml BD polystyrene tubes. Following introduction of induction medium as
described by the manufacturer, tubes were closed with vented caps from BD’s 25 cm2 tissue
culture flasks. After 21 days in culture with medium changes every third day, chondrogenic
assay products were carefully harvested using a pipette, fixed in 4% PFA in PBS and embed-
ded in agarose molds for further paraffin embedding by the Alberta Diabetes Histology Core.
5µm sections were stained 30 min with Alcian Blue solution (A.6.1) to reveal sulfated gly-
cosaminoglycan deposition characteristic for cartilage. Due to the nature of the assay – only
differentiated cells survive the culture in spheres–, no undifferentiated controls were included.
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3.3 Isolation of UCMSC from the Wharton’s jelly
3.3.1 Development of the protocol
MSC from the whole umbilical cord have been isolated using a variety of approaches [Mennan
et al., 2016]. In here, MSC from the Wharton’s jelly were isolated using a modification of the
method described by [Tsagias et al., 2011]. The authors of that very paper used a cocktail
of 2.7 mg/ml collagenase I and 0.7 mg/ml hyaluronidase in PBS to start digestion of the
Wharton’s jelly. A final incubation step in a 2.5% trypsin solution concluded the enzymatic
dissociation process [Tsagias et al., 2011]. In here, the enzyme amounts were adapted and
normalized to a specific activity rather than a weight. Moreover, the digestion media was
adapted to support the enzymatic activity (e.g. supplying bivalent cations like Mg2+ and Ca2+
as essential enzymatic co-factors) and provide substrates for the cell’s catabolism, thereby
enhancing the viability of the final cell isolates.
3.3.2 Isolation of UCMSC
Procedures described below were approved by the Health Research Ethics Board, Biomedical
Panel, at the University of Alberta, Edmonton, Canada under approval # Pro00004106.
Umbilical cords from healthy, term infants of either sex were collected at the Misericordia
Community Hospital (Edmonton, Alberta) from women who underwent scheduled cesarian
section. Parents were consented prior to the surgical procedure. Upon delivery, the cord was
separated from the placenta and cord blood remains were gently squeezed out of the vessels.
The tissue was transferred to sterile specimen beakers containing 50 ml chilled, sterile-filtered
cord storage solution, and transported to the research laboratory at the University of Alberta.
Until processing, the tissue was stored at 4°C.
Isolation was begun within 4 hours post natum. The cord was weighed and placed in a class
II biological safety cabinet. Large, visible blood clots were removed and prior to rinsing the
tissue three times in specimen containers containing a sterile solution of 30 % CPDA-1 (A.3.1)
in PBS to remove debris and as much blood as possible. The cord was then disinfected in a 50
ml tube containing 20 ml 10% providone-iodine for 5 min with gentle agitation. After rinsing
the tissue three times in tubes containing 25 ml 30% CPDA-1 in PBS, the ends of the cord
were ligated using sterile umbilical tape. The epithelium was incised carefully to expose the
Wharton’s jelly without nicking the vessels. After a second disinfection step and subsequent
rinsing as described, the cord was placed in 125 ml pre-warmed, sterile-filtered cord digestion
solution (750 U/ml Collagenase I, 500 U/ml Hyaluronidase and 50 U/ml deoxyribonuclease I
in D-PBS). The tissue was incubated for 4 h in a 38°C water bath with gentle agitation.
Digestion was stopped by chelating bivalent cations serving as co-factors [Worthington
and Worthington, 1993a] with 3 mmol/l EDTA. 500 UBAEE (= 26 UUSP/NF = 8.7 UTAME)
bovine trypsin were added per ml and remaining tissue was digested for further 30 min at
38°C. FBS was added up to 10% to inhibit tryptic activity [Worthington and Worthington,
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1993c]. Cord remnants were removed from the solution after rinsing them with PBS. The so-
obtained cell suspension was passed sequentially through 70 µm and 40 µm meshes to remove
clumps and undigested epithelial remains, on ice. After pelleting the cells by centrifugation
(500 × g, 5 min, 4°C) and three rinsing steps with cold PBS, the cells were counted and plated
at 20000 cells per cm2 or frozen as described. Cells were expanded in 0.2 ml α-modified MEM
supplemented with 20% FBS and antibiotics per cm2 culture surface under hypoxic (5% O2)
culture conditions. Harvesting, passaging, subculture and cryopreservation were performed
as described previously.
3.3.3 Characterization of UCMSC
3.3.3.1 Surface marker analysis (FACS)
Passage two cells were harvested and stained for FACS analysis as described for fetal lung
mesenchymal cells. Analysis was performed using a BD FACSCanto II at the University of
Alberta Flow Cytometry Core.
3.3.3.2 Differentiation
To demonstrate adipogenic and osteogenic differentiation potential, passage two cells were
seeded at 1000 - 1250 cells per cm2 in a 24 well plate with collagen-coated 12mm glass
coverslips. Cells were expanded in αMEMin a 5% oxygen atmosphere. For adipogenic differ-
entiation, cells were grown to post-confluency. After rinsing the cells with PBS, adipogenic
differentiation medium (A.2.1) was added and changed every second day for a total of 14
days. Differentiation was performed in normoxic atmospheres. Cells were fixed and stained as
described in 3.2.5.2 and mounted on microscope slides using water-based mounting medium.
Osteogenic differentiation was initiated upon cells reached approx. 70% confluence. After
rinsing with PBS, medium was changed to osteogenic differentiation medium (A.2.1), which
was replenished every second day for a total of 21 days. Cells were fixed on coverslips and
stained as described in 3.2.5.2. Coverslips were mounted on microscope slides in water-based
mounting medium. Chondrogenic differentiation potential was demonstrated as described in
3.2.5.2. After embedding the assay products, 5 µm sections were stained for 5 min using
Alcian Blue (A.6.1).
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3.4 Induction of oxidative damage and sample generation
3.4.1 Culture and hyperoxia treatment
Three populations passage two lung mesenchymal cells (15+6, 17+0 and 17+4 wk GA) and one
population passage two UCMSC were plated at 2500 cells/cm2 in 0.2 ml/cm2 media in 100
mm petri-dishes and allowed to grow to post-confluency (confluent culture + 3d). Culture
media was changed every third day as described. At the end of this expansion period, a
steady state in which the cell proliferation rate equaled the apoptosis rate was achieved in all
cultures (Figure 10, A & D).
After rinsing the dishes three times with 0.25 ml/cm2 PBS to remove non-adherent cells
and debris, new media was added at 0.2 ml/cm2. The dishes were then randomized to on-
culture in either 5% or 60% O2 atmospheres. Six individual dishes were randomized to each
culture condition. One triplicate was designated to the subsequent isolation of supernatants,
cellular and extracellular protein (Figure 2). A second triplicate was used to obtain cell
proliferation data and isolate RNA.
3.4.2 Conditioned medium
Media was changed in dishes designated for protein and cell stress analysis every third day
(e.g. 72 h and 144 h after randomizing) as described. To overcome the disadvantages of
“traditionally” prepared 24 h-CdM (see 2.3.4), a novel method to generate long-term CdM
was developed. Therefore, dishes assigned to eventual isolation of RNA and the analysis of
proliferation were treated differently, as the secreted proteins in the supernatants were also
analyzed. Here, the whole amount of media was removed from the dish at 72 h, 144 h and 168
h after randomization; volumes were measured and recorded. 0.2 ml/cm2 media were then
added to the dish at the 72 h and 144 h. Obtained tissue culture supernatants were placed on
ice, ddH2O was added to a total amount of 12 ml to correct for evaporative loss. Tubes were
then centrifuged 30 min at 4°C and 4000×g without delay prior to cryoconservation of the
debris-free supernatant at -80°C. Aliquots of these supernatants were then pooled at equal
volumes to contain the proteins secreted over the whole 7 days in the respective experimen-
tal condition. The so-generated samples were analyzed with ELISAs and membrane-based
antibody sandwich arrays (ProteomeProfiler Human Cytokine Array Panel A and Proteome-
Profiler Human Angiogenesis Array)
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Figure 2. Induction of oxidative damage and generation of long-term CdM. Confluent
dishes with P2 FLMSC were randomized to onculture in either 5% or 60% O2. Medium collected
during the oxygen exposure was pooled as described above. Cells were counted and processed for
analysis as described below.
3.4.3 Total cell numbers
Dishes dedicated to further isolation of RNA were rinsed with PBS, and cells were lifted
using TrypLE Express as decribed. Dishes were checked for a complete detachment of cells.
Following centrifugation as described, the cell pellet was carefully resuspended in 1.5 ml PBS
to obtain a single cell suspension. Two aliquots of 10 µl each were drawn, diluted with 90
µl PBS and counted using a Scepter Cell Counter with a 60 µm probe attached, counting
events >12.5 µm. The mean of the six measurements was used to subsequently normalize
ELISA and array results. Remaining cells were spun down as described, the cell pellet was
frozen down at -80°C for further RNA purification.
3.4.4 RNA
Total RNA from cells obtained for proliferation assessment was isolated from frozen cell pellets.
Following cell lysis utilizing a centrifuge-column system (QIAshredder), RNA was purified by
column binding-based techniques (RNEasy® or NuleoSpin® RNA II) as directed by the
manufacturers instructions. Following quantitation (amount by A260, purity by A260A280 > 2.0),
samples were frozen down and stored at -80°C.
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3.4.5 Protein
Protein was isolated from the dishes using a combination of mechanical and chemical cell
and matrix disruption. Following removal of non-adherent cells and debris by rinsing with
PBS, dishes were placed on ice. 20 µl/cm2 completed lysis buffer (A.3.2) was added and
incubated 10 min on ice. Cells and matrix were scraped into the buffer using a cell scraper
and passed through a syringe with a 27G needle. The so-obtained cell and matrix lysate was
then recovered from the dish, and centrifuged 10 min at 10000×g and 4°C. Supernatants were
collected and frozen down at -80°C after protein quantification using a modified Bradford




3.5.1 Selective proteome profiling
To analyze total secretion of cells in the respective experimental conditions, equal volumes
from each pooled supernatant triplicate were pooled together (Figure 2). ProteomeProfiler
human cytokine panel A and ProteomeProfiler human angiogenesis array kits were run as
directed by the manufacturer. All array membranes were visualized on autoradiography film
(Carestream Kodak BioMax MR) with 20 min exposure time. Films were developed using an
automated film processor.
Densitometry of spots was performed using Fiji on 600 dpi scanned blots. The mean
absolute pixel intensity of duplicate spots PIabs. was normalized to the mean of the six refer-
ence spots PIRef. to account for different ECL-exposure times of the individual membranes.
The so-obtained PISample was then divided by the total cell count [×106] to obtain a rela-
tive pixel intensity RPI per 1×106 cells of the underlying cell population. Relative up- or
downregulation of protein secretion in 60% O2 was subsequently calculated as follows:
Relative upregulation in 60% O2 =
RPI60% O2
RPI5% O2
Relative downregulation in 60% O2 = −
RPI5% O2
RPI60% O2
3.5.2 Enzyme-linked immunosorbent assays (ELISA)
Sandwich-ELISAs detecting human Stanniocalcin-1, FGF10 and Periostin were carried out
following the manufacturer’s instructions. A competitive binding ELISA was performed to
quantify PGE2 as directed by the manufacturer’s manual. Analyte levels were calculated from
a standard curve obtained by polynomial curve fitting and normalized to 1×106 cells of the
underlying cell population.
3.5.3 Western blotting
Amounts of single proteins were quantified by probing milk powder / TRIS-buffered saline
(MP / TBS)-blocked membranes with the primary antibodies diluted as summarized in
Table 6. Following incubation with HRP-conjugated secondary antibodies, bands were visu-
alized utilizing peroxidase-activated chemiluminescence (Amersham ECL Prime). Images of
the obtained autoradiography-films were then evaluated using Fiji [Schindelin et al., 2012].
Sample band pixel density was normalized to the pixel density of the respective GAPDH-band.
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Western blotting itself was performed by separating 20 µg or 30 µg protein per well utilizing
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). Protein was loaded
in Lämmli’s modified loading buffer (Roti®-Load) and denaturated for 5 minutes at 95°C.
Following successful PAGE, protein was transferred onto a nitrocellulose membrane. A
Mini-PROTEAN® electrophoresis cell and a Trans-Blot® semi-dry transfer apparatus (both
from Bio-Rad) were utilized. A 10-250 kDa protein ladder (Precision Plus ProteinTM Dual
Color), which was loaded together with the samples prior to SDS-PAGE, was visualized with
0.1% Ponceau S and thereby used to verify successful blotting and to estimate the molecular
weight ranges of the subsequently detected protein bands. If applicable, lysed human skin
fibroblasts from a 10-year old boy or lysed human induced pluripotent stem cells were ran
side-by-side with the samples as controls. These samples were generously provided by other
investigators in house. Refer to A.4.1 and A.4.2 for used reagents and buffer solutions.
Target Protein SDS-Gel Clone Species Dilution Buffer
Nanog 20 µg 10% polyclonal goat 1 : 200 MP / TBS-T
goat IgG polyclonal rabbit 1 : 5000 MP / TBS
β-Catenin 20 µg 8% polyclonal rabbit 1 : 8000 BSA / TBS-T
rabbit IgG polyclonal donkey 1 : 20000 MP / TBS
Oct-4A 30 µg 10% 653108 mouse 1 : 1000 BSA / TBS-T
rabbit IgG polyclonal donkey 1 : 20000 MP / TBS
SOX-2 30 µg 10% 245610 mouse 1 : 2500 BSA / TBS-T
mouse IgG polyclonal rabbit 1 : 10000 MP / TBS
PDGFRα 20 µg 8% D1E1E rabbit 1 : 1000 BSA / TBS-T
rabbit IgG polyclonal donkey 1 : 50000 MP / TBS
GAPDH 20 µg 8 & 10% H86045M mouse 1 : 20000 Roti®-Block
mouse IgG polyclonal rabbit 1 : 40000 MP / TBS
Table 6. Antibodies used for detection of proteins following western blotting. Primary
antibodies bold, secondary antibodies italic. BSA – bovine serum albumin, TBS-T – TRIS-buffered
saline with TWEEN20, MP – milk powder.
3.5.4 Quantitative (Real-Time) polymerase chain reaction (qPCR)
3.5.4.1 Transcription
2 µg RNA were transcribed into cDNA in duplicates using Moloney Murine Leukemia Virus
reverse transcriptase, RNase H minus (M-MLV RT [H-]). A 1:1 mix of random primers and
oligo(dT)-nucleotides was used to prime the reaction. Following 10 min incubation at 70°C,
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a mastermix containing RNase inhibitor, nucleoside triphosphate and M-MLV RT [H-] was
added on ice (see A.5). Transcription was performed by incubation for 60 min at 42°C
followed by a 5 min period at 95°C. A control PCR for GAPDH was carried out as described
in A.5 to confirm successful RNA to cDNA transcription; Biometra T3 thermocyclers from
Analytik Jena were used for all transcriptions.
3.5.4.2 Primers
Primers for qPCR were chosen using the National Institute’s qPrimerDepot database [Cui
et al., 2007] to span at least two introns and to recognize the non-mutated, wild-type form
of the specific gene transcript. Forward (“left”) and reverse (“right”) primers were chosen to
have a CG content of ca. 50% with resulting Tmelt. ≈ 60°C to facilitate optimal annealing.
The ∆Tmelt. between forward and reverse primers was aimed to be as small as possible, ide-
ally < 1.0°C to yield optimal results. Table 7 summarizes the primer sequences, respective
melting temperatures and sizes of the resulting cDNA amplicons.
Gene Direction Primer Sequence 5’ → 3’ |GC| Tmelt. ∆Tmelt. |Amp.|
COL1A1 Reverse 5’ CACACGTCTCGGTCATGGTA 3’ 55% 60.593°C
Forward 5’ AAGAGGAAGGCCAAGTCGAG 3’ 55% 60.892°C 0.299°C 91bp
FOXA2 Reverse TACGTGTTCATGCCGTTCAT 45% 59.995°C
Forward TAAAGTATGCTGGGAGCGGT 50% 59.73°C 0.265°C 134bp
FOXD1 Reverse CATAAATAGAGGGACCCGCA 50% 59.916°C
Forward GTCTTGGTGGTTCGGTGTTT 50% 59.867°C 0.049°C 144bp
FOXP1 Reverse CATGCATAATGCCACAGGAC 50% 59.955°C
Forward CGATCCCTTCTCTGATTTGC 50% 59.773°C 0.182°C 103bp
FOXP4 Reverse GTAAGCATCTGCGGCGAC 61.1% 60.536°C
Forward AGCAACAGGCTCTCCAAGTG 55% 60.589°C 0.053°C 145bp
POSTN Reverse 5’ TTCTCATATAACCAGGGCAACA 3’ 40.9% 59.474°C
Forward 5’ TTTGGGCACCAAAAAGAAAT 3’ 35% 59.429°C 0.045°C 110bp
STC1 Reverse 5’ ATCACATTCCAGCAGGCTTC 3’ 50% 60.226°C
Forward 5’ CCTGAAGCCATCACTGAGGT 3’ 55% 60.261°C 0.035°C 90bp
TITF1 Reverse GCTCATGTTCATGCCGCT 55.6% 60.971°C
Forward ACCAGGACACCATGAGGAAC 55% 59.817°C 1.154°C 116bp
TNFAIP6 Reverse 5’ GCTTGTATTTGCCAGACCGT 3’ 50% 60.14°C
Forward 5’ AAGGATGGGGATTCAAGGAT 3’ 45% 59.588°C 0.562°C 99bp
GAPD Reverse 5’ AATGAAGGGGTCATTGATGG 3’ 45% 59.605°C
Forward 5’ AAGGTGAAGGTCGGAGTCAA 3’ 50% 59.697°C 0.092°C 108bp
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← Table 7. Sequences, melting temperatures and resulting cDNA amplicon sizes of
primers used for quantitative (RT)PCR. Analyzed gene transcripts encoded for the following
proteins: COL1A1 – Collagen, α1 - chain, FOXA2, FOXP1, FOXP4, FOXD1 – Forkhead box proteins
A2, P1, P4 and D1, PDGFRA – Platelet - derived growth factor receptor α, POSTN – Periostin,
STC1 – Stanniocalcin-1, TGFB3 – Transforming growth factor-β3, TITF1 – Homeobox protein Nkx-
2.1, Thyroid transcription factor 1 / TTF-1, TNFAIP6 – TNFα - induced protein 6 / TSG-6. GAPD
– Glyceraldehyde-3-phosphate dehydrogenase served as housekeeping gene.
3.5.4.3 Dye-based qPCR analysis
Quantitative (real-time) PCR was performed using BRYT®-Green for the detection of double-
stranded DNA while carboxy-X-rhodamine served as inert reference dye. Promega’s GoTaq®
qPCR Master Mix was used as directed by the manufacturer. Sample cDNA and in-house
calibrator DNA were analyzed in duplicates using an Applied Biosystems 7300 real time PCR
instrument as instructed by the manufacturer, data analyzed using 7300 System SDS. GAPDH
served as housekeeping gene to calculate ∆ct.
3.5.5 Extracellular matrix assessment
Passage two cells were plated in 6 well plates as described and exposed to 5% or 60% oxygen for
7d. Total (tropo)elastin deposition of FLMSC in both culture conditions was evaluated using
a quantitative dye-binding based assay (FastinTM, Biocolor life science assays). Cells were
lifted using a non-enzyme based dissociation solution (Sigma-Aldrich) to avoid proteolysis by
trypsin. Following conversion of deposited elastin into α-elastin with 0.25 mol/l oxalic acid
at 100°C, the assay was performed as directed by the manufacturer.
Total deposited sulphated glycosaminoglycan (sGAG) was quantified using a similar dye-
based method (BlyscanTM). Following extraction of sGAG from wells using a 65°C solution
of 0.5 UnitsBAEE / ml papain in extraction buffer (A.3.2) for 3h, the assay was performed
as per manufacturer’s protocol. N - and O-sulphated sGAG species were differentiated by
nitrous acid cleavage as described by the manufacturer.
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3.6 Functional analysis of cells
3.6.1 Surface marker profiling – Array FACS
45-50 million P3 cells were harvested from expansion culture in HYPERFlasks as described. A
single-color (AlexaFluor® 647), multiwell plate-based surface marker screening assay system
(BD Lyoplate TM) was used to analyze the expression of 242 surface markers as directed by
the manufacturer. APC-conjugated αMSCA-1 (Anti-MSCA-1-APC, human (clone: W8B2))
was dropped in as an additional marker. Analysis was carried out as directed by the manu-
facturer utilizing a BD LSR II flow cytometer equipped with an automated high throughput
sampler (BD HTS). Data was obtained using BD FACSDiva and subsequently analyzed uti-
lizing FlowJo’s batch mode; emission spectra of stained cells were compared to spectra of
the respective isotype controls. Changes between populations were expressed as difference in
fraction (∆Fpos.) of positive cells:
∆Fpos. = Fpos.(60%O2)− Fpos.(5%O2)
Median fluorescence intensity (MFI) was also calculated using FlowJo. To account for inter-
assay variability, relative MFI of the individual stained sample was calculated using the mean




3.6.2 Assessment of colony forming efficacy
3.6.2.1 Limiting dilution CF-U
CFU-Assays were performed with two different seeding densities, two and five cells per cm2.
Passage two cells were harvested as described and filtered through a 40 µm mesh to obtain a
single cell-suspension. Aliquots of this suspension were drawn in triplicates and counted. The
solution was then diluted to a final concentration of 10 cells/ml or 25 cells/ml, respectively.
0.2 ml suspension per cm2 were plated in 25 cm2 flasks (BD Biosciences) and incubated at
37°C, 5% CO2 in either 5%, 21% or 60% O2. A set of three independent experiments, e.g.
three flasks per seeding density and culture condition was analyzed. Medium was changed
every three days as described. Flasks were checked daily for emerging colonies.
After nine (FLMSC) or twelve days (UCMSC) in culture, distinct colonies were visible.
Flasks were placed on ice, rinsed three times with PBS and fixed 10 min with ice-cold anhy-
drous Methanol at -20°C. Colonies were stained for 15 min with 0.5% Crystal Violet Solution.
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Colonies were evaluated using a Stuart Equipment / Cole-Parmer Colony Counter. Colony
forming efficacy was calculated as follows:
Colony Forming Efficacy [%] =
Number of plated cells
100
× Number of colonies
3.6.2.2 Single Cell Plating
Single cell plating was performed using a freshly prepared single-cell suspension of passage
two cells, which were stained with the live-dead dye propidium iodide (PI) as directed by the
manufacturer. Single, viable, PIneg. cells were plated in individual wells of a 96-well plate
(Greiner BioOne) pre-filled with 100 µl culture medium utilizing the BD FACSAria III sorter
at the CRTD Flow Cytometry Core Facility. Two 96 well plated were prepared per cell type
and randomized to culture in 5% or 21% O2, respectively. Cells were fixed and stained with
Crystal Violet after 14 d in culture as described previously for the limiting dilution CF-U
assay. Colony size was stratified into large colonies visible with the naked eye in back-lighting
and small colonies visible only with a stereoscopic microscope at 10× magnification. Analysis
of colony size with a transmission light microscope at 10×10 magnification revealed a cut-off
cell number of approximately 50 cells. Colony forming efficacy was calculated for both, small
and large colonies as described above (3.6.2.1).
3.6.3 Anti-BrdU-Immunocytochemistry
Cells were plated on collagen-coated coverslips as described. Following culture to confluency
and exposure to 5% or 60% O2 for 7 d, cells were pulsed for 60 min with 10 µm /l BrdU,
rinsed with PBS and fixed with 25% glacial acetic acid in methanol for 20 min. Following
nucleic acid denaturation with 2 mol/l HCl for 60 min at 38°C, cells were rinsed with three
times with sodium borate buffer, followed by three wash steps and 20 min of blocking at
room temperature. Incubation with a monoclonal antibody detecting BrdU (1:400 in DAKO
diluent, 60 min at 38°C), followed by three washing steps and incubation with the specific
biotinylated secondary (1:200 in wash buffer, 60 min at room temperature). Incubation with
peroxidase / streptavidin (Vectastain Elite® ABC) was then used to enable visualization
of BrdU-incorporation by 3,3’-Diaminobenzidine (DAB)-precipitation. Counterstaining was




3.7 Statistics and Data Visualization
Raw data was obtained as described above. Primary data calculated with the respective
software packages (FlowJo, Magellan, Fiji) was organized using Microsoft Excel. Subsequent
analysis was performed utilizing R [R Core Team, 2016]. For n ≥ 4 per group, data was
tested for significant differences using Welch’s unpaired, two-sample t-test [Ruxton, 2006].
If the type I (α) error was < 5 %, the difference between groups was considered significant







with xi being the value of the individual datapoint and x the arithmetic mean of all values
i...n. Data was visualized using R’s inherent graphics and plotmath packages as well as the
the additional plug-in plotrix [Lemon, 2006]. Boxplots depict the median (bold horizontal
line) and the upper and lower quartile (height of the box, equivalent to the interquartile range
IQR). Whiskers indicate the most extreme value not surpassing the quartile limits ± 1.5×IQR.
Values more extreme than the quartile limits ± 3×IQR were treated as outliers/measurement




Values in the text are given as mean ± one standard deviation where meaningful. Data is
visualized as described in 3.7. Mean refers to the arithmetic mean, unless otherwise stated.
For n ≥ 4, individual data points are visualized in the respective blots.
4.1 Successful isolation of MSC from the umbilical cord stroma
MSC were isolated from a total of six human umbilical cords weighing 26.73 ± 3.16 g. A mean
of 13.56 ± 7.15 × 106 cells was isolated per cord, corresponding to 2.84 ± 2.17 × 106 cells
per g of tissue. No correlation between the weight of the cord tissue and the cell yield was
seen (R2 = 0.389). The cells from all umbilical cords adhered after isolation and acquired a
fibroblast-like, spindle-shaped morphology within 24h (Figure 3, A). The few contaminating
cells visible in some preparations were monocyte-shaped and died within the first days of cul-
ture (data not shown). Endothelial or epithelial-like cells were not present, indicating efficient
purification of mesenchymal cell lines by the herein employed density-gradient centrifugation.
Cells from all isolations were expanded and characterized in accordance with current ISCT
criteria [Dominici et al., 2006].
Multicolor-FACS analysis of passage one cells demonstrated a pure (> 99%) population
of CD73pos. / CD90pos. / CD105pos. cells, which lacked expression (< 0.5%) of CD11b, CD19,
CD34, CD45, HLA-DR and GD2 (Figure 3, B - F). Robust differentiation potential along
adipogenic, osteogenic and chondrogenic lineages was demonstrated (Figure 7, D-F). More-
over, isolated UCMSC reliably yielded colonies (colony forming efficacy 50.6 ± 9.87%) when
plated at 2 cells / cm2 in single cell suspensions (Figure 12, A & D), thereby suggesting a
gentle and efficient isolation of actual MSC.
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Within the here presented work, cells from one of the six batches were analyzed. Cells
from the other batches were successfully tested for their efficacy in ameliorating neonatal
sepsis [Zhu et al., 2017].
Figure 3. Isolation and characterization of UCMSC. Spindle-shaped umbilical cord stroma
cells 24h after isolation, white scale bar 100 µm (A). Multicolor FACS-analysis of passage one cells
demonstrated absence of negative markers (B) and simultaneous positivity for MSC positive markers
CD73, CD90 and CD105 (D - F). No GD2 was detected (C). Refer to Figure 7 for photomicrographs
of differentiated cells.
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4.2 The human fetal lung is abundant in MSC
4.2.1 Isolation of mesenchymal cells from human fetal lung tissue
Mesenchymal cells were isolated from a total of six lung tissue samples (10+4, 15+6, 15+6,
17+0, 17+4 and 24+0 wk GA), weighing between 43.2 and 2607 mg. All lungs had a cell-rich
mesenchyme; the mesenchymal cells were concentrated around the developing canaliculi in
some, but not all sections (Figure 4).
2.28 × 103 to 60.72 × 103 cells per mg lung tissue were collected from the Ficoll-interphase
and plated for primary culture (Table 8). No correlation between the gestational age of the
lung specimens and the numbers of harvested lung mesenchymal cells was seen. Cells from
the lung obtained from a 24+0 wk GA fetus failed to adhere and proliferate subsequently;
most likely due to the presence of crystallized digitoxin in culture (data not shown). These
cells were therefore excluded from all further experiments.
ID GA Partisolation Weight Cellsinterphase Partfixed
total per g
10.4 10+4 wk Pulmo sinister 43.2 mg 2.4 × 106 55.56 × 106 Pulmo dexter
15.6(I) 15+6 wk Pulmo dexter 326 mg 4.6 × 106 14.11 × 106 Pulmo sinister
15.6(II) 15+6 wk not specified 2607 mg 14.5 × 106 5.56 × 106 not specified
17.0 17+0 wk Pulmo sinister 249 mg 15.1 × 106 60.72 × 106 Pulmo dexter
17.4 17+4 wk not specified 838 mg 8.4 × 106 10.02 × 106 not specified




Table 8. Characteristics of fetal lung samples, numbers of harvested mesenchymal cells.
The cells collected from the interphases of the five dissociated lungs (Figure 5, A) be-
tween 10+4 and 17+4 wk GA adhered to plain, tissue culture treated plastic and demon-
strated a typical, fibroblast-like morphology upon the first media change 24 h after isolation
(Figure 5, C). Epithelial cells and red blood cells were sufficiently depleted by the sepa-
ration over the density gradient (Figure 5, B) and subsequent plastic adherence selection.
However, minimal amounts of endothelial-shaped cells were retained in the cell population
collected from the interphase (Figure 5, D). These cells died within 2-4 days in culture.
The remaining, fibroblast-like shaped cells reached sub-confluence after 7 -14 days. 0.5×106
to 7.5×106 adherent, fibroblast-shaped cells were harvested after this adherence period and
seeded as P1 cells for subsequent expansion culture. Cells harvested from the pellet af-
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ter density gradient centrifugation stained weakly positive for surfactant protein-C (SP-C,
Figure 5, E), further substantiating the efficacy of the herein employed MSC-purification
protocol. Due to low initial cell numbers and the age of the sample, cells obtained from the
10.4 lung sample were not further analyzed within here.
Figure 4. The fetal lung’s mesenchyme. Photomicrographs of hematoxylin & eosin stained lung
sections obtained from a fetus at the age of 17+0 (A, B) and 17+4 (C, D) weeks of gestation at 10
× 10 (A, C) and 20 × 10 fold magnification (B, D). Note the differnt mesenchymal cell distribution
patterns. Black scale bar 300µm, white scale bar 100µm.
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Figure 5. Isolation and morphology of human fetal lung cells. Facies anterior of a left fetal
lung (A) and appearance of interphase (B, single white asterisk) and pellet (two white asterisks)
after centrifugation. Note the visual absence of red blood cells in the interphase. Cells collected
from the interphase adhered and exerted a typical fibroblast-like morphology 24h after isolation and
plating (C). Probable endothelial contaminants (single black asterisk) died within a couple of days
(D). Cells collected from the pellet after Ficoll-separation (E) stained weakly positive for pro-SP-C
in this 17+0 wk GA lung. Images taken using a non-calibrated microscope.
4.2.2 FACS demonstrated high expression of surface markers defining MSC
Cells collected from the Ficoll-interphase of digested 15.6, 17.0 and 17.4 lung tissue and ex-
panded for one passage were negative (< 0.5%) for markers labeling contaminating hematopoi-
etic (CD11b, CD19, CD34, CD45, HLD-DR) and endothelial (CD34, CD45) cells [Forsyth
et al., 1993; Fina et al., 1990]. Simultaneous > 96% positivity for all markers defining MSC
(CD73, CD90, CD105) as per current ISCT criteria [Dominici et al., 2006] was demonstrated




Figure 6. Multicolor FACS-analysis of human fetal lung mesenchymal cells. Analyzed cell
population (pink gate) after exclusion of debris (A). 10 000 gated events were subsequently analyzed.
Cells were negative for markers labeling contaminants (B) while simultaneously being positive for
markers defining MSC, as exemplified by CD73 (C). Single histograms for MSC-positive markers
CD73 (D), CD90 (E), and CD105 (F). Stained cells depicted by blue curves, signal of the respective
isotypes red. Color-coded density dot plots visualize the simultaneous positivity of CD146 and CD73
on analyzed cells (G) while GD2 was negative (H).
Moreover, CD146 – a proposed marker distinguishing fibroblasts from MSC [Halfon et al.,
2011] – was shown to be positive on > 99% of the isolated cells (Figure 6, G). GD2 /
Disialoganglioside-2, a neural biofunctional lipid prominently expressed on MSC isolated from
the bone marrow [Freund et al., 2010] and thus presumably distinguishing these BM-MSC
from other marrow cells [Martinez et al., 2007], was not detectable (< 0.5%, Figure 6, H).
Expression of neither of the investigated markers was correlated with the gestational age of
the fetuses the cells derived from.
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4.2.3 Isolated mesenchymal lung cells differentiated along adipogenic, os-
teogenic and chondrogenic lineages
Passage two mesenchymal cells from the fetal lung demonstrated robust differentiation poten-
tial along adipogenic lineages, as illustrated by prominent deposition of Oil Red Opos. lipid
droplets in the cell’s soma (Figure 7, B). Not induced control cells kept in αMEM with 10%
FBS as described had only minor amounts of Oil Red-Opos. lipid droplets. Osteogenic induc-
tion led to vast deposition of calcified extracellular matrix, which was visualized by Alizarin
Red S staining (Figure 7, A). Again, not induced cells showed only minor staining, thereby
indicating an efficient differentiation induction process and ruling out spontaneous differenti-
ation. Chondrogenic induction led to formation of small cartilage spheres approx. 2 mm in
diameter in all culture tubes. Upon fixation and embedding, staining with Alcian Blue 8GX
demonstrated prominent deposition of acetic mucins, thus verifying successful differentiation
along chondrogenic lineages (Figure 7, C).
Figure 7. Differentiation capacity of human fetal lung and umbilical cord-derived mes-
enchymal cells. Representative photomicrographs of differentiated passage two cells which have
been stained with either Alizarin Red S after osteogenic (A, D), Oil Red O after adipogenic (B, E)
or Alcian Blue 8GX after chondrogenic induction (C, F). Not induced cells are pictured in inserts.
White scale bar 100 µm, black scale bar 300 µm.
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4.2.4 FLMSC express stem cell transcription factors SOX2 and Oct4
Western blotting revealed high expression of transcription factors SOX2 and its direct interac-
tion partner, POU domain class 5 transcription factor 1 (Octamer-binding protein 4 / Oct4) in
FLMSC (Figure 8). Both proteins are critically involved in the regulation of gene expression
in stem cells, thereby directly controlling stem cell proliferation and -differentiation [Taka-
hashi et al., 2007]. SOX2 and Oct4 were absent in skin fibroblasts from a 10 year-old boy and
prominently present in iPS cells used as positive control (data not shown). Four (Oct4) or five
(SOX2) individual blots were performed for each sample. However, levels of Oct4 and SOX2
in the analyzed FLMSC-samples did not show any correlation with gestational age (data not
shown).
Isolated UCMSC also expressed stem cell transcription factors SOX2 and Oct4 (Figure 8).
Levels of SOX2 detected in UCMSC trended lower as compared to FLMSC, levels of Oct4 were
significantly lower in UCMSC. No expression of Homeobox protein NANOG, a transcription
factor crucially driving self-renewal of embryonic stem cells [Chambers et al., 2003] was seen
in FLMSC or UCMSC on protein level (data not shown).
Figure 8. Expression of SOX2 and Oct4 in FLMSC, UCMSC and fibroblasts. Relative
SOX2 levels of 15.6(II), 17.0 and 17.4 FLMSC, UCMSC and skin fibroblasts (A). Five individual blots
were performed per sample. GAPDH-normalized Oct4 levels (B), four individual blots per sample.
*** = p < 0.001, * = p < 0.05.
4.2.5 FLMSC express proteins crucial for normal lung development
High levels of β-catenin, a key modulator of distal lung development [Mucenski et al., 2003]
and effector molecule of the canonical Wnt-pathway, were detected in FLMSC samples. The
levels of β-catenin decreased with increasing gestational age of the cells (Figure 9, A). The
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same held true for platelet-derived growth factor-receptor α (PDGFRα, Figure 9, B), which
is critically involved in normal alveolarization [Popova et al., 2014].
Figure 9. Expression of β-catenin and PDGFRα decreases with maturation of FLMSC.
Relative β-catenin (A) and PDGFRα levels (B) of 15.6, 17.0 and 17.4 FLMSC cultured in 5% O2.
Experiments were performed in triplicates, two individual blots performed per sample. Representative
autoradiography films of membranes probed with primary antibodies against PDGFRα, β-catenin and
GAPDH (C). Position of ladder bands on the left-hand side. 15.6 refers to 15.6(II) cells.
Moreover, high levels of mRNA encoding for crucial transcription factors of mid- and
late lung development were noticed in FLMSC. Most notably, significant amounts of FOXP1
(∆ct = 5.65 ± 0.46) and FOXP4 (∆ct = 5.18 ± 0.30) transcripts were detected (Figure 11,
C & D). Levels of FOXA2 (∆ct = 13.86 ± 0.43) and NKX2-1 (∆ct = 15.32 ± 0.55), which
are both crucially involved in especially early lung morphogenesis [Morrisey and Hogan, 2010],
trended lower (Figure 11, A & E). No correlation of mRNA-levels with gestational age was
seen. Interestingly, high levels of FOXD1 (∆ct = 1.71 ± 0.15), a transcription factor described
to be enriched in lung mesenchymal progenitors, thereby distinguishing mesenchymal lung
progenitor cells from lung fibroblasts [Hung et al., 2013], were noted (Figure 11, B).
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4.3 Oxygen leads to functional impairment of FLMSC in vitro
4.3.1 Hyperoxia impairs proliferation inhibition of FLMSC
Culture of FLMSC in hyperoxic atmospheres for seven days following confluency led to sig-
nificantly higher cell numbers (Figure 10, E) as compared to culture in hypoxia. Analyzing
three FLMSC populations, a mean of 0.234 ± 0.047 × 106 cells was harvested per cm2 from
dishes exposed to 5% O2 (n = 9) after confluence, whereas 0.42 ± 0.062 × 106 cells were
obtained per cm2 from dishes randomized to hyperoxic culture (n = 9). With three indi-
vidual samples per group, no differences in terms of proliferation were detected between the
three differentially aged FLMSC-subgroups. However, a trend towards lower cell yields with
increasing gestational age was noticed (Figure 10, F). Comparing all FLMSC in both cul-
ture conditions, a mean-fold change of 1.81 ± 0.133 towards 60% O2 exposure was calculated.
Conversely, umbilical cord-derived MSC yielded overall lower cell numbers per cm2 and did
not exert signs of dysfunctional proliferation inhibition in hyperoxia (0.055 × 106 cells 5% O2
and 0.054 × 106 in 60% O2, respectively).
Short-term pulsing with BrdU revealed extensive de novo DNA-synthesis in FLMSC ex-
posed to hyperoxia, whereas cells cultured in (physiologic) hypoxia remained in a quiescent
state. Cells in hypoxia formed a monolayer (Figure 10, A), indicating functioning contact
inhibition mechanisms [Schutz and Mora, 1968]. Conversely, FLMSC kept in hyperoxia for
seven days following confluency seem to loose these contact inhibition mechanisms and grew
in multilayers on top of each other (Figure 10, B & C) – patterns, that are usually seen
in in vitro cancer models [Weinstein and Moorhead, 1967]. Umbilical cord-derived MSC ar-
rested their proliferation after becoming confluent, indicating intact cell-cell contact inhibition
processes in both, hyper- and hypoxia (Figure 10, D & E).
4.3.2 Hyperoxia induces overexpression of lung transcription factors
Alongside the malignancy-like proliferation of FLMSC in hyperoxia, upregulation of several
essential lung transcription factors was noticed on mRNA-level (Figure 11), represented
by lower ∆ct levels. Significant ∆∆ct were noted for FOXD1 (∆∆ct = -0.383 ± 0.176),
FOXP1 (-0.752 ± 0.182), FOXA2 (-0.520 ± 0.150) and NKX2-1 (-0.806 ± 0.357). All these
transcription factors are known to integrate several cellular signaling pathways and induce
proliferation of stem- or progenitor cells in normal development and cancer [Lam et al., 2013].
Spatially and temporally fine-tuned expression of these transcription factors is essential for
normal lung development and growth [Morrisey and Hogan, 2010], and every alteration of this
balance leads to severe lung development and -regeneration defects [Li et al., 2012]. Especially
FOXD1, which is expressed at high levels in the herein investigated FLMSC (see 4.2.4) and
significantly increased in hyperoxia (p = 0.00063) is crucial for normal alveolar development
support by lung mesenchymal progenitor cells. Postnatally, spatial over-expression of FOXD1
in lung mesenchymal progenitors contributes to the development of pulmonary fibrosis [Hung
et al., 2013].
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Figure 10. Proliferation of fetal lung and umbilical cord MSC in hyperoxic atmospheres.
Representative photomicrographs (A-D) of 60 min BrdU-pulsed passage two cells exposed to 5%
or 60% O2 for seven days following confluency. Monolayers of quiescent fetal lung MSC in 5% O2
atmospheres (A) and excessively proliferating FLMSC (B,C) in hyperoxia with multiple layers of
cells growing on top of each other (C). Minimal BrdU-staining was seen in UCMSC kept in hyperoxic
atmospheres (D). Staining anti-BrdU/HRP/DAB, counterstaining CytoBlue, white scale bar 100 µm.
Numbers of harvested cells after exposure to 5% or 60% O2 for seven days following confluency (E).
FLMSC depicted as closed, UCMSC as open circles. *** = p < 0.001 between FLMSC groups.
F visualizes the numbers of 15.6(I), 17.0 and 17.4 FLMSC after 7d in 5% (closed squares) or 60%
O2 (open squares), respectively.
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Figure 11. Hyperoxia increases expression levels of essential lung transcription factors.
Relative mRNA levels in FLMSC cultured in 5% or 60% O2, expressed as ∆ct for FOXA2 (A),
FOXD1 (B), FOXP1 (C), FOXP4 (D) and NKX2-1 (E), normalized to the expression of GAPD.
Three individual PCRs performed per cell type, cumulative data from 15.6(II), 17.0 and 17.4 FLMSC
depicted. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, n.s. = p > 0.05.
4.3.3 Relative and absolute hyperoxia leads to impaired colony formation
When plated as single cells with a density of two cells per cm2, the four analyzed FLMSC
populations (15.6(I), 15.6(II), 17.0, 17.4) reliably yielded colonies with an efficacy of 72.3 ±
10.6 % after nine days (Figure 12, A). Upon culture in 21 % O2 atmospheres, this number
decreased significantly to 50.3 ± 22.5%. Only single colonies were visible after nine days in 60
% O2 (0.3 ± 0.4 %). Unlike with proliferation, no trend towards an age-dependency was seen
within the limited window of gestational ages investigated herein (Figure 12, B). Notably,
UCMSC formed colonies with lower efficiency at hypoxic atmospheres (50.6 ± 9.9 %) and
were more severely impaired by culture in normoxia (8.6 ± 1.2 %) than FLMSC (Figure 12,
C & D).
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Figure 12. Colony formation by fetal lung and umbilical cord MSC. Colony forming-efficacy
of fetal lung (closed circles) and umbilical cord-derived (open circles) MSC (A). *** = p < 0.001
between FLMSC groups. Analysis of the respective FLMSC subgroups in 5% (closed squares) and
21% oxygen (open squares) revealed no clear correlation with gestational age (B). Representative
images of colony forming-efficacy assays of FLMSC (C) and UCMSC (D) in the respective oxygen
concentrations. E: Efficacy of FLMSC to form large (dark gray) and small colonies (light gray) in 5%
and 21% O2 after single cell plating in a 96 well plate; representative images of colonies evaluated as
“small” (F, 21% O2) and “large” (G, 5% O2) after staining with crystal violet. Note the dysmorph




To further analyze colony formation of MSC at 5% and 21% oxygen, FACS-assisted single
cell plating was utilized. After nine days, 46.9 ± 16.2% (5% O2) and 16.0 ± 5.1% (21%O2)
of the analyzed wells had visible colonies (Figure 12, E, dark gray bars). However, upon
microscopical evaluation, colonies sized 25 cells and below were detected (Figure 12, F), thus
leading to total colony forming-efficacies of 62.9 ± 9.6% (5% O2) and 50.0 ± 5.5% (21% O2),
respectively. A mean of 26.8% of all detected colonies were small colonies in hypoxia, whereas
68.2% of colonies detected after culture in room air were sized below 25 cells. Moreover,
most small colonies contained dysmorph cells (Figure 12, F). These so-called "fried egg
morphology" cells have previously been described as characteristic for senescent mesenchymal
cell populations [Wagner et al., 2010a].
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4.4 Hyperoxia impairs the FLMSC’s secretory function
4.4.1 Impairment of angiokine production in hyperoxia
Membrane-based array systems were used to quantitatively evaluate differences of angiokine
and cytokine secretion. Analysis of long-term conditioned media obtained from dishes with
and without cells first revealed effective detection of secreted proteins without detection of
FBS-derived cytokines, thus suggesting valid assay readouts (Figure 13, C) without prior
sample concentration or modification.
Analysis of proteins associated with angiogenesis revealed broad secretion of pro-angio-
geneic factors by all three analyzed cell populations in (physiologic) hypoxia (Figure 13,
A – green bars). Numbers of detected angiokines positively correlated with the gestational
age of the samples (9, 10 and 16 detected angiokines in 15.6, 17.0 and 17.4 FLMSC culture
supernatants, respectively). The more “mature” the cells were, the more complex the se-
cretion pattern appeared, including not only proteins and peptides promoting vasculo- and
angiogenesis, but also vessel maturation and inhibition of overshooting vascularization.
Some proteins detected are consecutively secreted by all three FLMSC populations. Among
them, vascular endothelial growth factor (VEGF) is of outstanding importance for the de-
veloping lung. VEGF is the crucial mediator of late lung vascularization and alveolariza-
tion [Thébaud et al., 2005], and was detected at very high levels in all FLMSC. Moreover,
Angiopioetin-1 was detected in two out of the three cell preparations. This protein crucially
drives maturation of novel vessels by facilitating the connection of immature endothelial cells
among themselves as well as with the surrounding matrix proteins and pericytes [Thébaud
and Abman, 2007]. Besides proteins promoting vasculogenesis, angiogenesis and vessel mat-
uration, other growth factors were consecutively secreted – TIMP1, the tissue inhibitor of
metalloproteinase 1 for example, which may acts as potent growth factor for lung fibrob-
lasts [Dong and Ma, 2017], or several transport- and binding proteins for insulin-like growth
factor (IGF), another crucial driver of organ development [Maki, 2010]. The roles of the
other proteins secreted by the three FLMSC populations in conditions mimicking the in-
trauterine environment (Angiogenin, Petraxin 3, Thrombospondin-1 (TSP1), Urokinase-like
plasminogen-activator (uPA), and the serin protease inhibitors e1 and f1) in normal lung
development have not been described.
In hyperoxia, the secretion of the majority of analyzed proteins was diminished in all
FLMSC preparations (Figure 13, A – red bars). Most notably, VEGF production was
reduced over 2.5-fold (Figure 13, D). However, hyperoxia led to de novo secretion of hepa-
tocyte growth factor (HGF), a critical pleiotropic growth factor acting downstream of VEGF




Figure 13. Hyperoxia impairs angiokine and cytokine secretion by FLMSC. Normalized
pixel intensities of membrane-based arrays analyzing angiokines (A) and cytokines (B) in the super-
natants of FLMSC (CdM) cultured in 5% O2 (green) or 60% O2 (red) for seven days. The relative up-
and downregluation of selected angiokine and cytokine secretion in 60% O2 as compared to culture in
5% O2 ( = 1) is presented in (D) - only proteins that were consistently up- or downregulated by all
FLMSC-populations are depicted. Representative autoradiography films of membranes probed with
either long-term CdM or serum-containing cell culture medium (C). 15.6 refers to 15.6(II) cells.
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4.4.2 FLMSC acquire a pro-inflammatory, MSC-attracting phenotype
Following confirmation of assay validity with medium derived from cell-free dishes (data not
shown), cytokine production of FLMSC in 5% and 60% O2 was analyzed using membrane-
based array systems. In contrast to the angiokine data, a much more homogenous secretion
profile was observed (Figure 13, B). In (physiologic) hypoxia, all cells secreted the inter-
leukins 6 and 8 (IL-6 & IL-8), C-C motif chemokine 2 / Monocyte chemoattractant pro-
tein 1 (MCP-1), Macrophage migration inhibitory factor (MIF), Growth-regulated α protein
(GROa), Granulocyte-macrophage colony-stimulating factor (GM-CSF) and minor amounts
of stromal cell-derived factor 1 (SDF-1).
However, when challenged with 60% O2, de novo production of IL-23 and complement
factor 5 (C5) was observed, two potent activators of early inflammatory response [Korkmaz
et al., 2017]. Levels of IL-6, MIF, MCP-1 and especially IL-8, which acts as both, pro-
inflammatory cytokine and potent promotor of angiogenesis [Matsuo et al., 2009] were reduced
(Figure 13, D). Production of PGE2, which acts both, anti-inflammatory [Nemeth et al.,
2009] and anti-fibrotic [Walker et al., 2012] on paracrine levels, was significantly diminished
upon exposure to hyperoxia (Figure 17, C). Interestingly, FLMSC increased transcription
of TNFAIP6, the gene encoding for TSG-6, in hyperoxia (Figure 14, C).
But most notably, FLMSC secreted significant amounts of SDF-1 when exposed to hy-
peroxia. An over 13-fold increase in SDF-1 levels as compared to hypoxic culture was noted
(Figure 13, D). This molecule is of outstanding importance as it attracts healthy MSC after
organ injury, which subsequently engraft into the damaged tissue in order to regenerate it [Li
et al., 2017; Dong et al., 2012a; Ratajczak et al., 2006].
4.4.3 FLMSC reduce production of Stanniocalcin-1 and FGF10 in 60% O2
Substantial levels (211.74 ± 22.58 pg/ml and 106 cells) of Stanniocalcin-1 were detected in
FLMSC cultured in 5% O2 on both, protein and mRNA levels (Figure 14, A). Stanniocalcin-
1 plays an important role in lung regeneration and protection, being secreted by BM-MSC
[Waszak et al., 2012; Block et al., 2009] that home to the injured lung sites [Ono et al., 2015].
Once secreted, Stanniocalcin-1 potently protects lung alveolar cells from apoptosis caused by
reactive oxygen species by uncoupling the mitochondria’s respiratory chain [Ohkouchi et al.,
2012] and prevents onset of lung fibrosis [Ono et al., 2015] after injury.
Once challenged with 60% O2, significantly reduced mRNA transcripts (corresponding to
significantly higher ∆ct-values) of the respective gene STC1 were observed in lysed FLMSC,
alongside significantly reduced protein levels (87.37 ± 9.94 pg/ml and 106 cells) in the long-
term CdM of the very same cells (Figure 14, A).
FLMSC also reduced secretion of FGF10, a crucial mediator of mesenchymal-epithelial and
mesenchymal-endothelial crosstalk and putative marker of postnatal lung MSC facilitating
lung regeneration [Chao et al., 2015; El Agha and Bellusci, 2014] after being exposed to
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hyperoxia (Figure 14, D). Selective reduction of FGF10-levels in the developing lung has
already been associated with alveolar simplification and impaired branching morphogenesis
in rodents [Ramasamy et al., 2007]; moreover, infants that died with severe BPD had lower
levels of FGF10 in their lung tissue [Benjamin et al., 2007], thus suggesting a critical role of
that growth factor in normal, and impaired lung development.
Figure 14. Hyperoxia causes significant changes of Stanniocalcin-1, FGF10, and Periostin
production. Protein levels (closed circles) and mRNA levels, depicted as ∆ct vs. GAPDH (closed
triangles) of Stanniocalcin-1 (A) and Periostin (B). Relative mRNA-amounts (∆ct vs. GAPDH) of
TNFAIP6-mRNA, encoding for the TSG-6 protein (C); absolute protein levels of FGF10 secreted by
FLMSC in 5% and 60% O2 depicted in (D). *** = p < 0.001, ** = p < 0.01.
4.4.4 Increased production of Periostin by FLMSC in hyperoxia
On both, mRNA and protein levels, significantly increased production of Periostin (from
3112.47 ± 805.91 to 7990.69 ± 1748.37 pg/ml and 106 cells) was noted in hyperoxia
(Figure 14, B). Periostin is of particular interest in BPD as its complete knockout pro-
tects mice from hyperoxia-induced alveolar simplification and lung fibrosis [Ahlfeld et al.,
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2013; Bozyk et al., 2011]. Moreover, infants dying from severe BPD had elevated levels of
Periostin in their lung’s mesenchyme while term infants dying from non-pulmonary causes
had not [Bozyk et al., 2011]. Periostin seems to act as crucial mediator of subepithelial lung
fibrosis and plays a role in asthma exacerbation [Izuhara et al., 2016], thus suggesting a role
in long-term BPD outcome.
4.4.5 Culture in 60% O2 impairs extracellular matrix production
FLMSC secrete significant amounts of extracellular matrix (ECM) components crucial for
normal lung development. Most notably, high levels of elastin (13.99 ± 3.18 mg per 106 cells)
were detected in dishes cultured seven days in hypoxic atmospheres resembling intrauterine
conditions (Figure 15, A). Elastin is one of the crucial drivers of lung maturation and
alveolarization [Mižíková and Morty, 2015], and sufficient amounts of elastin are inevitable
for normal alveolar development [Pierce et al., 1997; Bruce et al., 1989]. No correlation
between elastin production in vitro and gestational age was seen (data not shown).
57
Results
← Figure 15. Matrix production by FLMSC. Fetal lung MSC secrete vast amounts of Elastin
(A) and sulfated proteoglycans and glycosaminoglycans (sGAG, B). Production of both matrix com-
ponents is reduced in hyperoxia. Differentiation (D) of detected sGAG into N− (e.g. heparan
sulphate, light gray bars ) and O−sulphated sGAG (e.g. chondroitin sulphate, dark gray bars). Cycle
thresholds (∆ct) of COL1A1-mRNA, encoding for the α1-chain of type-I-collagen (C) of cells cultured
in 5 or 60 % oxygen. ** = p < 0.01, *** = p < 0.001.
Sulfated proteoglycans and glycosaminoglycans (sGAG), ECM components also involved
in normal lung development [Caniggia et al., 1992; Horwitz and Crystal, 1975], were detected
at levels of 7.28 ± 0.96 µg per 106 cells (Figure 15, B). The majority (73.39 ± 4.83 %) of
detected total sGAG were O-sulfated sGAG species like chondroitin 4-sulfate, 26.61 ± 3.52
% N -sufated sGAG like heparan sulfate (Figure 15, D). A fine-tuned balance between N -
and O-sulfated sGAG is important for normal mesenchymal-epithelial development [Mižíková
and Morty, 2015; Caniggia et al., 1992].
In cells exposed to hyperoxia, a significantly different ECM-production pattern was seen:
Amounts of elastin and sGAG were both reduced by half (6.68 ± 1.48 mg elastin and
3.36 ± 1.41 µg sGAG per 106 cells, respectively; Figure 15, A & B). Moreover, pro-
portions of N - to O-sulfated sGAG changed towards N -sulfated sGAG-species in hyperoxia
(Figure 15, D); a pattern previously described in senescent lung tissue [Horwitz and Crystal,
1975]. Messenger RNA-levels of COL1A1, encoding for the α1-chain of (pro-fibrotic) type-
I-collagen were increased, as represented by significantly lower ∆ct (0.90 ± 0.60 vs. 0.21 ±
0.11, Figure 15, C).
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4.5 Hyperoxia alters the human FLMSC’s surface marker pro-
file
A 96 well plate-based HTS-FACS screening of 17.4 FLMSC cultured in either 5% or 60%
O2 revealed downregulation of several surface marker proteins (Table 9) in hyperoxic culture,
including the surface markers defining MSC as per current ISCT-criteria – CD73, CD90 and
CD105 – [Dominici et al., 2006] and the “non-classical” positive markers CD140b, CD146 and
CD200 [Camilleri et al., 2016; Mendicino et al., 2014].
Moreover, expression of proposed MSC positive markers SSEA-4 [Gang et al., 2007],
CD51/CD61 [Erices et al., 2000], CD108 [Subramanian et al., 2015], CD165 [Al-Nbaheen
et al., 2013], CD166 [Mendicino et al., 2014] and CD273 [Camilleri et al., 2016] was dimin-
ished in hyperoxia by both measurements, relative mean fluorescence intensity (rel. MFI) and
fraction of positive cells versus respective isotype (Fpos., Figure 16, A and Table 8). The
levels of CD56 were decreased in hyperoxia, but the role of this marker in MSC biology is not
well described [Skog et al., 2016].
Conversely, increased amounts of CD91 were noted on cells exposed to 60% O2 for seven
days (Figure 16, B). Both, rel. MFI and Fpos. increased by one order of magnitude (rel.
MFI5% = 1.95, rel. MFI60% = 12.6 / FPos.,5% = 0.087, FPos.,60% = 0.833). The proposed
MSC positive marker CD106 [Mendicino et al., 2014] was slightly upregulated in hyperoxia.
Proposed “non-classical” MSC positive markers previously described [Camilleri et al., 2016;
Buhring et al., 2007] to distinguish MSC from other cell types (CD36, CD163, CD271 and
MSCA-1) were absent (FPos. < 0.05 = 5% vs. isotype) on cells cultured in either oxygen con-
centration, as well as the MSC negative markers CD34, CD45, CD14/CD11b, CD19/CD79α
and HLA-DR (Figure 16, C).
Antigen Fpos. rel. MFI Antigen Fpos. rel. MFI
5% 60% ∆ 5% 60% R 5% 60% ∆ 5% 60% R
CD51 0.89 0.39 -0.50 10.6 5.1 0.48 CD140b 1.00 0.94 -0.06 45.8 26.5 0.58
CD56 0.57 0.15 -0.42 5.6 2.6 0.47 CD146 0.99 0.96 -0.04 40.9 24.5 0.60
CD73 0.96 0.78 -0.18 33.7 20.2 0.60 CD165 0.99 0.33 -0.66 16.3 5.2 0.32
CD90 1.00 0.99 -0.01 90.5 71.6 0.79 CD166 0.97 0.68 -0.29 36.6 9.9 0.27
CD91 0.09 0.83 +0.75 2.0 12.6 6.45 CD200 0.11 0.06 -0.06 1.7 1.3 0.78
CD105 1.00 0.94 -0.06 36.3 17.7 0.49 CD273 0.70 0.13 -0.58 6.9 3.4 0.49
CD106 0.03 0.23 +0.20 1.1 2.6 2.32 SSEA-4 0.76 0.31 -0.45 9.7 3.4 0.35
CD108 0.95 0.65 -0.31 23.2 9.0 0.39
Table 9. Hyperoxia causes differential expression of surface markers on FLMSC. Differ-
ences (∆) between positive fractions (Fpos.) and ratio (R) of the relative mean fluorescence intensity
(rel. MFI) calculated as described above.
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Figure 16. Surface marker expression on FLMSC in 5% and 60% O2. Fractions (red, left-
hand side) and respective relative median fluorescence intensities (green, right-hand side) of positively
stained (FPos. ≥ 0.05 = 5% vs. isotype) cells and the respective differences (∆; R) between FLMSC
exposed to 5% or 60% O2 (A). Results of a detailed FACS-analysis of CD91-stained FLMSC after
exposure to hypo- or hyperoxia depicted in (B); tested, but not detected (FPos. < 0.05 = 5% vs.
isotype) surface antigens in (C). 17.4 FLMSC were analyzed.
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4.6 UCMSC secrete lung-protecting proteins in vitro
Analysis of supernatants derived from passage two human UCMSC expanded in 5% O2 re-
vealed profound secretion of soluble factors known to beneficially interact with damaged lung
tissue. Levels of stanniocalcin-1 (909.71 ± 11.80 pg/ml and 106 cells, Figure 17, A) and
PGE2 (6922.60 ± 44.80 pg/ml and 106 cells, Figure 17, C) ranged one to three orders of mag-
nitude higher than respective levels secreted by FLMSC exposed to 60% O2 (stanniocalcin-1:
87.37 ± 9.94 pg/ml and 106 cells, PGE2: 1.81 ± 0.63 pg/ml and 106 cells). Transcripts of the
TNFAIP6 gene encoding for TSG6 were significantly higher (depicted as significantly lower
∆ct) in UCMSC-lysates (Figure 17, B) as compared to FLMSC-lysates.
Figure 17. Differential protein and mRNA expression pattens of UCMSC and FLMSC.
Relative stanniocalcin-1 (A) and PGE2 (C) levels in the supernatants of FLMSC cultured in either
5% or 60% O2 as compared to UCMSC. Normalized pixel intensities from membrane-based cytokine
and angiokine arrays, summarizing the pooled secretion profile by three FLMSC-populations in 60%
O2 (red) as compared to UCMSC (green, D). GAPD-normalized ∆ct of TNFAIP6-mRNA encoding
for TSG6 protein depicted in (B). *** = p < 0.001.
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Moreover, membrane-based arrays evaluating cytokine- and angiokine production revealed
substantial secretion of lung growth and -maturation promoting factors by UCMSC. Per 106
cells, sixfold higher levels of angiopoietin-1 [Thébaud and Abman, 2007], tenfold higher levels
of TIMP-1 [Dong and Ma, 2017], 16-fold higher levels of KGF [Ito et al., 2015] and 22-fold
higher levels of HGF [Seedorf et al., 2016] were measured as compared to FLMSC kept in
60% O2. Tenfold higher amounts of IL-8 were measured in the supernatants of UCMSC as
compared to FLMSC. Levels of VEGF produced by UCMSC were about two-thirds lower
than the ones secreted by FLMSC (Figure 17, D).
However, UCMSC also released potent pro-inflammatory cytokines into the culture medium.
Detected levels of IL-6 and IL-23 were eight- and 14-fold higher as compared to FLMSC su-
pernatants. In stark contrast to the tissue-resident, damaged FLMSC, UCMSC were not able
to produce detectable amounts of SDF-1 (Figure 17, D).
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5. Discussion
5.1 Novel protocols for the isolation of MSC from human fetal
lung and umbilical cord tissues
The two protocols developed within here reliably yielded mesenchymal stem- or stromal cells
from both, human fetal lung and human umbilical cord tissue. Using a combination of me-
chanical dissociation, enzymatic digestion adapted to the extracellular matrix of the source
tissue – hyaluronidase, collangenase and DNAse for umbilical cord tissue (3.3.1), collagenase,
neutral protease and DNAse for lung tissue (3.2.1) – and density gradient centrifugation, mes-
enchymal cells were obtained from a total of six human umbilical cords and six human fetal
lung samples. Both protocols have successfully been published in form of original articles [Zhu
et al., 2017; Collins et al., 2016] or granted patents [Möbius et al., 2017].
MSC have previously been isolated from the whole umbilical cord using several methods.
In here, a combination of mechanical dissociation and enzymatic digestion was used, adapted
from the method described by [Tsagias et al., 2011]. Slight modifications of the enzyme
concentrations to match the extracellular matrix composition of the Wharton’s jelly better
and change of the digestion media to Mg2+ / Ca2+ / pyruvate-containing D-PBS led to
a fivefold increase in MSC-yield per g of umbilical cord tissue as compared to the original
protocol (2.84 × 106 per g of tissue described in here vs. 0.52 × 106 cells per g of tissue
reported by [Tsagias et al., 2011]).
Analysis of cells obtained with the herein developed protocol showed full compliance with
ISCT-criteria in terms of differentiation potential and surface marker expression (see 4.1).
Moreover, colony-forming efficacies of 9% in normoxia and 51% in hypoxia were one order of
magnitude higher than the ones described in the literature [Davies et al., 2017], indicating
a gentle and effective isolation and expansion. An automated, current good-manufacturing
compliant modification of the protocol using the whole umbilical cord tissue rather than the




The protocol used to isolate mesenchymal cells from fetal lung tissue herein is the first
one known to the author to yield actual human fetal lung MSC upon expansion. As outlined
previously, other groups used either minced lung tissue [in ’t Anker et al., 2003a] with subse-
quent bead-selection [Noort et al., 2002] or -depletion [in ’t Anker et al., 2003b], or enzymatic
digestion alone [Hua et al., 2009] to liberate cells from human fetal lung tissue. None of these
approaches led to human mesenchymal stem cells fulfilling the ICST criteria for MSC, and
neither did the culture of commercially available whole fetal lung cells in media designed for
the expansion of BM-MSC [Rolandsson Enes et al., 2016].
The gentle enzymatic dissociation with 250 U/ml collagenase I, 3 U/ml neutral protease,
and 50 U/ml deoxyribonuclease I effectively cleaved off the lung’s extracellular matrix, thus
liberating single cells more efficiently than mincing the whole lung tissue through cell strainers
or comparable meshes alone (unpublished in-lab data). The combination of the enzymes with
a specifically adapted digestion medium supporting both, enzyme activity and cell metabolism
supported a fast, but gentle digestion process with high viability rates. After density-gradient
centrifugation and depletion of most contaminating cells, significant amounts of nearly-pure
lung mesenchymal cells were obtained. This confirms data from Bertoncello’s group, which
demonstrated that mesenchymal cells are enriched (approx. 15 % of the whole interphase cells)
within the low-density fraction after 1.077 g/cm3 density gradient centrifugation [McQualter
et al., 2009]. Although not quantified by FACS in here, it is plausible that centrifugation over
an even more selective gradient (1.073 g/cm3) led to higher purity of mesenchymal cells in the
interphase. Microscopical evaluation of plated pellet cells revealed no evidence for significant
presence of mesenchymal cells in the pellet – neither in this study, nor in in other, previously
published work using even less selective density gradients and mouse lung tissue [McQualter
et al., 2009].
5.2 The mesenchyme of the fetal lung comprises of extensive
amounts MSC
The vast majority of the so-obtained interphase cells adhered within 24 h in deep hypoxic
atmospheres while acquiring a typical fibroblast-like morphology. On average, 2.5×106 -
5×106 cells were harvested after 7-14 days of initial culture. Moreover, high initial yields of
lung mesenchymal cells enabled the use of cells that were minimally expanded (two passages)
after initial adherence for assessment of cellular identity by FACS, differentiation and single-
cell plating. Consequent use of low-expansion protocols allowed to use minimally expanded
cell populations for the other experiments: cells were used up to passage three in here, thus
resulting in a maximum of 15 population doublings for every analyzed cell.
This represents a contrast to previously published reports where only single colonies count-
ing a few hundred cells per colony could have been harvested after initial cell isolation [Bozyk
et al., 2011]. Those protocols then required extensive expansion over multiple passages with
high individual cell population doubling numbers to yield enough cells for subsequent analy-
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ses, including characterization. This process causes transdifferentiation in vitro, and changes
in surface marker profile and bioactivity of such cells (reviewed by [Wuchter et al., 2015]
and [Wagner et al., 2010a]). A cell population obtained after such long expansion periods
therefore does not represent the actual cell population in vivo best, and data obtained from
such experiments is prone to be confounded by artifacts of ex vivo cell expansion. Previ-
ously published reports investigating lung mesenchymal cells moreover utilized 21% oxygen-
expanded cells at high passage numbers – up to P15 [Hua et al., 2009], resulting in at least 45
population doublings – or from sources with unknown previous expansion regimens [Rolands-
son Enes et al., 2016]. In contrast, the Dutch group that first described fibroblast-like cells
growing out of the CD34pos./CD45neg. cell fraction of mechanically dissociated human fetal
lung tissue also used a low-passage approach to analyze their cells [in ’t Anker et al., 2003b;
in ’t Anker et al., 2003a; Noort et al., 2002], but did not report on exact culture regimens. In
here, low-expansion regimens and culture in physiologic low-oxygen atmospheres were utilized
to mimic the intrauterine conditions as closely as possible.
FACS analysis of the so-isolated lung mesenchymal cells revealed a high homogeneity of
the Ficoll-purified, minimally expanded cell population. Over 96% of the analyzed cells pre-
sented with the “classical” MSC surface marker profile CD73pos. / CD90pos. / CD105pos. while
lacking expression (< 0.5%) of CD14 / CD11b, CD19, CD34, CD45 and HLA-DR. More-
over, all isolates were highly positive (> 98%) for CD146. This is of particular interest as
this marker has been shown to become downregulated with prolonged passage and thereby
induced aging of MSC [Halfon et al., 2011]. It is moreover thought that CD146 distinguishes
between CD146neg. lung fibroblasts and CD146pos. lung MSC [Collins et al., 2016]. In the
CD34pos. lung cell population investigated by Noort et al. and in’t Anker er al., cells were
moderately (90%) positive for CD90 and CD105 while primary cells selected to be CD34neg.
only showed poor (20 - 50% positivity) expression of these markers [in ’t Anker et al., 2003b].
The cells described by Hua and colleagues were negative for CD90, CD45 and CD34 while
being questionably positive for CD105 – FACS and IHC data did not match and data re-
porting is, unfortunately, inconsistent in that paper [Hua et al., 2009]. The cells isolated and
investigated by Rolandsson Enes and colleagues were highly ( > 98%) positive for CD90 and
CD73, but had poor expression of CD105 (68%). CD146 was detected on 89% of the cells in
that report [Rolandsson Enes et al., 2016].
Differentiation of herein analyzed passage two lung mesenchymal cells revealed robust
differentiation potential along adipogenic, osteogenic and chondrogenic lineages. Although
difficult to accurately quantify and dependent on various factors, visual comparison of dif-
ferentiation responses described in here (Figure 7, A - C) with images presented in [Hua
et al., 2009; Noort et al., 2002] and the supplemental data of [Rolandsson Enes et al., 2016]
suggests a notably higher differentiation potential of the cells isolated and analyzed in here.
Interestingly, when comparing the herein obtained cell population with MSC isolated
utilizing clonal outgrowth methods from the tracheal aspirate of adult patients [Lama et al.,
2007], the same differences can be seen – a detectable, but comparatively low differentiation
potential combined with an intermediate expression of markers defining MSC (CD73 82%,
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CD90 85%, CD105 75%). All adult tracheal aspirate MSC were negative for CD14, CD34
and CD45. The same held true when analyzing MSC from the tracheal aspirate – again,
isolated using outgrowth methods – of neonatal patients: CD73 was detected on 79%, CD90
on 90% and CD105 on 95% of the analyzed cells, alongside a comparatively low differentiation
potential. Interestingly, CD34 was weakly positive on some (26%) of the neonatal tracheal
aspirate cells in that report [Bozyk et al., 2011].
Although demonstrating distinct, lung-specific gene expression patterns, it is not clear
where the MSC described in these investigations derive from and how they enter the tracheal
fluid. The observation, that fetal lung MSC are highly positive for essential MSC surface
markers allow the speculation that the MSC isolated from the tracheal aspirate may represent
a transdifferentiated (or somehow activated) cell population derived from endogenous lung
MSC, which entered the airways upon lung injury and lost some of their characteristics on
that way. This may also explain the increased MSC numbers in the tracheal aspirate of those
premature infants that develop BPD during their clinical course [Popova et al., 2010a] and
adult patients with lung diseases such as the bronchiolitis obliterans syndrome [Badri et al.,
2011]. Low-passage or primary resident lung MSC are missing as side-by-side controls to the
tracheal aspirate cells, and single-cell transcriptome and -proteome analyses of unexpanded
primary lung and tracheal aspirate cells are required to elucidate the origin and function of
these tracheal aspirate MSC.
Analysis of colony formation by single cells, an estimator of stem cell frequency in isolates
[Wuchter et al., 2015], revealed surprisingly high colony forming efficacies in passage two
cells. In here, 72% of the seeded cells were capable of clonal expansion without cell-cell
contact, comparable to the data published by [Rolandsson Enes et al., 2016]. Single-cell
plating confirmed these numbers, although the efficacies trended lower (47%). This is probably
caused by mechanical stress the cells experience during the automated sorting and plating
process. In contrast, MSC from the bone marrow form colonies at frequencies three to four
orders of magnitude lower than that (0.01 to 0.001%), indicating that only a minority in
these populations are true mesenchymal stem cells – despite full differentiation potential and
complete FACS characterization [Davies et al., 2017; Wuchter et al., 2015].
The majority of the fetal lung’s mesenchyme therefore consists of CD73pos. / CD90pos.
/ CD105pos. / CD146pos. MSC that form colonies at very high frequencies. This supports
data obtained by in’t Anker and colleagues [in ’t Anker et al., 2003b], who analyzed a single
cell suspensions of the whole lung. They report that approximately 2% of all fetal lung cells
(epithelial, mesenchymal, endothelial and blood-derived) are capable of forming colonies of
fibroblast-shaped cells – indicating that these cells were mesenchymal stem cells at the time
of plating. The real frequency of MSC in these report is probably higher, as the cells were
cultured in 21% oxygen atmospheres. This leads to a significant reduction of colony forming-
efficacy by FLMSC, as further shown within here.
The high colony forming efficacy correlates with high levels of genuine stem-cell transcrip-
tion factors SOX2 and Oct4. Both are highly expressed in embryonal stem cells and their
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direct derivates at early stages of human development, but only at very low levels in adult
tissues [Takahashi et al., 2007]. Expression of these factors in FLMSC can therefore been seen
as indicator of a relatively low differentiation state with consecutively high differentiation-
or development potential of the individual cell. Moreover, crucial transcription factors in-
evitable for normal lung development and maturation were detected in the herein isolated
cells. Forkhead box proteins P1, P4 and D1 were detected at high levels in isolated FLMSC
on mRNA level. Levels of FOXA2 and NKX2-1, both crucially involved in early mesodermal-
endodermal crosstalk mechanisms and lung branching morphogenesis [Morrisey and Hogan,
2010] were low, thus suggesting a “relative maturity” of the FLMSC isolated. Moreover, β-
catenin and PDGFRα, proteins in the center of several crucial lung development and lung
maturation pathways, were detected. Besides the expression of important transcription fac-
tors, the isolated FLMSC secreted proteins acting upstream of the previously described (and
many other) transcription factor pathways, thereby influencing other cells and regulating lung
development and maturation.
But most notably, FLMSC were capable of releasing FGF10, IL-8, VEGF, TIMP-1, and
angiopoietin-1 into the culture medium when kept in oxygen atmospheres resembling the con-
ditions in utero – besides many other growth factors. FGF10 enables both, early branching
morphogenesis and late alveolarization [El Agha and Bellusci, 2014] and acts as crucial medi-
ator of mesenchymal-epithelial crosstalk [Chao et al., 2015]. VEGF, IL-8 and angiopoietin-1
are critical mediators of lung endothelial development as they facilitate the generation and
maturation of novel vessels [Matsuo et al., 2009; Thébaud and Abman, 2007]. It is known
that systemic inhibition of VEGF signaling in rats leads to a phenotype resembling BPD with
loss of lung capillaries and impaired alveolarization. Postnatal gene-transfer selectively re-
activating pulmonary VEGF signaling reverses this effect; co-transfer of angiopoietin-1 leads
to further maturation the novel vessels [Thébaud et al., 2005]. Sufficient levels of both pro-
teins are therefore inevitable for normal pre- and postnatal lung development, and FLMSC
seem to produce at least a proportion of them. However, FLMSC also produced vast amounts
of growth factors with unknown roles in fetal lung development. TIMP-1 for example, which
acts as potent growth factor for fibroblasts in postnatal lung fibrosis [Dong and Ma, 2017]
or Thrombospondin-1, which acts predominantly anti-angiogeneic postnatally [Smadja et al.,
2011; De Paepe et al., 2010].
All these results – high differentiation potential and colony-forming ability, vast expres-
sion of crucial MSC surface markers, the expression of important lung development- and stem
cell transcription factors as well as the secretion of several growth factors involved in lung
development – indicate the successful isolation of functional, non-transdifferentiated FLMSC
populations from human fetal lungs and suggest that the mesenchyme of the herein investi-
gated fetal lung tissue consists mainly of MSC rather than fibroblasts.
However, two potential sources of bias need to be considered: It can be the case, that MSC
are the only cells that proliferate in vitro, thus leading to an “overgrowth” of the potentially
isolated fibroblasts in the initial culture. It can also be possible, that fibroblasts are more
prone to die during the isolation procedure than MSC, thus leading to an over-representation
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of MSC in the initial culture. Both sources of bias can not be ruled out completely with the
herein used methods, and represent one of the major disadvantages of in vitro cell analysis.
But given the utilization of low expansion protocols in here, the very high proliferation rate of
fibroblasts, and the low amount of dead cells in the initial culture, the impact of both effects
on the herein presented results is considered to be only minimal. However, using single-cell
analysis methods (FACS, single-cell plating and single-cell proteomics) on freshly isolated,
completely unexpanded fetal lung mesenchymal cells may overcome this issue.
5.3 Hyperoxia induces a BPD-supporting phenotype in FLMSC
in vitro
When challenged with non-physiologic oxygen levels, the herein isolated FLMSC responded
with loss of colony formation, thus indicating activation of transdifferentiation pathways caus-
ing a transition from FLMSC to fibroblasts. That was also evident at ambient oxygen levels,
suggesting the adaptation of FLMSC to the hypoxic conditions in the fetal lung in utero.
FLMSC moreover changed their surface marker profile; a pronounced up-regulation of CD91
during hyperoxia-exposure was seen. CD91 acts as lipoprotein- and scavanger-receptor on
phagocytes in the lung [Vandivier et al., 2002]; its role in MSC biology is currently unclear.
Elucidating the function of CD91 in MSC biology and lung development, and figuring out
whether CD91 represents a novel marker of transdifferentiated MSC or not needs is the subject
of further, currently ongoing research.
FLMSC moreover lost normal proliferation control by contact-inhibition, proliferated and
de-regulated transcriptional control via FOXP1/P4 pathways in 60% O2. That was accom-
panied by a reduction of expression of surface markers defining MSC. Besides that, signs for
a significant upregulation of transcriptional control via the FOXD1 pathway were noted –
a pattern seen in postnatal murine mesenchymal progenitors responding to lung injury with
proliferation, transdifferentiation into fibroblasts and subsequent onset of lung fibrosis [Hung
et al., 2013]. Long-term exposure to hyperoxia moreover increased transcription of COL1A1,
encoding for the alpha chain of the “fibrotic” type-I subfamily of collagen. These findings
correspond to the histopathological changes – mesenchymal thickening with bold fibrosis – in
infants dying with pronounced “old” BPD [Jobe, 1999; Northway et al., 1967].
Culture in hyperoxia also impaired the secretion of proteins driving alveolarization and
lung maturation, corresponding to the “new” BPD. The FLMSC’s inherent ability to secrete
the extracellular matrix proteins elastin and sGAG – both drivers of lung growth and mat-
uration [Pierce et al., 1997; Caniggia et al., 1992] – was significantly impaired in hyperoxia,
thus promoting the development of BPD [Mižíková and Morty, 2015].
Moreover, FLMSC kept in 60% O2 released less VEGF and FGF10 as compared to cells
in hypoxic conditions, thereby reducing the stimulation of vasculogenesis and alveologenesis –
which subsequently causes to the characteristic arrest of alveolarization in new BPD [Thébaud
and Abman, 2007; Benjamin et al., 2007]. Levels of periostin produced by oxygen-challenged
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FLMSC were significantly increased, substantiating the observations made by [Ahlfeld et al.,
2013; Bozyk et al., 2011] in mice and human neonatal lung tissue. Both authors described a
significantly positive correlation between the levels of periostin in the lung’s mesenchyme and
BPD.
Exposure of FLMSC to hyperoxia lead to both, activation and inactivation of pathways
protecting the lung from inflammation. The production of oxidative-damage preventing stan-
niocalcin-1 [Ohkouchi et al., 2012] and anti-inflammatory / anti-fibrotic PGE2 [Walker et al.,
2012; Nemeth et al., 2009] was significantly reduced upon culture in 60% O2 while potent
pro-inflammatory IL-23 was produced. However, FLMSC also upregulated SDF-1 and TGS-
6. Both molecules can be considered as “danger signals” in the case of inflammation or
organ injury. SDF-1 facilitates the recruitment and homing of circulating MSC to the site of
injury [Li et al., 2017; Ratajczak et al., 2006] in order to prime organ regeneration. TSG-6
is considered as one of the “distant effector molecules” of MSC, which release this molecule
during early inflammation into the systemic circulation. TSG-6 is then thought to blunt
secretion of pro-inflammatory cytokines by activated tissue-resident macrophages [Prockop,
2013], thereby reducing inflammation.
Hepatocyte growth factor (HGF) was solely secreted by FLMSC exposed to 60% oxygen.
HGF is of particular interest in BPD as it acts downstream of VEGF to promote AEC 2
proliferation [Yamamoto et al., 2007]. HGF is secreted by lung mesenchymal cells growing
out of term fetal sheep lung explants and promoted AEC 2 proliferation in direct co-culture of
both cell types [Seedorf et al., 2016]. The lung mesenchymal cells used in that study stained
weakly positive for CD90 (40%) and highly positive for α-smooth muscle actin by FACS,
indicating that it is most likely the lung fibroblasts and not the lung MSC producing HGF.
It can therefore been speculated that herein, oxygen induced a partial transdifferentiation of
FLMSC into lung fibroblasts which then start production of HGF. However, whether HFG
production is characteristic for lung fibroblasts or not needs to be investigated.
5.4 UCMSC secrete factors ameliorating impaired lung devel-
opment in vitro
Conversely, UCMSC were capable of secreting vast amounts of HGF, alongside other lung-
protecting proteins like TSG-6, PGE2 and Stanniocalcin-1 as well as angiopoietin-1 and KGF.
The in vitro secretome of UCMSC can therefore be considered a therapeutic agent itself,
protecting, and maturing the lung. That is supported by data from investigators using ad-
ministration of (BM or umbilical cord blood-derived) MSC-CdM rather than of whole cells as
therapy in models of BPD (summarized in Table 4) and demonstrated improved alveolariza-
tion and vascularization in animals receiving the MSC-CdM as compared to untreated con-
trols. Angiopoietin-1, KGF, HGF, Stanniocalcin-1 and TSG-6 exert their effect in a paracrine
fashion and can therefore be administered systemically as purified proteins. Indeed, admin-
istration of recombinant KGF [Oswari et al., 2001], recombinant HGF [Seedorf et al., 2016],
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recombinant TSG-6 [Foskett et al., 2014], recombinant Stanniocalcin-1 [Ono et al., 2015] or
induced overexpression of angiopoietin-1 in pulmonary cells [Thébaud et al., 2005] reduced
hallmarks of lung injury in animal models. PGE2, however, is a genuine pro-inflammatory and
pyrogenic mediator with significant immunologic (e.g., fever) and hemodynamic (persistence
of fetal circulation) side effects when administered systemically. On the other hand, it can
also act as anti-inflammatory protein by inducing a switch from pro-inflammatory M1 to anti-
inflammatory M2 resident macrophage phenotypes, which then release IL-10 [Prockop, 2013].
Moreover, PGE2 reduces transdifferentiation of adult lung MSC towards potent pro-fibrotic
fibroblasts in an autocrine-paracrine fashion [Walker et al., 2012].
However, it is not clear to what extent the secretion profile of UCMSC investigated in vitro
represents the actual secretome in vivo. Exogenous MSC are thought to act as part drug, part
vehicle that senses its surroundings and responds by secreting a cytokine and growth factor
cocktail designed to meet the exact requirements of the injured or damaged tissue [Fischbach
et al., 2013]. Data from endogenous endothelial progenitor cells leaving the bone marrow
in case of lung injury to secrete growth factors and heal the lung support this hypothesis
[Balasubramaniam et al., 2007]. Analyzing the secretome in vitro omits the paracrine, physical
and bio-mechanical stimuli the UCMSC e.g. gets while crossing the damaged lung after being
injected intravenously into a preterm infant receiving invasive ventilatory support. Short-term
preconditioning BMMSC with high levels of oxygen in vitro led to an increase in the secretion
of some beneficial growth factors, most notably STC-1 [Waszak et al., 2012]. However, in here,
long-term culture of UCMSC in hyperoxia caused the exact opposite and reduced secretion of
STC-1. Given the concept of the stem cell niche and the manifold cell-cell interactions MSC
have in situ, it is imperative that in vivo, UCMSC produce a slightly different secretome
than in vitro. Nevertheless, thorough characterization and optimization of in vitro culture
and CdM preparation will pave the road towards cell-free MSC derived therapies, which may
overcome disadvantages of whole-cell therapies or open new windows for novel indications.
This especially holds true as UCMSC-CdM investigated in here also contained cytokines (IL-6,
IL-23) that may have adverse effects when administered.
5.5 Limitations
All data presented in here derived from investigations in vitro. This study has therefore im-
portant limitations. First, culture of cells in monolayers, on plastic surfaces and with media
containing ill-defined bovine growth factors [Goedecke et al., 2011] always represents a sim-
plification of the actual tissue situation and does not mimic the conditions in situ best. As
outlined in 5.2, proliferation of different cell types in culture is not predictable, and propor-
tions of cell types may change during expansion. Although the bias was reduced as much as
possible – gentle cell isolation methods, low passage, low oxygen-culture regimens, usage of
only one lot of FBS per set of experiments, novel CdM preparation strategies minimizing the
cellular stress during analysis – it can not be made sure in such experimental setting that
the cellular effects seen and described in here represent the actual situation in vivo. Culture
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of cells in complex, three-dimensional, matrix-based culture systems like decellularized lung
scaffolds and subsequent single-cell analyses might mimic the biological reality better, espe-
cially in the light of the manifold cell-matrix interactions in the developing and maturing lung
(2.2, [Mižíková and Morty, 2015]).
Second, the fetal lung cells were isolated from only four fetuses at 16 to 18 weeks of
gestation. Although genes that are known to be crucially involved in early, and not late
lung development were already silenced or downregulated, the mesenchymal cells investigated
in here do not represent the mesenchymal cells in an infant’s lung at the age of 22 to 24
weeks – the youngest age for an immature infant to survive and therefore be at risk for BPD.
It is likely that the lung’s mesenchymal cells mature over this time in utero and therefore,
exert different features than the ones investigated in here. The low frequencies of actual
lung MSC in adult human [Lama et al., 2007] and neonatal rodent lungs [McQualter et al.,
2009] among high amounts of fibroblasts substantiate that and imply a profound maturation
and transdifferentiation process during late pregnancy, probably associated with the thinning
of the mesenchymal layer by apoptosis during the late saccular stage of lung development
[Morrisey and Hogan, 2010]. The impact of transition from intrauterine- to extrauterine life
on this FLMSC maturation process is also unclear. Whether, and if and to what extent a
mesenchymal maturation process similar to the one proposed in utero is also present in the
first days after premature birth, is not clear. Further research efforts aiming to elucidate the
role of the endogenous stem-and progenitor cells during that critical transition period from
intra- to extrauterine life are urgently required to better understand normal and disrupted
lung development [Möbius and Thébaud, 2017].
The herein utilized hyperoxia-model to induce cellular alterations in FLMSC has also some
important limitations that need to be considered. As outlined in the introduction, BPD is a
multifactorial disease caused by oxidative and mechanical stress, malnutrition, inflammation
and several other factors. In here, only one of these factors – hyperoxia – was investigated. But
only the “old” BPD is caused by harsh ventilation with high fractions of inspiratory oxygen.
Today, even the sickest premature infants rarely need supplementation with ≥ 60% O2 for
seven days, and BPD occurs even in infants that required only minor oxygen supplementation.
The injury model used herein therefore does not represent the actual clinical situation best, but
gives starting points to reach out from in further animal- or patient-based research activities




Using a novel isolation approach, it has been shown in here that the vast majority of the
fetal lung’s mesenchyme at the early canalicular stage consists of cells that fulfill all ISCT
characterization criteria to identify them as mesenchymal stromal cells. The herein described
protocol is therefore the first one known to the author to yield completely characterized human
fetal lung MSC, the herein presented work represents the first description of actual human
FLMSC from the early canalicular stage of lung development.
The mesenchyme of the human fetal lung at the investigated gestational ages mainly
consists of MSC, and not – like neonatal and postnatal lung’s mesenchymal tissue – fibrob-
lasts, thus raising novel questions on human lung mesenchymal maturation and mesenchymal
cell differentiation. It can therefore be hypothesized, that fetal lung MSC transdifferentiate
during late lung development and -maturation, thus giving raise to the variety of mesenchy-
mal cells seen in human neonatal and adult lung tissue – adult lung MSC, myofibroblasts,
lipofibroblasts and other, thereof derived cells. That would suggest a complex mesenchymal
stem/progenitor cell - fibroblast hierarchy in the developing and adult human lung. However,
further experiments are required to substantiate that hypothesis.
The FLMSC investigated in here secrete growth factors and matrix proteins inevitable for
normal lung development, thus implying a crucial, previously underinvestigated role of the
human FLMSC in both, early and late human lung mesenchymal development. The secretion
of growth factors influencing cells from other, i.e. epithelial and endothelial lineages moreover
suggests a regulatory role of FLMSC in lung maturation during late pregnancy and beyond.
When challenged with hyperoxia, human FLMSC lost features defining stem- or progenitor
cells. Moreover, profound dysregulation of pathways regulating lung maturation, epithelial-
mesenchymal and endothelial-mesenchymal crosstalk as well as an increased production of
pro-inflammatory cytokines was noted. That provides first in vitro evidence for a functional
impairment of extremely premature human FLMSC by extrauterine conditions and sheds
light into the cellular mechanisms by which premature birth and exposure of the immature
“extrauterine fetus” to the hostile environment outside the womb impairs organ development,
leading to diseases like BPD.
In vitro, exogenous UCMSC secrete a protein cocktail that contains factors the oxygen-
impaired endogenous MSC lack to produce: proteins protecting the endogenous lung cells
from further oxidative and inflammation-induced stress as well as growth factors promoting
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lung epithelial and -endothelial development, thus linking endogenous MSC impairment and
exogenous MSC action. Nevertheless, given the complex role of the endogenous MSC in
lung development and -maturation, the exact roles of exogenous MSC in BPD need to be
investigated in models of prematurity, where the therapeutically active cells interact with
actual premature lung cells. The in vitro experiments presented in here represent just the
starting point of a series of further investigations in such animal models to elucidate the “why”
and “how” of exogenous MSC action in the lung.
Of man and sage
Cur moritatur homo, cui salvia crescit in horto? – Why should a man die whilst sage grows in
his (own) garden? The verse from the high middle age-written Regimen sanitatis Salernitanum
gives raise to a theory of exogenous MSC action in premature infants suffering from BPD.
It is known from adult rodents, that MSC from the bone marrow enter the systemic
circulation and migrate towards sites of injury [Nitzsche et al., 2017; Sordi, 2009]. These
MSC then exert repair capabilities in the damaged tissue, causing a blunting of injury or the
onset of regeneration. It is moreover known that prematurity itself leads to a reduction of
systemically circulating repair cells (EFCF in the human cord blood that case, [Baker et al.,
2013]).
It can therefore been hypothesized, that the MSC evasion and homing mechanisms are
disturbed in prematurity and its complications. Due to the abrupt confrontation of the
prematurely born infant with the hostile, unphysiological environment (“extrauterine fetus”)
and the cellular maturation processes in all organs – including the lung and the bone marrow
– may become disturbed. If then an injury occurs – and preterm birth and exposure to the
extrauterine environment itself represents a potent cause cellular injury – the non-mature
BMMSC can not evade the bone marrow or are unable to home to the immature lung tissue.
The damaged endogenous MSC – for example, in the lung – tries to mature and secretes
danger signals, but BMMSC are unable to respond to that. FLMSC then transdifferentiate
as response to the continuing injury, loose their genuine function to regulate lung development,
and BPD sets off.
Not all premature infants develop BPD and the BMMSC evasion and homing functionality
probably matures and develops postnatally. However, exogenous MSC given to the premature
patient may be able to “bridge” the time between the onset of injury (premature birth) and
the onset of a permanent, more or less mature endogenous BMMSC-based repair mechanism.
That would explain why exogenous MSC exert prominent repair effects that persist beyond
the presence of the repair cell in the damaged tissue [Pierro et al., 2013] and may explain
the superiority of early or preemptive MSC-administration regimens [Chang et al., 2013; van
Haaften et al., 2009].
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So, why is the infant affected by a disease for which it has the potential cure in its
own body? Maybe because the endogenous repair cells are not ready to, or not able to
respond. Exogenous cells – e.g. from the umbilical cord – may act by bridging the time the
endogenous repair cells need to gain functionality and protect the organ from further damage.
However, this is a theory which gives raise to multiple hypotheses – which then have to be
carefully tested in premature organisms. Much more knowledge is required on endogenous
lung-resident, endogenous bone marrow-resident and exogenous MSC in order to understand




Background: Despite great achievements in neonatal and perinatal medicine over the past
decades, the immature lung remains the most critical organ to care for after premature birth.
As a consequence, impairment of of postnatal lung development – bronchopulmonary dyspla-
sia or BPD – remains the most common complication of extreme prematurity and a major
healthcare burden. There is no therapy for BPD, except prevention of premature birth. Re-
cently, exogenous mesenchymal stromal cells (MSC) have been shown to prevent and rescue
impaired lung development in animal models. Understanding the mechanisms behind the
beneficial action of these cells is crucial for a successful, safe, and effective clinical translation
of these promising MSC-based cell therapies in neonates.
Hypothesis: Endogenous lung-resident MSC contribute to normal lung development and
become impaired in conditions resembling premature birth, thus playing a part in the patho-
genesis of BPD. Exogenous MSC act by supporting and/or preserving the endogenous mes-
enchymal cell’s function.
Methods and Results: Using lung tissue from aborted fetuses, a novel enzyme/density
gradient technique was employed to obtain endogenous human fetal lung mesenchymal cells
(FLMSC). The vast majority of the so-isolated cells fulfilled all criteria of MSC, making
the herein presented work the first complete description of MSC from human fetal lung tis-
sue. Human umbilical cord-derived (UC)MSC were isolated by enzymatic digestion of the
Wharton’s jelly. When cultured in hypoxic atmospheres resembling intrauterine conditions,
resident FLMSC exerted a gene expression- and cytokine profile supporting epithelial and en-
dothelial lung development, and secreted extracellular matrix components crucial for normal
lung growth. After exposure to hyperoxia – thus mimicking premature birth and subsequent
treatment on a neonatal intensive care unit – FLMSC showed signs of transdifferentiation,
acquired a pro-inflammatory / anti-angiogeneitic secretory profile, diminished production of
crucial extracellular matrix components and send out danger signals to other cells. Conversely,
UCMSC secreted various paracrine factors protecting lung cells, and proteins contributing to
lung growth and alveolarization.
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Discussion and Conclusions: The human fetal lung’s mesenchyme at the late canalic-
ular stage of development mainly consists of MSC rather than fibroblasts, thus implying
a complex mesenchymal stem-/progenitor cell hierarchy and previously undescribed cellular
transdifferentiation processes of human endogenous lung mesenchymal progenitors during late
pregnancy. Evidence for a contribution of FLMSC to normal lung development was generated
in vitro, suggesting a co-ordination of endothelial and epithelial cell fate by human endogenous
lung MSC. When challenged with hyperoxia, FLMSC cells acquire a phenotype contributing
to the pathogenesis of the BPD. Conversely, UCMSC harbor the potential to provide the fac-
tors that these damaged resident MSC lack to produce. The endogenous MSC may therefore
represent a potential target of cell-based therapies of BPD. However, in vivo data obtained
from premature animals is inevitable to gain further insights into the contribution of endoge-
nous lung MSC to normal and disrupted lung development and to clinically translate potent




Hintergrund: Der medizinische Fortschritt der letzten Jahrzehnte verbessert das Überleben
insbesondere extrem kleiner Frühgeborener. Bei diesen stellt die adäquate Oxygenierung über
die unreife Lunge den kritischsten Prozess in der klinischen Betreuung dar, an dessen Ende
häufig eine Beeinträchtigung der postnatalen Lungenentwicklung und -reifung steht. Klin-
isch als Bronchopulmonale Dysplasie (BPD) imponierend, stellt diese Erkrankung die häu-
figste Folge der extremen Frühgeburtlichkeit dar und ist im weiteren Verlauf mit einer be-
deutenden Langzeitmortalität und gesundheitsökonomischen Belastung verbunden. Außer der
Vermeidung der Frühgeburtlichkeit existiert keine Therapie für BPD. Exogene Mesenchymale
Stromazellen (MSC) erwiesen sich jedoch in Tiermodellen der BPD als therapeutisch ausge-
sprochen wirksam und stellen somit einen vielversprechenden Therapieansatz dar. Dennoch ist
wenig über die Mechanismen der exogenen MSC-Wirkung in der frühgeborenen Lunge bekannt;
ein Verständnis dieser ist jedoch unabdingbar für eine sichere und effektive Translation von
MSC-basierten Therapien in die klinische Anwendung.
Hypothese: Lungenresidente MSC sind an der normalen Lungenentwicklung beteiligt, werden
durch Bedingungen, welche die zu frühe Geburt simulieren, beeinträchtigt, und tragen so zur
Pathogenese der BPD bei. Exogene MSC unterstützen die lungenresidenten MSC in ihrer
normalen Funktion und/oder schützen sie vor Schaden.
Methoden und Resultate: Um mesenchymale Zellen aus human-fetalem Lungengewebe
(FLMSC) zu isolieren, wurde eine Methode zur enzymatischen Gewebedissoziation mit an-
schließender selektiver Dichtegradientenzentrifugation entwickelt. Der überwiegende Mehrheit
der isolierten Lungenmesenchymzellen wurde als MSC identifiziert. Damit ist mit der hier vor-
liegenden Arbeit erstmals die vollständige Beschreibung von humanen, fetalen Lungen-MSC
gelungen. Nabelschnur (UC)MSC wurden durch enzymatischen Verdau der Wharton-Sulze
gewonnen. Kultur der FLMSC in einer hypoxischen, den intrauterinen Bedingungen ähnlichen
Atmosphäre resultierte in einem das Lungenwachstum stimulierenden Cytokin- und Genex-
pressionsmuster. Zudem produzierten die FLMSC für Lungenwachstum und -reifung unabd-
ingbare Extrazellulärmatrixproteine. Unter Exposition gegenüber hyperoxischen Kulturbedin-
gungen – welche die zu frühe Geburt mit anschließender Behandlung auf einer Neugeborenen-
intensivstation simulierten – begannen FLMSC einen Transdifferenzierungsprozess und sez-
ernierten proinflammatorische und antiangiogene Signalmoleküle. Zudem wurde eine Reduk-
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tion der Produktion von für die Lungenentwicklung unabdingbaren Matrixproteinen beobachtet.
FLMSC sendeten zudem “Danger-Signale” an andere Zellen, sobald sie Hyperoxie ausgesetzt
wurden. Exogene UCMSC sezernierten in vitro große Mengen an Proteinen, welche Lungen-
zellen vor Schaden schützen und Lungenwachstum und -differenzierung unterstützen.
Diskussion und Schlussfolgerung: Das Mesenchym der humanen fetalen Lunge am Ende
der kanalikulären Entwicklungsphase besteht zum Großteil aus MSC, und nicht Fibroblasten.
Das impliziert eine mesenchymale Stamm- und Progenitorzellhierarchie in der fetalen Lunge
sowie bislang unbeschriebene zelluläre mesenchymale Transdifferenzierungsprozesse im weit-
eren intrauterinen Entwicklungsverlauf. In vitro wurde Evidenz für eine Beteiligung der en-
dogenen Lungen-MSC an der normalen Lungenentwicklung generiert; eine Beteiligung an der
Koordination von epithelialem und endothelialem Lungenwachstum und -reifung durch die en-
dogenen MSC kann auf Grund der vorliegenden Daten angenommen werden. Nach Exposition
gegenüber Hyperoxie entwickelten FLMSC einen die BPD unterstützenden Phänotyp. Exogene
UCMSC besitzen das Potential, die in diesem Zustand fehlenden Faktoren bereitzustellen. En-
dogene pulmonale MSC sind daher potentielles Ziel und potentielle Effektorzellpopulation einer
MSC-basierten Therapie für BPD. Dennoch sind weitere in vivo Experimente mit Tiermod-
ellen der extremen Frühgeburtlichkeit unabdingbar, um die Rolle der endogenen MSC in der
normalen, und insbesondere gestörten Lungenentwicklung zu verstehen und folgend potente,
und vor allem sichere zellbasierte Therapeutika für unsere wohl verletzlichste Patientenpopu-
lation – Frühgeborene – bereitzustellen.
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A. Appendix
A.1 Materials and Reagents
A.1.1 Isolation of FLMSC and UCMSC
Experiments were performed at WCHRI in Edmonton, Alberta / Canada.
A.1.1.1 Reagents
• Adenine Sigma-Aldrich, St. Louis, MO, USA
• CaCl2 Sigma-Aldrich, St. Louis, MO, USA
• C6H12O6 Thermo Fisher, Waltham, MA, USA
• Citric acid Sigma-Aldrich, St. Louis, MO, USA
• Collagenase I Worthington, Lakewood, NJ, USA
• DNAse I Sigma-Aldrich, St. Louis, MO, USA
• D-PBS (Mg2+/Ca2+/glu/pyr) Life Technologies, Carlsbad, CA, USA
• Edetate disodium Thermo Fisher, Waltham, MA, USA
• Hyaluronidase Worthington, Lakewood, NJ, USA
• KCl Sigma-Aldrich, St. Louis, MO, USA
• KH2PO4 Sigma-Aldrich, St. Louis, MO, USA
• MgCl2 × 6H2O VWR, Radnor, PA, USA
• NaCl VWR, Radnor, PA, USA
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• NaH2PO4 Thermo Fisher, Waltham, MA, USA
• Na2HPO4 × 2H2O Sigma-Aldrich, St. Louis, MO, USA
• Na-pyruvate Sigma-Aldrich, St. Louis, MO, USA
• Neutral Protease Worthington, Lakewood, NJ, USA
• Povidone-idoine Purdue Pharma, Pickering, ON, Canada
• Trisodium citrate VWR, Radnor, PA, USA
A.1.1.2 Materials and instruments
• Automated Cell Counter Merck/Millipore, Darmstadt, Germany
• Bottle Top Filters 0.4µm Corning Life Sciences, Corning, NY, USA
• Cell Strainer 40µm BD Biosciences, Franklin Lakes, NJ, USA
• Cell Strainer 100µm VWR, Radnor, PA, USA
• Centrifuge tubes, 15 ml Greiner Bio-One, Kremsmünster, Austria
• Centrifuge tubes, 50 ml BD Biosciences, Franklin Lakes, NJ, USA
• Surgical instruments Aesculap-Werke, Tuttlingen, Germany
• Umbilical cord tape Ethicon, New Brunswick, NJ, USA
A.1.2 MSC expansion and characterization
Experiments were performed at WCHRI in Edmonton, Alberta / Canada.
A.1.2.1 Reagents
• Anti-CD146 Antibody BD Biosciences, Franklin Lakes, NJ, USA
• Anti-GD2 Antibody BD Biosciences, Franklin Lakes, NJ, USA
• αMEM, Eagle’s Modification Sigma-Aldrich, St. Louis, MO, USA
• Adipogenic differentiation BulletKit Lonza, Basel, Switzerland
• Alcian Blue 8GX, BSC-grade Sigma-Aldrich, St. Louis, MO, USA
• Alizarin Red S, BSC-grade Sigma-Aldrich, St. Louis, MO, USA
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• β-Glycerophosphate disodium hydrate Sigma-Aldrich, St. Louis, MO, USA
• Bovine serum albumine (BSA) Sigma-Aldrich, St. Louis, MO, USA
• CH3COOH VWR, Radnor, PA, USA
• C3H7OH Thermo Fisher, Waltham, MA, USA
• CH3OH VWR, Radnor, PA, USA
• Chondrogenic differentiation medium R&D Systems, Minneapolis, MN, USA
• Collagen, rat tail-derived BD Biosciences, Franklin Lakes, NJ, USA
• Crystal Violet Sigma-Aldrich, St. Louis, MO, USA
• Dexamethasone Sigma-Aldrich, St. Louis, MO, USA
• Dimethylsulfoxide Thermo Fisher, Waltham, MA, USA
• DMEM, low glucose Life Technologies, Carlsbad, CA, USA
• Fetal bovine serum, Lot# 11M069 Sigma-Aldrich, St. Louis, MO, USA
• Hydrocortisone Sigma-Aldrich, St. Louis, MO, USA
• Hydroxyethylstarch, 130/0.4, 10% in NS Baxter, Deerfield, IL, USA
• Indomethacin Sigma-Aldrich, St. Louis, MO, USA
• Insulin Sigma-Aldrich, St. Louis, MO, USA
• Isobutylmethylxanthine Sigma-Aldrich, St. Louis, MO, USA
• KCl Sigma-Aldrich, St. Louis, MO, USA
• KH2PO4 Sigma-Aldrich, St. Louis, MO, USA
• L-Ascorbic acid 2-phosphate Sigma-Aldrich, St. Louis, MO, USA
• L-Glutamine Life Technologies, Carlsbad, CA, USA
• NaCl VWR, Radnor, PA, USA
• NaH3 VWR, Radnor, PA, USA
• Na2HPO4 × 2H2O Sigma-Aldrich, St. Louis, MO, USA
• MSC analysis kit, BD StemflowTM BD Biosciences, Franklin Lakes, NJ, USA
• Oil Red O, BSC-grade Sigma-Aldrich, St. Louis, MO, USA
• Osteogenic differentiation BulletKit Lonza, Basel, Switzerland
• Paraformaldehyde Thermo Fisher, Waltham, MA, USA
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• PSF / Antibiotic-Antimycotic Life Technologies, Carlsbad, CA, USA
• Trypan blue Life Technologies, Carlsbad, CA, USA
• Trypsin-EDTA, 0.05% [wt/vol] Life Technologies, Carlsbad, CA, USA
A.1.2.2 Materials and instruments
• Cell strainers, 40µm Partec, Görlitz, Germany
• Centrifuge tubes, 15 ml Greiner Bio-One, Kremsmünster, Austria
• Centrifuge tubes, 50 ml BD Biosciences, Franklin Lakes, NJ, USA
• Cryogenic vials, 2.0 ml Corning Life Sciences, Corning, NY, USA
• FACS tubes BD Biosciences, Franklin Lakes, NJ, USA
• Neubauer Chamber Brand, Wertheim, Germany
• FACS Canto II Flow Cytometer BD Biosciences, Franklin Lakes, NJ, USA
• Tissue culture flasks, 25cm2 Greiner Bio-One, Kremsmünster, Austria
• Tissue culture flasks, 75cm2 BD Biosciences, Franklin Lakes, NJ, USA
• Tissue culture flasks, 175cm2 Corning Life Sciences, Corning, NY, USA
• Tissue culture flasks, 175cm2 Greiner Bio-One, Kremsmünster, Austria
• Tissue culture flasks, 525cm2 BD Biosciences, Franklin Lakes, NJ, USA
A.1.3 Expansion and single cell plating
Experiments were performed at UKD in Dresden, Saxony / Germany.
A.1.3.1 Reagents
• αMEM, Eagle’s Modification Biochrom, Berlin, Germany
• Bovine serum albumine (BSA) Sigma-Aldrich, St. Louis, MO, USA
• CH3OH Carl Roth, Karlsruhe, Germany
• C2H5OH Carl Roth, Karlsruhe, Germany
• Crystal Violet Sigma-Aldrich, St. Louis, MO, USA
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• Dimethylsulfoxide WAK Chemie, Steinbach/Taunus, Germany
• Fetal bovine serum, Lot# 025D11 Sigma-Aldrich, St. Louis, MO, USA
• KCl VWR, Radnor, PA, USA
• KH2PO4 VWR, Radnor, PA, USA
• L-Glutamine Life Technologies, Carlsbad, CA, USA
• NaCl Carl Roth, Karlsruhe, Germany
• NaH3 VWR, Radnor, PA, USA
• Na2HPO4 × 2H2O Carl Roth, Karlsruhe, Germany
• Paraformaldehyde, 4% in PBS/Methanol Carl Roth, Karlsruhe, Germany
• PSF / Antibiotic-Antimycotic Life Technologies, Carlsbad, CA, USA
• Trypan blue Life Technologies, Carlsbad, CA, USA
• Trypsin-EDTA, 0.05% [wt/vol] Life Technologies, Carlsbad, CA, USA
A.1.3.2 Materials and instruments
• C-Chamber Biospherix, Parish, NY, USA
• Cell strainers, 40µm VWR, Radnor, PA, USA
• Centrifuge tubes, 15 ml Greiner Bio-One, Kremsmünster, Austria
• Centrifuge tubes, 50 ml Greiner Bio-One, Kremsmünster, Austria
• Cryogenic vials, 2.0 ml Greiner Bio-One, Kremsmünster, Austria
• Colony Counter Stuart Equipment, Stone/Staffordshire, UK
• FACS tubes BD Biosciences, Franklin Lakes, NJ, USA
• Neubauer Chamber Brand, Wertheim, Germany
• FACS Aria II Cell Sorter BD Biosciences, Franklin Lakes, NJ, USA
• Tissue culture flasks, 25cm2 BD Biosciences, Franklin Lakes, NJ, USA
• Tissue culture flasks, 75cm2 Greiner Bio-One, Kremsmünster, Austria
• Tissue culture flasks, 175cm2 Greiner Bio-One, Kremsmünster, Austria
• 96 well microtiter plates Corning Life Sciences, Corning, NY, USA
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A.1.4 Hyperoxia exposure, protein/RNA isolation, FLMSC differentiation
and protein arrays
Experiments were performed at OHRI in Ottawa, Ontario / Canada.
A.1.4.1 Reagents
• αMEM, Eagle’s Modification Sigma-Aldrich, St. Louis, MO, USA
• CH3COOH VWR, Radnor, PA, USA
• C3H7OH Thermo Fisher, Waltham, MA, USA
• CH3OH VWR, Radnor, PA, USA
• Collagen, rat tail-derived BD Biosciences, Franklin Lakes, NJ, USA
• Dimethylsulfoxide Thermo Fisher, Waltham, MA, USA
• Dithiothreitol (DTT) Thermo Fisher, Waltham, MA, USA
• Fetal bovine serum, Lot# 025D11 Sigma-Aldrich, St. Louis, MO, USA
• HSCH4OH VWR, Radnor, PA, USA
• Hydroxyethylstarch, 130/0.4, 10% in NS Baxter, Deerfield, IL, USA
• KCl Sigma-Aldrich, St. Louis, MO, USA
• KH2PO4 Sigma-Aldrich, St. Louis, MO, USA
• L-Glutamine Life Technologies, Carlsbad, CA, USA
• NaCl VWR, Radnor, PA, USA
• NaF Sigma-Aldrich, St. Louis, MO, USA
• NaH3 VWR, Radnor, PA, USA
• Na2HPO4 × 2H2O Sigma-Aldrich, St. Louis, MO, USA
• Na4P2O7 × 10 H2O Sigma-Aldrich, St. Louis, MO, USA
• MSC analysis kit, BD StemflowTM BD Biosciences, Franklin Lakes, NJ, USA
• Oil Red O, BSC-grade Sigma-Aldrich, St. Louis, MO, USA
• Osteogenic differentiation BulletKit Lonza, Basel, Switzerland
• Paraformaldehyde Thermo Fisher, Waltham, MA, USA
• Phosphatase inhibitor cocktail Sigma-Aldrich, St. Louis, MO, USA
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• Protease inhibitor cocktail #1 Sigma-Aldrich, St. Louis, MO, USA
• Proteome ProfilerTM Angiokine Array R&D Systems, Minneapolis, MN, USA
• Proteome ProfilerTM Cytokine Array R&D Systems, Minneapolis, MN, USA
• PSF / Antibiotic-Antimycotic Life Technologies, Carlsbad, CA, USA
• Sucrose Merck, Darmstadt, Germany
• TRIS-HCl Thermo Fisher, Waltham, MA, USA
• Triton X-100 Sigma-Aldrich, St. Louis, MO, USA
• Trypan blue Life Technologies, Carlsbad, CA, USA
• Trypsin-EDTA, 0.05% [wt/vol] Life Technologies, Carlsbad, CA, USA
• Tween-20 Sigma-Aldrich, St. Louis, MO, USA
A.1.4.2 Materials and instruments
• Cell scrapers Corning Life Sciences, Corning, NY, USA
• Cell homogenization columns (QIAshredderTM) Qiagen, Hilden, Germany
• Centrifuge tubes, 15 ml Corning Life Sciences, Corning, NY, USA
• Centrifuge tubes, 50 ml Corning Life Sciences, Corning, NY, USA
• Cryogenic vials, 2.0 ml Greiner Bio-One, Kremsmünster, Austria
• Amersham Hypercassette GE Healthcare, Amersham, United Kingdom
• Hyperfilm ECL GE Healthcare, Amersham, United Kingdom
• Medical Film Processor SRX-101A Konica Minolta, Chiyoda, Japan
• Microcentrifuge tubes, 1.5 ml VWR, Radnor, PA, USA
• RNA isolation columns (RNeasyTM) Qiagen, Hilden, Germany
• Tissue culture dishes, 100mm Greiner Bio-One, Kremsmünster, Austria
• Tissue culture flasks, 75cm2 Greiner Bio-One, Kremsmünster, Austria
• Tissue culture flasks, 175cm2 Greiner Bio-One, Kremsmünster, Austria
• XVivo System Biospherix, Parish, NY, USA
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A.1.5 Western blotting, protein/RNA isolation, protein arrays, ELISA,
qPCR and ECM analysis
Experiments were performed at UKD in Dresden, Saxony / Germany.
A.1.5.1 Reagents
• Acrylamide/Bis-, 30% [wt/vol] in ddH2O Carl Roth, Karlsruhe, Germany
• Anti-β-Catenin Antibody Cell Signaling Technology, Danver, MA, USA
• Anti-GAPDH Antibody Meridian Life Science, Memphis, TN, USA
• Anti-NANOG Antibody R&D Systems, Minneapolis, MN, USA
• Anti-OCT4A Antibody R&D Systems, Minneapolis, MN, USA
• Anti-PDGFRα Antibody Cell Signaling Technology, Danver, MA, USA
• Anti-SOX2 Antibody R&D Systems, Minneapolis, MN, USA
• C2H5OH Carl Roth, Karlsruhe, Germany
• C2H5NO2 Serva Electrophoresis, Heidelberg, Germany
• Cell Dissociation Solution, non-enzymatic Sigma-Aldrich, St. Louis, MO, USA
• CH3COOH Thermo Fisher, Waltham, MA, USA
• CH3OH Carl Roth, Karlsruhe, Germany
• CO2HCOOH Serva Electrophoresis, Heidelberg, Germany
• CXR reference dye Promega, Fitchburg, WI, USA
• dNTPs Promega, Fitchburg, WI, USA
• EDTA Carl Roth, Karlsruhe, Germany
• ECL-Plus GE Healthcare, Amersham, United Kingdom
• FGF10 ELISA Abbexa, Cambridge, United Kingdom
• GoTaq Green® Promega, Fitchburg, WI, USA
• GBX developer/fixer Carestream Health, Rochester, NY, USA
• HCl Thermo Fisher, Waltham, MA, USA
• KCl VWR, Radnor, PA, USA
• KH2PO4 VWR, Radnor, PA, USA
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• Lämmli’s modified loading buffer Carl Roth, Karlsruhe, Germany
• MgCl Taq-buffer Promega, Fitchburg, WI, USA
• Milk Powder, non-fat Klinikapotheke UKD, Dresden, Germany
• M-MLV RT [H-] reverse transcriptase Promega, Fitchburg, WI, USA
• Na2HPO4 × 2H2O Carl Roth, Karlsruhe, Germany
• NaCl Carl Roth, Karlsruhe, Germany
• NaF Klinikapotheke UKD, Dresden, Germany
• NaH3 VWR, Radnor, PA, USA
• (NH4)2S2O8 Serva Electrophoresis, Heidelberg, Germany
• Oligo-dT mix Eurofins Scientific, Lëtzebuerg, Luxembourg
• Papain Sigma-Aldrich, St. Louis, MO, USA
• PCR buffer 5× Promega, Fitchburg, WI, USA
• PGE2 ELISA R&D Systems, Minneapolis, MN, USA
• Primer as per Table 7 Eurofins Scientific, Lëtzebuerg, Luxembourg
• qPCR Master Mix BRYT Green® Promega, Fitchburg, WI, USA
• Random primer mix Eurofins Scientific, Lëtzebuerg, Luxembourg
• RNasin® Promega, Fitchburg, WI, USA
• SDS Serva Electrophoresis, Heidelberg, Germany
• Stanniocalcin-1 ELISA R&D Systems, Minneapolis, MN, USA
• Taq-polymerase Promega, Fitchburg, WI, USA
• TEMED Carl Roth, Karlsruhe, Germany
• TRIS-HCl Carl Roth, Karlsruhe, Germany
• Tween 20 Serva Electrophoresis, Heidelberg, Germany
A.1.5.2 Materials and instruments
• AB 7300 real-time PCR System Thermo Fisher, Waltham, MA, USA
• Azure c300 Imaging Platform Azure Biosystems, Dublin, CA, USA
• CASY TT Cell Counting System OMNI Life Sciences, Bremen, Germany
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• Kodak BioMax MR films Carestream Health, Rochester, NY, USA
• Biometra T3 Thermocycler Analytik Jena, Jena, Germany
• Hybond blotting paper GE Healthcare, Amersham, United Kingdom
• Amersham Hypercassette GE Healthcare, Amersham, United Kingdom
• Infinite M200 plate reader Tecan, Männedorf, Switzerland
• Mini-PROTEAN Tetra Cell System Bio-Rad Laboratories, Hercules, CA, USA
• Microcentrifuge tubes, 1.5 and 2.0 ml Eppendorf, Hamburg, Germany
• Microwellplates, 6, 24 and 96 well Greiner Bio-One, Kremsmünster, Austria
• Nitrocellulose membranes GE Healthcare, Amersham, United Kingdom
• RNA isolation columns (NucleoSpin RNA II) Macherey-Nagel, Düren, Germany
• Trans-Blot SD Transfer Cell Bio-Rad Laboratories, Hercules, CA, USA
A.1.6 HyperFlask-Expansion and HTS-FACS
Experiments were performed at CRTD in Dresden, Saxony / Germany.
A.1.6.1 Reagents
• αMEM, Eagle’s Modification Biochrom, Berlin, Germany
• CellFix BD Biosciences, Franklin Lakes, NJ, USA
• L-Glutamine Life Technologies, Carlsbad, CA, USA
• Lyoplate FACS Panel BD Biosciences, Franklin Lakes, NJ, USA
• PBS CRTD Media Kitchen, Dresden, Germany
• Standardized fetal bovine serum (FBS superior) Biochrom, Berlin, Germany
• Staining and wash buffer IBA, Göttingen, Germany
• Trypan blue Life Technologies, Carlsbad, CA, USA
• Trypsin-EDTA, 0.05% [wt/vol] Life Technologies, Carlsbad, CA, USA
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A.1.6.2 Materials and instruments
• Cell strainers, 40µm VWR, Radnor, PA, USA
• 250 ml centrifuge tubes Corning Life Sciences, Corning, NY, USA
• Hemocytometer / Neubauer Chamber Brand, Wertheim, Germany
• 12 Layer-HyperFlasks Corning Life Sciences, Corning, NY, USA
• LSR II custom-build FACS BD Biosciences, Franklin Lakes, NJ, USA
• Robotic HTS loader BD Biosciences, Franklin Lakes, NJ, USA
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A.2 Media and cell culture reagents
A.2.1 Differentiation media
• Osteogenic differentiation medium
– 4.34 mg L-Ascorbic acid 2-phosphate sesquimagnesium hydrate 150 µmol/l
– 38.4 µl Dexamethasone (100 µg / ml ddH2O stock) 0.1 µmol/l
– 43.21 mg β-Glycerophosphate disodium hydrate 10 mmol/l
– 1 ml PSF 1% [vol/vol]
– 10 ml Fetal Bovine Serum 10% [vol/vol]
– 1 ml L-Glutamine 10 mmol/l
– 88 ml Minimal Essential Medium, α Modification
Mix, filter sterile using 0.22 µm filter with low protein binding membrane. Store for
max. 14d at 4°C.
• Adipogenic differentiation medium
– 11.1 mg Isobutylmethylxanthine (IBMX) 0.1 mmol/l
– 21.5 µl Indomethacin (100 mg / ml ddH2O or DMSO stock) 60 µmol/l
– 100 µl Insulin (1 mg/ ml ddH2O stock) 1 mg/l
– 18.1 µl Hydrocortisone (1 mg/ ml ddH2O stock) 0.5 µmol/l
– 1 ml PSF 1% [vol/vol]
– 10 ml Fetal Bovine Serum 10% [vol/vol]
– 89 ml Dulbucco’s Modified Eagle Medium, low glucose
Solubilize IBMX in 100µl DMSO. Mix all compounds, filter sterile using 0.22 µm filter
with low protein binding membrane. Store for max. 14d at 4°C.
A.2.2 Solutions and buffer for cell isolation and cell culture
• Cell rinsing buffer for MSC isolation
– 5 ml FBS (fetal bovine serum) 5 % [vol/vol]
– 95 ml PBS
Mix, filter sterile using 0.22 µm filter with low protein binding membrane. Store for a
week at 4°C.
• Cell freezing stock buffer
– 1500 µl CPDA-1 12.5 % [vol/vol]
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– 2400 µl FBS (fetal bovine serum) 20 % [vol/vol]
– 6000 µl Hydroxyethylstarch 130 / 0.4 in 0.9% NaCl 6 % [wt/vol]
– 300 µl NaCl in ddH2O
Mix, filter sterile using 0.22 µm filter with low protein binding membrane. Store for
a week at 4°C or freeze down at -20°C in aliquots for up to a year. Add 5% [vol/vol]
DMSO to complete as described in (methods).
• Collagen coating solution
– 629 µl CH3COOH (glacial acetic acid) 20 mmol/l
– 500 ml ddH2O
Mix, filter sterile using 0.22 µm filter. Add commercially available Type I collagen
solution to a final concentration of 50 µg /ml. Use right away, 125 µl per 12 mm cover
slip.
A.3 General buffers and prepared reagent solutions
A.3.1 Organic and anorganic salt solutions
• PBS stock solution
– 80.0 g NaCl 1370 mmol/l
– 2.0 g KCl 27 mmol/l
– 3.6 g KH2PO4 20 mmol/l
– 18.0 g Na2HPO4 × 2H2O or 80 mmol/l
– 14.4 g Na2HPO4 80 mmol/l
Add to 250 - 350 ml ddH2O in 1000 ml graduated flask, stir until dissolved, add
ddH2O up to 1 liter. Stabile for a year at room temperature.
• PBS working solution
– 100 ml PBS stock solution 1:10
– 900 ml ddH2O
Mix, filter sterile (0.22 µm pore size), store at 4°C for up to a month. Final electrolyte
concentrations Na+ 153 mmol/l, Cl− 139.7 mmol/l, K+ 4.7 mmol/l, PO 3−4 10 mmol/l.
• Dulbecco’s PBS with Mg2+/Ca2+/glucose/pyruvate
– 100 mg CaCl2 0.9 mmol/l
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Dissolve in 50 - 100 ml ddH2O, prepare fresh in a seperate vessel.
– 1 000 mg C6H12O6 (D-glucose) 5.55 mmol/l
– 200 mg KCl 2.66 mmol/l
– 100 mg MgCl2 × 6H2O 0.49 mmol/l
– 8 000 mg NaCl 137.9 mmol/l
– 200 mg KH2PO4 1.47 mmol/l
– 1 434 mg Na2HPO4 × 2H2O 8.06 mmol/l
– 36 mg CH3COCOONa (sodium pyruvate) 0.33 mmol/l
Dissolve compounds in 250 ml ddH2O in a 1 000 ml graduated flask. Add ddH2O to
approx. 800 ml once dissolved. Add prepared CaCl solution dropwise (!) while stirring
to avoid precipitation of calcium phosphates. Add ddH2O to 1000 ml. Filter sterile
using a using 0.22 µm filter and store at 4°C for up to a month. Alternative: prepared
solution from ThermoFisher.
• CPDA-1
– 26.30 g C6H5Na3O7 × 2H2O (trisodium citrate) 90 mmol/l
– 3.27 g C6H8O7 ×H2O (citric acid) 15.5 mmol/l
– 31.8 g C6H12O6 (D-glucose) 176 mmol/l
– 275 mg C5H5N5 (adenine) 2 mmol/l
– 2.22 g NaH2PO4 18.5 mmol/l
Add to 250 - 350 ml ddH2O in 1 000 ml graduated flask, stir until dissolved, add
ddH2O up to 1 liter. Filter sterile using 0.22 µm filter. Stabile for a month at 4°C.
• Cord storage solution
– 30 ml CPDA-1 30 % [vol/vol]
– 1 ml PSF (antibiotic / antimycotic) 1 % [vol/vol]
– 69 ml PBS
Combine, filter sterile using a using 0.22 µm filter and store at 4°C for a week or at
-20°C for a year.
• EDTA Digestion Stopping Solution
– 5.58 g C10H14N2Na2O8 × 2H2O (Edetate disodium) 150 mmol/l
Dissolve in 100 ml ddH2O. Adjust pH to 7.4 using NaOH 5 mol/l or 10 mol/l. Filter
sterile using 0.22 µm filter, store at room temperature for > three years. Chelates all
free bivalent cations in the digestion buffer with a surplus of 100% when added at 1 ml
per 30 ml buffer.
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A.3.2 Protein extraction buffer for cells and tissues
• Stock protein extraction buffer (500 ml)
– 1.21 g NH2C(CH2OH)3 ×HCl (Tris-HCl) 20 mmol/l
– 1.46 g NaCl 50 mmol/l
– 1.05 g NaF 50 mmol/l
– 1.12 g Na4P2O7 × 10 H2O 5 mmol/l
– 42.8 g C12H22O11 (Sucrose) 250 mmol/l
Add reagents to 400 ml ddH2O in 500ml graduated flask, stir to dissolve, then add
ddH2O to 500 ml. Cool down to 4°C (pHTRIS = f(temp.) ) and adjust pH to 7.4 with
1 mol/l HCl while cold. Store at 4°C for 12 months.
• DTT stock solution
– 154.2 mg C4H10O2S2 (Dithiothreitol) 1 mol/l
Prepare fresh. Dissolve in 800 µl ddH2O. Add ddH2O to 1000 µl.
• Completed lysis buffer
– 9.7 ml Stock protein extraction buffer
– 10 µl DTT stock solution 1 mmol/l
– 100 µl Protease Inhibitor Cocktail #1 1:100
– 100 µl Phosphatase Inhibitor Cocktail 1:100
– 100 µl Triton X-100 1:100
Mix well. Stable for a week at 4°C.
A.4 Western blot buffer
A.4.1 Stock and working buffers
• 2 mol/l TRIS-HCl stock solution pH 6.8
– 242.28 g NH2C(CH2OH)3 ×HCl (TRIS-HCl) 2000 mmol/l
Add to 500 ml ddH2O in 1000ml graduated flask, stir, then add ddH2O to approx. 950
ml. Cool down to 4°C (pHTRIS = f(temp.) ) and adjust pH to 6.8 with 5 mol/l HCl,
filter, and store at roome temperature for up to a year.
• 2 mol/l TRIS-HCl stock solution pH 7.4
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– 242.28 g NH2C(CH2OH)3 ×HCl (TRIS-HCl) 2000 mmol/l
Add to 500 ml ddH2O in 1000ml graduated flask, stir, then add ddH2O to 1000 ml.
Cool down to 4°C (pHTRIS = f(temp.) ) and adjust pH to 7.4 with 2.5 - 5 mol/l HCl,
filter, and store at roome temperature for up to a year.
• 2 mol/l TRIS-HCl stock solution pH 8.5
– 242.28 g NH2C(CH2OH)3 ×HCl (TRIS-HCl) 2000 mmol/l
Add to 500 ml ddH2O in 1000ml graduated flask, stir, then add ddH2O to 1000 ml.
Cool down to 4°C (pHTRIS = f(temp.) ), check pH and adjust to 8.5 (if necessary).
Filter, and store at roome temperature for up to a year.
• EDTA stock
– 18.6 g C10H14N2Na2O8 × 2H2O (Edetate disodium) 500 mmol/l
Dissolve in 80 ml ddH2O, then add ddH2O to 100ml. Filter, store at room temperature
for > three years.
• 4x Stacking gel stock buffer pH 8.5
– 10 ml Sodium dodecyl sulfate (SDS), 20% [wt/vol] in ddH2O 0.4% wt/vol
– 375 ml TRIS-HCl, 2 mol/l stock solution pH 8.5 1500 mmol/l
Combine reagents in 500ml graduated flask, stir, then add ddH2O to 500 ml. Store at
4°C for 12 months.
• 4x Resolving gel stock buffer pH 6.8
– 10 ml Sodium dodecyl sulfate (SDS), 20% [wt/vol] in ddH2O 0.4% wt/vol
– 125 ml TRIS-HCl, 2 mol/l stock solution pH 6.8 1500 mmol/l
Combine reagents in 500ml graduated flask, stir, then add ddH2O to 500 ml. Store at
4°C for 12 months.
• 10x TAE buffer pH 7.7
– 20 ml EDTA, 500 mmol/l stock 10 mmol/l
– 23 ml C2H4O2 (Glacial acetic acid) 2.3 % [vol/vol]
– 250 ml TRIS-HCl, 2 mol/l stock solution pH 8.5 500 mmol/l
Combine reagents in 1000ml graduated flask, stir, then add ddH2O to 1000 ml. Cool to




• 20x TRIS-buffered saline (TBS) stock
– 100 ml TRIS-HCl, 2 mol/l stock solution pH 7.4 200 mmol/l
– 175.32 g NaCl 3000 mmol/l
Add reagents to 200 ml ddH2O in a 1000ml graduated flask, stir until dissolved, then
add ddH2O to 1000 ml. Filter and store at room temperature for up to 12 months.
• TRIS-buffered saline (TBS) working solution
– 50 ml 20x TRIS-buffered saline (TBS) stock 1x
– 950 ml ddH2O
Mix in a 1000ml graduated flask and adjust volume to 1000ml with ddH2O, if necessary.
Cool to 4°C (pHTRIS = f(temp.) ), check pH and adjust to 7.4. Store at 4°C for up to
12 months. Final concentrations: 150 mmol/l Na+, 150 mmol/l Cl−, 10 mmol/l TRIS.
• 0.1% TBS-T (TRIS-buffered saline - Tween)
– 500 µl Tween 20 (Polysorbat 20) 0.1% [vol/vol]
– 500 ml TBS working solution
Mix by shaking. Store at 4°C temperature for up to 12 months.
• 10x Electrophoresis running stock buffer pH 8.5
– 50 ml Sodium dodecyl sulfate (SDS), 20% [wt/vol] in ddH2O 1% wt/vol
– 125 ml TRIS-HCl, 2 mol/l stock solution pH 8.5 250 mmol/l
– 144.1 g C2H5NO2 (Glycin) 1920 mmol/l
Add reagents to 250 ml ddH2O in a 1000ml graduated flask, stir, then add ddH2O to
1000 ml. Filter and store at 4°C for up to a month.
• Electrophoresis running buffer pH 8.5
– 100 ml 10x Electrophoresis running stock buffer pH 8.5 1x
– 900 ml ddH2O
Mix in a 1000ml graduated flask, adjust volume to 1000ml with ddH2O and store at
4°C for up to a week.
• APS working solution
– 125 mg (NH4)2S2O8 (Ammonium persulfate) 12.5% [wt/vol]
– 1000 µl ddH2O
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Add ddH2O directly into weighboat with APS and mix by pipetting. Use fresh.
• MP / TBS antibody diluent and blocking buffer
– 500 mg non-fat milk powder 5% [wt/vol]
– 10 ml TBS working solution
Mix thoroughly, store at 4°C for up to a week.
• BSA / TBS-T antibody diluent
– 500 mg bovine serum albumine 5% [wt/vol]
– 10 mg NaN3 (Sodium azide) 0.01% [wt/vol]
– 10 ml 0.1% TBS-T working solution
Mix thoroughly and store at 4°C for up to a month.
A.4.2 Gels
• 8% SDS-PAGE resolving gel (for 4 Mini-PROTEAN casting frames)
– 6 ml 4x Resolving gel stock buffer pH 6.8 1x
– 6.4 ml Acrylamide, 30% [wt/vol] in ddH2O 8% [wt/vol]
– 96 µl APS working solution 0.05% [wt/vol]
– 20 µl (CH3)2NCH2CH2N(CH3)2 (Tetramethylethylenediamine) 0.08% mmol/l
– 11.5 ml ddH2O
Add all reagents to ddH2O, mix, cast resolving gels right away. Wait 15 min to allow
polymerization before proceeding with the stacking gel. Overlay the top of the gels with
50% [vol/vol] isopropanol in ddH2O to prevent drying.
• 10% SDS-PAGE resolving gel (for 4 Mini-PROTEAN casting frames)
– 6 ml 4x Resolving gel stock buffer pH 6.8 1x
– 8 ml Acrylamide, 30% [wt/vol] in ddH2O 10% [wt/vol]
– 96 µl APS working solution 0.05% [wt/vol]
– 20 µl (CH3)2NCH2CH2N(CH3)2 (Tetramethylethylenediamine) 0.08% mmol/l
– 9.9 ml ddH2O
Add all reagents to ddH2O, mix, cast resolving gels right away. Wait 15 min to allow
polymerization before proceeding with the stacking gel. Overlay the top of the gels with
50% [vol/vol] isopropanol in ddH2O to prevent drying.
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• Stacking gel (for 4 Mini-PROTEAN casting frames)
– 3.7 ml 4x Stacking gel stock buffer pH 8.5 1x
– 2.2 ml Acrylamide, 30% [wt/vol] in ddH2O 4.4% [wt/vol]
– 50 µl APS working solution 0.04% [wt/vol]
– 30 µl (CH3)2NCH2CH2N(CH3)2 (Tetramethylethylenediamine) 0.2% mmol/l
– 9.0 ml ddH2O
Add all reagents to ddH2O, mix, layer stacking gels solution right away onto polymerized
resolving gels and insert comb. Wait at least 30 min to allow thorough polymerization
before proceeding with loading the samples.
A.5 PCR buffer
• RNA to cDNA transcription master mix
– 0.5 µl RNAse inhibitor (RNasin)
– 1.1 µl dNTP mix
– 7.0 µl 5× GoTaq buffer
– 1.0 µl M-MLV RT [H-] reverse transcriptase
Prepare on ice. Yields 9.6 µl per sample, add 2 µg sample RNA to 9.6 µl master mix
and incubate as described in 3.5.4.1.
• GAPDH cDNA-transcription control PCR
– 4.0 µl 5× GoTaq Green buffer
– 1.2 µl MgCl Taq-buffer
– 0.6 µl dNTP mix
– 1.0 µl GAPDH Primer
– 0.1 µl Taq-polymerase
– 12.1 µl ddH2O , DNAse free
Prepare on ice. Yields 19 µl per sample, add 1 µl sample cDNA and incubate 7min
at 94°C, followed by 30 cycles of 30 sec at 94°C → 30 sec at 60°C → 30 sec at 72°C.
5min at 72°C and cool down to 10°C conclude the PCR process. Run a routine agarose
electrophoresis, bands are visible without further staining.
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A.6 Dye- and staining solutions
N.b.: The colour index number (C.I.) for definite identification of a dye accompanies the C.I.
generic name as per current version of the Colour Index by the British Society of Dyers and
Colourists and the American Association of Textile Chemists and Colorists. All dyes have
been certified by the Biological Stain Commission (BSC).
A.6.1 Dyes
• Crystal Violet Staining Solution
– 500 mg Crystal Violet (C.I. 42555) 0.5 % [wt/vol]
– 25 ml CH3OH (Methanol) 25 % [vol/vol]
– 75 ml ddH2O
Combine methanol and water. Add dye, filter, and store in the dark at room tempera-
ture. Stabile for at least one year.
• Picro-Sirius Red Solution
– 500 mg Sirius Red F3B (C.I. 35782) 0.1 % [wt/vol]
– 500 ml Saturated aqueous solution (1.3 % [wt/vol]) of picric acid
Add dye into picrinic acid solution, stir, filter and store in the dark at room temperature.
Stabile for at least 3 years.
• Oil Red O Solution
– 500 mg oil red O (C.I. 26125) 0.5 % [wt/vol]
– 60 ml C3H7OH (isopropanol) 60 % [vol/vol]
– 40 ml ddH2O
Dissolve, add ddH2O while stirring, filter and use within 24h after preperation. Alterna-
tive: prepared, stabilized 0.5 % Oil Red-O solution in 60 % isopropanol (Sigma-Aldrich).
• Alizarin Red S Solution
– 2 g Alizarin Red S (C.I. 58005) 2 % [wt/vol]
– 100 ml ddH2O
Add dye into water, stir, adjust the pH to 4.2 with 10 % [wt/vol] ammonium hydroxide
in ddH2O, filter and use solution within 60 min.
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• Alcian Blue 8GX Solution
– 1 g Alcian Blue 8GX (C.I. 74240) 1 % [wt/vol]
– 3 ml C2H4O2 (glacial acetic acid) 3 % [vol/vol]
– 97 ml ddH2O
Combine glacial acetic acid and water. Stir in dye, adjust pH to 2.5 with glacial acetic
acid. Filter and store in the dark at room temperature. Stabile for at least one year.
Alternative: prepared 1 % Alcian Blue in 3 % acetic acid (Sigma-Aldrich).
• Safranin O Solution
– 100 mg Safranin O (C.I. 50240) 0.1 % [wt/vol]
– 100 ml ddH2O
Dissolve by stirring and filter. Stabile for at least one year when kept in the dark at
room temperature.
A.6.2 Staining buffer
• PFA Fixation Buffer
– 10 g HO(CH2O)8−100H (Paraformaldehyde) 4% [wt/vol]
– 250 ml PBS
– NaOH and HCl, 2 mol/l in ddH2O
Heat PBS to 60-65°C in on a magnetic stirrer. Mix in PFA powder and stir at 60-65°C
until dissolved. If not dissolved within 5 min, add 2 mol/l NaOH drop-wise until the
solution clears. Cool solution down, filter, adjust volume to 250ml with ddH2O and pH
to 7.0 with 2 mol/l HCl. Freeze down in aliquots at -20°C for storage up to three years.
• BrdU stock (1000x)
– 30.71 mg C9H11BrN2O5 (5-Bromo-2’-deoxyuridine) 10 mmol/l
– 10 ml PBS
Mix by shaking in a 15ml conical tube, filter to remove impurities, aliquot, and store
for up to six months at -20°C.
• Sodium borate buffer for BrdU-ICC
– 3.8 g Na2B4O7 × 10 H2O (disodium tetraborate) 100 mmol/l
– 100 ml ddH2O
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Mix by stirring, adjust pH to 8.5 using 5 mol/l HCl, filter to remove impurities and
store for up to three years at room temperature.
• ICC rinsing solution
– 250 µl Tween 20 (Polysorbat 20) 0.05% [vol/vol]
– 500 ml PBS working solution
Mix by shaking. Store at room temperature for up to 12 months.
• Immunocytochemistry (ICC) blocking buffer
– 1000 µl Normal animal serum (species depending on AB) 10 % [vol/vol]
– 100 µg Bovine serum albumine (BSA) 1 % [wt/vol]
– 50 µl TWEEN-20 0.5 % [vol/vol]
Mix in 5 ml PBS, bring to 10 ml with PBS, filter to remove impurities and store for up
to a week at 4°C.
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